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chapter 1
General introduction  
and aims of the thesis
Partly based on:
Review of current and emerging treatment options in acromegaly.
A. Muhammad, A.J. van der Lely, S.J.C.M.M. Neggers
The Netherlands journal of medicine. 2015;73:362-367.
Combined treatment of somatostatin analogues with pegvisomant in acromegaly.
S.E. Franck*, A. Muhammad*, A.J. van der Lely, S.J.C.M.M. Neggers
Endocrine. 2016;52:206-213.
How to position pasireotide LAR treatment in acromegaly?
E.C. Coopmans*, A. Muhammad*, A.J. van der Lely, J.A.M.J.L. Janssen, S.J.C.M.M. 
Neggers
The Journal of clinical endocrinology and metabolism. 2019;104:1978-1988.
*Shared first authorship
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This introductory chapter of the thesis will focus on the medical treatment of acro-
megaly. This is preceded by a brief description of the central and peripheral regula-
tion of the GH-IGF-I axis with a focus on dysregulation of this axis in acromegaly.
PItuItAry glANd PHysIology
General characteristics
The pituitary gland is often called the “master gland” of the endocrine system, 
because its hormones play a central role in a vast array of physiological feedback 
functions such as growth, metabolism, energy balance, osmoregulation, and stress 
response (1). The normal pituitary gland is a bean-shaped gland with an average 
weight of 0.6 grams (figure 1). The gland is located inferior the hypothalamus within 
the sella turcica and linked to the hypothalamus via the pituitary stalk which contains 
a highly vascularized portal system. The pituitary is comprised of three anatomically 
and functionally distinct lobes, the anterior lobe (adenohypophysis), the intermedi-
ate lobe, and the posterior lobe (neurohypohysis). The anterior lobe contains five 
different hormone-secreting cell lineages which produce the following hormones: 
figure 1. Normal anatomy of the pituitary gland.
Normal anatomy of the pituitary gland with its surrounding structures. The borders of the pitu-
itary are composed of the sella turcica below (retrosellar), the optic chiasm above (suprasellar), 
and the cavernous sinuses on both sides (parasellar). The sella turcica is situated above the 
sphenoid sinus. The cavernous sinuses constitute a thin-walled venous network that receive blood 
from the superior and inferior ophthalmic veins, the sphenoparietal sinus, and the superficial 
middle cerebral veins. Structures crossing the cavernous sinuses lateral to the pituitary gland 
include the internal carotid artery, cranial nerve III (oculomotor), cranial nerve IV (trochlear), 
cranial nerve VI (abducens) nerve, two branches of cranial nerve V (trigeminal nerve branch 1 
and 2), the ophthalmic branch V1, and the maxillary branch V2. Source: Molitch ME, Diagnosis 
and Treatment of Pituitary Adenomas: A Review, JAMA. 2017;317:516-524. Image reproduced with 
permission of the rights holder, JAMA.
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the corticotrophs that produce adrenocorticotrophin (ACTH), the gonadotrophs that 
produce the gonadotrophins luteinizing hormone (LH) and follicle-stimulating hor-
mone (FSH), the somatotrophs that produce growth hormone (GH), the lactotrophs 
that produce prolactin (PRL) and, the thyrotrophs that produce thyroid-stimulating 
hormone (TSH). The somatotrophs may also produces both GH and PRL. In addition, 
the anterior lobe also contains folliculo-stellate cells or pituicytes that are support 
cells (2). The intermediate lobe contains only α-melanotrophin (α-MSH). In humans 
this lobe is considered rudimental as it regresses at the 15th week of gestation. In 
contrast to the anterior lobe, the posterior consists of mainly neural projections from 
the hypothalamus that produces arginine, antidiuretic hormone (ADH, or vasopressin) 
and oxytocin.
Growth hormone
The somatotrophs, which synthesize, store and secrete GH, are the predominant cell 
type of the anterior pituitary, constituting about 45% of the pituitary cell population. 
GH is a single-chain 191-amino acid polypeptide and over 90% of GH in the circulation 
constitutes a 22 kilodaltons (kDa) molecule (3). About 50% of circulating GH is bound 
to GH binding protein (GHBP), which is the soluble version of the extracellular domain 
of the GHR, and is important for the bioavailability and bioactivity of GH (4, 5). 
Binding of GH to the GHR induces dimerization of the GHR and sets a intracellular 
signaling cascade in motion which leads to activation of the tyrosine kinase JAK2, 
which activates the STAT5, PI3K, and MAP kinase pathways (6-8).
Normal GH secretion occurs in a pulsatile circadian rhythm with the majority of its 
secretion occurring during deep sleep. During hypoglycemia and physical exercise GH 
secretion is amplified, while hyperglycemia and leptin suppress GH secretion (9-13). 
Circulating GH is high at 20 weeks of gestation, and subsequently falls during the 
neonatal stage and childhood until puberty, when GH secretion peaks to 2 mg/day, 
after which it declines progressively through aging (14).
GH is a pleiotropic hormone due to its involvement in the regulation of many physi-
ological processes, such as growth, glucose, lipid and bone metabolism, reproduction, 
osmoregulation and the immune system. GH has both anabolic and catabolic actions. 
Most of the anabolic actions of GH are mediated via IGF-I. GH is the primary regulator 
of IGF-I production (15). GH is mainly a catabolic hormone during fasting and in the 
absence of IGF-I but becomes anabolic in the presence of IGF-I after food intake. 
The most well-known (anabolic) action of GH is stimulation of cellular growth and 
differentiation. The catabolic actions of GH derive from its lipolytic effects on adipose 
tissue. GH administration stimulates lipolysis and inhibits lipogenesis which results in 
General introduction and aims of the thesis
11
1
elevated free fatty acids (FFAs), whereas GH deficiency is associated with increased 
lipid mass. GH is a counter-regulatory hormone that antagonizes the effects of insulin, 
while IGF-I promotes insulin sensitivity (16, 17). Therefore, GH and IGF-I display op-
posing effects on insulin homeostasis.
Growth hormone-pituitary-hypothalamus axis
Central GH secretion is positively regulated by the hypothalamus through GH re-
leasing hormone (GHRH) and acylated ghrelin (AG) which stimulate GH secretion, 
and negatively regulated by somatostatin (somatostatin release inhibiting factor, 
SRIF) which inhibits GH secretion (Figure 2). The peripheral actions of GH are 
figure 2 Central and peripheral components that regulate the GH axis.
Central and peripheral components that regulate the GH axis. NPY, neuropeptide Y; FFA, free fatty 
acids; GH, growth hormone; IGF1, insulin-like growth factor 1; GHRH, GH-releasing hormone; SRIF, 
somatotrophin release inhibitory factor. Image reproduced with permission of the rights holder, 
JAMA.
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predominantly mediated via hepatic IGF-I production, but also through direct actions 
on local tissues.
Ghrelin
ghrelin was discovered in 1999 by the group of Kojima and Kangawa as the endog-
enous ligand of the GH secretagogue receptor type 1a (GHSR1a). Ghrelin is a 28-amino 
acid peptide hormone secreted mainly from neuroendocrine X/A cells in the stomach 
(18, 19), circulating as both acylated ghrelin (AG) and unacylated ghrelin (UAG) 
isoforms (20). Unique to AG is the n-octanoyl acylation by the enzyme ghrelin O-acyl 
transferase (GOAT) at its serine-3 residue. In the circulation AG is rapidly deacylated 
by carboxylesterases into UAG (21). After binding to GHSR1a, AG potently stimulates 
pituitary GH secretion and food intake (orexigenesis). Inversely, GH itself inhibits AG 
secretion (22-25). But there are also conflicting reports on the interaction between 
ghrelin and GH, indicating that the physiological role of ghrelin in the regulation of 
GH secretion is not fully understood (26-29). Although AG was initially discovered 
as a GH secretagogue, it is now recognized as a multifunctional hormone, as it can 
modulate gut motility, stress response, sleep, learning, memory, cellular prolifera-
tion, differentiation and survival, immune response, energy homeostasis, glucose ho-
meostasis, and insulin secretion (29, 30). UAG has several biological functions which 
are mediated independently from the GHSR1a receptor, and metabolic actions that 
counteract AG action. For example, AG displays diabetogenic actions such as suppres-
sion of glucose-stimulated insulin secretion and insulin sensitivity (31-38), while UAG 
shows the opposite (30, 31, 39). Although much work has been done, the cognate 
receptor(s) for UAG has yet to be identified. More about ghrelin is written in chapter 
6 of this thesis.
AcroMegAly
History
Acromegaly is a severe systemic disease most commonly caused by a benign GH-
secreting (somatotroph) pituitary adenoma leading to excessive GH and IGF-I levels 
(40). Excessive GH secretion causes gigantism if it occurs prior to epiphyseal fusion 
and acromegaly after this time. The term acromegaly is from Greek meaning “large 
extremities”, and was originally named by the French neurosurgeon Pierre Marie in 
1886, who provided the characteristic clinical description the disease (41). However, 
many other physicians before Marie have described acromegaly (42, 43). In 1567 the 
Dutch surgeon Johannes Wierus provided probably the first reliable medical descrip-
tion of acromegaly and gigantism (44).
General introduction and aims of the thesis
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Epidemiology
According to recent epidemiologic data, the estimated incidence of acromegaly is 
1.8-13.7 cases per 100.000 people and the annual incidence is 0.2-1.1 cases per 
100.000 people (45-51). The diagnosis of acromegaly is usually made in the fifth de-
cade of life. The duration of symptoms until diagnosis is considerable with a median 
diagnostic delay of 5 years with some delays of over 15 years have been reported (47, 
48, 52, 53). Many cases go unreported due to the insidious presentation and the lack 
of awareness of acromegaly among physicians.
Pathology
Acromegaly is almost always (≥95%) caused by a somatotroph adenoma. In very rare 
cases acromegaly may be caused by extrapituitary GH or GHRH hypersecretion from a 
pancreatic islet-cell tumour, bronchial carcinoid, or non-Hodgkin’s lymphoma (54-59). 
Somatotroph adenomas can be classified as densely and sparsely granulated subtypes 
based on their appearance under an electron microscope. Sparsely granulated so-
matotroph adenomas (SGSA) are characterized by a more aggressive clinical behavior 
than densely granulated somatotroph adenomas (DGSA), as they are more likely 
to represent invasive macroadenomas which express lower somatostatin receptor 
subtype 2 (SST2) protein expression and are resistant to first-generation long-acting 
somatostatin receptor ligand (SRL) therapy (60-63).
Clinical manifestations
The manifestations of acromegaly are due to the local effects of the pituitary tumour 
or the peripiheral actions of chronic GH and IGF-I hypersecretion (table 2). Central 
manifestations are mainly caused by large invasive macroadenomas and include head-
ache, visual field defects due to impingement of the optic chiasm, cranial nerve palsy 
due to impingement of cranial nerves III, IV, and VI causing diplopia, or nerve V leading 
to trigeminal facial pain. Peripheral manifestations include soft tissue hypertrophy 
leading to characteristic enlargement of the hands, nose, forehead, eyebrow, jaw 
and feet. Clinicians should be aware of the possibility of acromegaly in patients with 
two or more of the following comorbidities: new-onset diabetes, diffuse arthralgias, 
new-onset or difficult-to-control hypertension, cardiac disease including biventricular 
hypertrophy and diastolic or systolic dysfunction, fatigue, headaches, carpal tunnel 
syndrome, sleep apnea syndrome, diaphoresis, and loss of vision (64).
Active acromegaly unmasks the diabetogenic effects of GH. Prolonged exposure to 
GH and IGF-I leads to insulin resistance and overt diabetes. In the general population 
insulin resistance and diabetes are associated with increased body fat, which is hall-
mark of the metabolic syndrome. However, many patients with acromegaly present 
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with insulin resistance and diabetes despite having a “favourable” body composition 
with a decreased body fat mass and increased muscle mass (65, 66).
Uncontrolled acromegaly is associated with a reduced life expectancy. If patients 
achieve biochemical control life expectancy is similar to the general population, 
despite this many patients with acromegaly have a reduced quality of life (QoL) (40, 
67). Active acromegaly is associated with increased mortality. Normalization of GH 
and IGF-I levels largely reduces mortality to that of the general population (68).
Diagnosis
The biochemical diagnosis of acromegaly is based on demonstration of autonomous 
GH hypersecretion and elevated serum IGF-I levels. Due to the pulsatility and the 
short half-life of GH, concentration of GH may be undetectable in acromegaly pa-
tients (69). Measurement of single random GH levels is therefore not recommended. 
In contrast, serum IGF-I levels are relatively stable and show a log-linear correlation 
with GH (70), and have a long half-life of about 15 hours. In addition, IGF-I can be 
measured independent of time of the day and food intake. IGF-I serves as the integra-
tive biomarker of GH secretion. A normal IGF-I within the age adjusted normal limits 
effectively excludes the diagnosis of acromegaly. However, in non-clear cut cases with 
IGF-I levels just above or around the upper limit of normality, confirmation is required 
by showing a lack of suppression of GH to less than 1 μg/L following a documented 
hyperglycemia during an oral glucose tolerance test (OGTT) (64). In acromegaly 
patients with poorly controlled diabetes mellitus the oral glucose tolerance test is 
not reliable and serum IGF-I levels should be re-assessed when glycemic control has 
been established. Systemic illnesses, hepatic or renal failure, malnutrition, diabetes 
mellitus and oral oestrogens may decrease IGF-I levels which might result in false-
negative interpretations (64, 71, 72). False-positive elevated IGF-I levels can occur 
during pregnancy. Large variability inter-individual and intra-individual variability 
exists between the different IGF-I immunoassays (73). When monitoring IGF-I levels 
over time, it is recommended that the same immunoassay is used from laboratories 
that adhere to the international performance standards and use the appropriated 
normative data (74).
Following biochemical diagnosis, contrast enhanced magnetic resonance imaging (MRI) 
of the sellar region is required to assess tumour size, localization and invasiveness. 
A clinically relevant distinction which affects the surgical cure rates is microadeno-
mas (≤1 cm) and macrodenomas (≥1 cm), invasiveness in the cavernous sinus, and 
impingement of the optic chiasm. In adenomas close to the optic chiasm visual fields 
assessment should be performed.
General introduction and aims of the thesis
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treatment modalities
Surgery
Transsphenoidal surgery is the primary treatment for patients with small and, 
therefore, curable tumours or for large adenomas causing impingement of the optic 
chiasm (75, 76). Surgical results depend on preoperative GH and IGF-I levels, tumour 
table 1. Different clinical manifestations of acromegaly
clinical manifestations of acromegaly
Local tumour effects
Visual field defects
Headache
Cranial nerve palsy
Metabolic
Impaired glucose tolerance
Hyperinsulinemia and insulin resistance
Diabetes mellitus
Lipids
Hypertriglyceridemia
Endocrine – hypopituitarism
Erectile dysfunction
Galactorrhoea
Amenorrhea
Secondary thyroid deficiency
Secondary adrenal deficiency
Cardiovascular
Hypertension
Arrhythmias
Cardiomyopathy
Ventricular hypertrophy
Congestive heart failure
Pulmonary
Central and obstructive sleep apnoea
Dermatological
Skin tags
Hyperhidrosis
Acanthosis nigricans
Gastrointestinal
Adenomatous colon polyps
Dolichocolon
Neuropsychological
Somatic
Acral enlargement
Frontal bossing
Prognathism
Macrognathia
Diastema
Carpal tunnel syndrome
Arthralgias
Osteoarthritis
Decreased bone quality
Vertebral fractures
Myopathy
Visceromegaly
Goitre
Macroglossia
Hepatomegaly
Splenomegaly
Renal hypertrophy
Mineral
Hypercalciuria
Hyperphosphaturia
Increased levels 25-hydroxyvitamin D3
Renal
Increased aldosterone levels
Nephrolithiasis
Psychological
Impaired quality of life
Decreased self-esteem
Depression
16
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invasiveness and surgical skills. Surgery is the treatment of choice for microadenomas 
and well-defined intrasellar macroadenomas. In these cases experienced surgeons can 
achieve remission rates of about 80%, defined as postoperative normalization of IGF-I 
levels and suppression of GH levels to < 1 mg/l after an oral glucose load. These rates 
can drop to 20-30% for macroadenomas. For macroadenomas that are not entirely 
surgically resectable (eg, those with cavernous sinus extension) surgery may be con-
sidered with the goal of debulking the tumour mass. Debulking seems to increase the 
efficacy of postoperative treatment with SRLs (77-79), although conflicting data were 
reported as well (80). Preoperative treatment of macroadenomas with SRLs has been 
shown to improve surgical outcome (81-84). Successful surgery is accompanied by a 
rapid fall in GH and IGF-I levels and the costs are relatively low compared to life-long 
drug therapy, although the efficacy of surgery might be overestimated as the data on 
surgical outcome are almost exclusively reported from high specialist centers. In the 
United Kingdom, an efficacy rate for microadenonomas < 37% and for macroadenomas 
< 20% has been reported, for all centres together (85).
Radiotherapy
During the early 1900s radiotherapy was the treatment of choice for acromegaly (86, 
87). To date, radiotherapy (RT) is considered a third line of treatment for acromegaly 
in most centres. Currently, RT is recommended for patients with residual tumour 
mass following surgery and medical therapy, and if medical therapy is not tolerated, 
unsuccessful, or unavailable (88-90). The method with the longest experience is con-
ventional radiotherapy (CRT). CRT is administered in 20-30 fractions with a total dose 
of 40-45 Gray (91). CRT induces remission in about 50% of patients after a follow-up 
of 10 years. However, radiation-induced hypopituitarism is the main side-effect of 
all types of CRT, as 50-80% of patients develop pituitary insufficiencies within 5 to 10 
years (92-94). Another drawback is that it takes sometimes years before RT induces 
biochemical remission, which comes along with a negative impact on quality of life 
(95). Analyses of the UK acromegaly database showed that CRT was associated with an 
increased mortality risk, and cerebrovascular disease as the main cause of death (96). 
Additionally, studies assessing QoL observed a lower QoL in patients treated with CRT 
that further decreased during follow-up (95, 97, 98). Joint problems are important 
factors affecting the QoL after radiotherapy (97). Other rare but severe side-effects of 
CRT include, optic neuropathy, radiation-induced cerebral tumours, cerebrovascular 
disease, and regrowth of pituitary adenomas. Stereotactic radiosurgery (SRS) methods 
has been developed with the aim to provide more precise targeting of the tumour and 
therefore less targeting of healthy brain tissue. SRS may be more safe than CRT, but 
long-term studies evaluating safety are lacking at the moment (99).
General introduction and aims of the thesis
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Medical therapy
Dopamine agonists
Under normal physiological conditions dopamine stimulates GH secretion (100, 101). 
However, in the 1970s it was discovered that administration of L-DOPA paradoxically 
reduced GH hypersecretion in patients with acromegaly (102). Subsequently, dopa-
mine receptors (DR) were found on somatotroph adenomas (103). Of the 5 distinct 
DR subtypes, the D2 receptor (DR2) is the predominantly expressed DR subtype (104, 
105). Until the 1980s dopamine agonists (DA) have been the only class of pharmaceu-
tical agents available for acromegaly. Bromocriptine is a first-generation DA which 
normalized IGF-I levels in only about 10% of patients (106). Cabergoline is a second-
generation ergot derivative DA with a high affinity for DR2, and has been used as 
monotherapy and in combination with SRLs (107). Due to its higher efficacy and better 
tolerability it has replaced bromocriptine as the DA of choice for treatment of hyper-
prolactinemia. Because cabergoline has a modest efficacy of about 30% in normalizing 
only IGF-I levels (< 1.5 x ULN) (88, 108). Cabergoline monotherapy is considered a 
good add-on therapy in patients with partial response to SRLs, and for patients with no 
access to pegvisomant (107, 109). Cabergoline can be taken orally and is inexpensive. 
It has a favourable safety profile, the adverse effects of cabergoline are considered 
mild and include postural hypotension, headache and nausea (110). Seldomly, psycho-
logical symptoms such as psychosis and impulse control disorders have been reported 
(111-113). Furthermore, long-term use of very high doses of cabergoline (3.5 mg/
day) has been linked to valvular heart disease in patients with Parkinson’s disease 
(114, 115). Although patients with acromegaly use much lower doses of cabergoline, 
active acromegaly itself is associated with increased risk of valvular heart disease 
(116-119). However, latest data from a longitudinal study showed no increased risk 
between cabergoline-treated acromegaly patients and a matched control population 
with untreated acromegaly (120).
Somatostatin receptor ligands
Somatostatin (SST or SRIF) was discovered in 1973 by the group of Roger Guillemin 
as the first hypothalamic hormone to regulate GH secretion (121). Somatostatin 
exerts inhibitory effects on hormone secretion from the pituitary, pancreas and the 
gastrointestinal tract (122). SST is a cyclic peptide with two active isoforms present 
in the circulation, SRIF-14 and SRIF-28. The biological effects of SST are mediation 
by its binding to five G protein-coupled receptor (GPCR) subtypes of somatostatin 
receptors (SSTs) (123, 124). SST are widely expressed in tissue specific patterns. 
In the normal human foetal pituitary gland all five SSTs expressed, but SST2 and 
SST5 are most important for regulation of hormone secretion (125). Somatotroph 
18
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adenomas mainly express SST2, SST5 and to a lesser extent SST1 (126-131) (table 1). 
In the pancreas SST is an important regulator of glucose homeostasis, as it tightly 
regulates the secretion of insulin, glucagon and GLP-I. α-cells which produce glucagon 
express mainly SST2, β-cells which produce insulin express predominantly SST5 and to 
a lesser degree SST1, and δ-cells which produce SSTR-14 express mainly SST5. Further-
more, enteroendocrine L-cells located in the ileum and colon, which produce GLP-I 
express mainly SST5 (132-135).
Although native SST has potent anti-proliferative and anti-secretory effects on dif-
ferent tissues, it is clinically not useful due to its very short half-life of less than 3 
minutes and the post-infusion rebound phenomenon (136). These limitations have 
been overcome by the development of more stable somatostatin receptor ligands 
(SRLs) which have a longer half-life and increased affinity for SSTRs. The short-
acting immediate release SRLs, octreotide (137) and lanreotide (138) were initially 
developed. These first-generation SRLs show preferential binding to SST2 and have an 
increased half-life of about 2 hours allowing for multiple daily injections. To date, 
more practical long acting depot formulations octreotide Long Acting Release (octreo-
tide LAR) and lanreotide autogel (lanreotide ATG) are used which allow for 4 weekly 
injections. Both formulations are equivalent in terms of efficacy, but differ in their 
mode of administration; lanreotide is available in pre-filled syringes injected deep 
subcutaneously and octreotide LAR requires reconstitution before being injected in-
tramuscularly (139, 140). First-generation SRLs represent the first line medical treat-
ment for acromegaly (141). High SST2 protein expression of the somatotroph adenoma 
is the main pathophysiological rationale for their efficacy in acromegaly. Biochemical 
normalization of IGF-I and GH levels can be achieved in about 40% of treatment-naïve 
patients with SRLs (142, 143). Clinically relevant tumour volume reduction of over 
20% is frequently observed (40-63%) during SRL treatment and the decrease in GH 
levels generally occurs within the first 4 months (143-147). SRLs have a favourable 
safety and tolerability profile. Relatively few side effects do occur; in the first few 
weeks transient mostly self-limiting gastrointestinal complaints such as abdominal 
discomfort, nausea and steatorrhea occurs in most patients (148). Asymptomatic 
gallbladder stones or bladder sludge can develop in the first 18 months in up to 20% 
of patients (149). In 2018, Cozzolino and co-workers published a large meta-analysis 
of 47 prospective interventional trials studying the effect of first generation SRLs on 
glucose homeostasis in 1297 patients with acromegaly (150). The authors show that 
both lanreotide ATG and octreotide LAR significantly reduced insulin secretion which 
was not (completely) counterbalanced by the reduction in GH and IGF-I levels (150). 
In general, the net effect of SRLs on glucose metabolism is considered marginal, but 
it is clinically relevant in patients with insulin resistance and overt diabetes.
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Pegvisomant
The GH molecule has two sites which interact with the extracellular region of the 
GHR performed dimer. Site 1 of the GH molecule interacts with one the GHRs and 
then GH site 2 interacts with the other GHR which leads to a functionally dimerized 
complex that induces GH-dependent intracellular signalling (152). Glycine at position 
120 of the third alpha helix in binding site 2 of GH is crucial for GH action. In the 
early 1990s it was discovered that substitution of this glycine by lysine blocks intracel-
lular signalling, converting GH into a GHR antagonist (153). Additional mutations in 
binding site 1 increased the affinity of PEGV to the GHR. Due to the short half-life 
of GH, the GHR antagonist was PEGylated by covalent addition of 4 to 6 5-kDa linear 
polyethylene glycol (PEG) molecules, extending the half-life to about 70 hours, which 
resulted in the marketed drug pegvisomant (PEGV; Somavert®) (154). PEGV itself 
can form dimers with the GHR and is internalized by the GHR, but does not induce 
GH-dependent intracellular signalling (155). Recently it has been shown that PEGV 
also inhibits GHR nuclear localization (156).
PEGV was approved in the United States in 2003 followed by approval in Europe in 
2004 (154, 157). It is currently used as a second line therapy in patients that are in-
adequately controlled with SRLs monotherapy (88). Early clinical trials demonstrated 
IGF-I normalization in over 90% of patients resistant to SRL (158-160). Because PEGV 
is a competitive GHR blocker, virtually all patients with acromegaly can be controlled 
provided that the treating physicians adequately titrate the dose of PEGV. More re-
cent real-life registry studies showed lower IGF-I remission rates of 60-70% (161-163), 
which is mainly attributed to an inadequate dose titration of PEGV.
table 1. SST expression in normal pituitary and in somatotroph adenoma. Binding affinities of the 
difference somatostatin analogues to the five somatostatin receptor subtypes (SST1-5)
SST1 SST2 SST3 SST4 SST5
Somatotroph adenomas 60%
+
95%
+++
45%
+
<5%
−
90%
++
somatostatin receptor ligands
SRIF-14 0.1-2.26 0.2-1.3 0.3-1.6 0.3-1.8 0.2-0.9
Octreotide 280 0.38 7.1 >1000 6.3
Lanreotide 180 0.54 14 230 17
Pasireotide 9.3 1.0 1.5 >100 0.16
The percentage somatostatin receptor subtype (SSTR) expression and the quantitative estima-
tion of receptor expression in somatotroph adenomas. In the rows below the binding affinities 
of endogenous somatostatin and the different somatostatin analogues is shown, expressed as IC50 
values nmol/L (124, 136, 151).
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Treatment with PEGV results in a rapid fall of serum IGF-I levels which usually leads 
to a paradoxical rise of serum GH levels, due to the negative feedback loop via the 
hypothalamus and the pituitary (159, 164). Cross-reactivity between PEGV and en-
dogenous GH in commercial assays disables proper assessment of the endogenous GH 
levels (165). For these reasons GH cannot be reliably assessed in patients treated with 
PEGV, unless specific assays are used (166). Therefore, the key biomarker during the 
treatment of PEGV are serum IGF-I level with specific signs such as ring-size and body 
fat mass.
SRL and PEGV combination treatment
Because the majority of acromegaly patients are resistant to SRLs, additional thera-
pies are required to achieve control of disease activity. Combining SRLs with PEGV 
combination treatment has several advantages because of their different mode of 
action. The first advantage of combination treatment is the much lower (around 
50%) required weekly dose of PEGV (164). Because SRLs inhibit GH secretion, PEGV 
encounters less competition of endogenous GH around the GHR resulting in a lower 
necessary dose of PEGV to block all GHRs during combination therapy and addition-
ally reduces the number of GHRs on the hepatocytes (164, 167, 168). In addition, 
combination treatment induces a 20% increase in PEGV serum levels than during PEGV 
monotherapy (169). The underlying mechanism for the observed rise in PEGV serum 
levels remains unknown (170). Besides direct inhibition of pituitary GH secretion, 
which leads lower hepatic IGF-I production, SRLs have also non-pituitary action on 
IGF-I production. SRLs can indirectly suppress hepatic IGF-I production by reducing 
portal insulin levels, which leads to a reduction in hepatic GHR expression (171). 
In addition, data from rodent studies has demonstrated that somatostatin can also 
directly suppress hepatic IGF-I production and possibly receptor-mediated clearance 
of GH (172). Taken together, these data suggest that SRLs induce a state of GH resis-
tance in the liver, while peripheral extra-hepatic tissues might still be exposed to GH 
excess. Blocking peripheral GH action using PEGV can therefore be useful in treating 
extra-hepatic acromegaly (173). Based on this concept Neggers et al demonstrated 
in a prospective double blind placebo controlled crossover study that low doses of 
PEGV may improve quality of life in patients controlled with SRL monotherapy (174). 
Furthermore, PEGV is the treatment of choice for acromegaly patients with insulin 
resistance or diabetes, as it has beneficial effects on glucose metabolism. PEGV im-
proves hepatic and peripheral insulin sensitivity, reduces hepatic gluconeogenesis and 
reduces free fatty acids (175-180).
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Safety
The most common adverse events associated with the use of PEGV are transient 
elevated liver transaminases (TETs) >3 times the upper limit of normal which seemed 
to occur more frequently during combination treatment (162, 164, 167, 168, 181). 
Although many risk factors have been brought forward, the underlying pathophysiol-
ogy of PEGV-induced TET development remains unclear (167, 168, 182, 183). The 
incidence of lipodystrophy at the injection site was reported in 3% of patients, but is 
clinically not significant as it regresses in most patients when PEGV is discontinued 
(184). Initially there were concerns that the reduced pituitary feedback inhibition 
from GH blockade would stimulate growth of the pituitary tumour (remnant). How-
ever, there is currently is no clear evidence that PEGV causes a clinically significant 
increase in tumour size. Therefore, PEGV can be considered as a safe approach, 
especially when combined with SRLs
Pasireotide
Pasireotide long-acting release (PAS-LAR) was approved by the FDA and EMA in 2014 
and is the only second-generation SRL on the market. Pasireotide is a stable cyclo-
hexapeptide showing high affinity to multiple SSTRs, with the highest affinity to SST5 
followed by SST2, SST3 and SST1 compared with SRIF, octreotide and lanreotide (151). 
The higher affinity for SST5 (and to other SSTRs) forms the pathophysiological rational 
for the use of pasireotide in acromegaly. Besides its broader SSTR binding profile, 
pasireotide has unique functional post-receptor effects. SSTR activation and traffick-
ing are modulated in a manner distinct from SRIF and octreotide. Pasireotide shows 
lower SST2 internalization, less β-arrestin mobilization and lower activation of second 
messenger pathways such as lower activation of ERK pathway, less increase of intra-
cellular Ca2+ and less cAMP inhibition (185-187). Therefore, pasireotide is considered 
to be a biased agonist for SST2.
Efficacy
Two phase III studies reported the efficacy of PAS-LAR treatment in acromegaly (188, 
189). The C2305 trial was double blind randomized head-to-head superiority study 
between PAS-LAR and octreotide LAR in medically naïve acromegaly patients (190). 
After one year of treatment, IGF-I normalization was achieved in significantly more 
patients using PAS-LAR (38.6%) than octreotide LAR (23.6%). However, GH reduction 
(≤2.5 g/L) was similar between patients using PAS-LAR (48.3%) and octreotide LAR 
(51.6%) (190). In the PAOLA study patients with acromegaly who were inadequately 
controlled despite ≥ 6 months treatment on maximum doses of first-generation 
SRLs were randomly assigned to pasireotide LAR at 40 mg, 60 mg, or continued 
on their treatment with octreotide LAR or lanreotide ATG (active control) (189). 
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After 24 weeks, biochemical control was achieved by 15% of patients using pasireotide 
LAR 40 mg and 20% using PAS-LAR 60 mg, compared with no patients in the active 
control group (189).The extension phase of both studies showed comparable response 
rates (191, 192). Also, about 17% of the patients with inadequate biochemical control 
after 12 months of treatment with octreotide LAR, achieved biochemical control after 
switching to PAS-LAR treatment (193). Although the effects of PAS-LAR and octreotide 
LAR treatment on the reduction of GH levels were superimposable in the C2305 study, 
PAS-LAR treatment was more effective in lowering IGF-I levels (188, 194).
Tumour volume reduction
Results from a phase II study in 61 patients with active acromegaly showed that treat-
ment with short-acting pasireotide resulted in clinically significant (>20%) tumour vol-
ume reduction in 39% of patients after 3 months of treatment, which increased to 54% 
after 6 months of treatment (195). However, in the C2305 study PAS-LAR and octreotide 
LAR treatment were equally effective in reducing tumour volume (188). In the PAOLA 
study, tumour volume reduction occurred more frequently in patients using PAS-LAR 
40 mg (19%) and 60 mg (11%), than in patients in the active control group (2%) (189). 
This finding is not entirely surprising because it is plausible that patients who were in-
adequately controlled with first-generation SRLs are more likely to respond to PAS-LAR 
treatment than medically naïve patients. The mean decrease in tumour volume during 
the extension study was 25% for crossover to PAS-LAR and 18% for crossover to octreo-
tide LAR, while 54% of PAS-LAR treatment and 42% of octreotide LAR patients achieved 
significant tumour volume reduction (193). Taken together, these clinical studies sug-
gest that PAS-LAR might exert a greater effect on tumour control in patients that show 
no tumour shrinkage after first-generation SRL treatment. In addition, patients with 
large tumours due to genetic causes such aryl hydrocarbon receptor-interacting protein 
(AIP) mutations and X-linked acrogigantism are frequently resistant to first-generation 
SRL, and could therefore be more responsive to PAS-LAR treatment (196-198).
Quality of life and symptoms
In medically naïve patients, PAS-LAR and octreotide LAR showed similar improvements 
in acromegaly symptoms score (188). In the PAOLA study, the patients in the PAS-LAR 
treatment groups showed more improvement in acromegaly symptoms than patients 
in the active control group (189). As mentioned above, the observed improvement in 
acromegaly symptoms in the PAS-LAR treatment groups was to be expected. Neverthe-
less there is evidence that pasireotide has an analgesic effect on headache symptoms 
of acromegaly patients (190, 199-201).
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Safety
PAS-LAR is generally well-tolerated and has a comparable safety profile to first-
generation SRLs, except for a greater frequency and degree of hyperglycemia-related 
adverse events (188, 189). Hyperglycemia-related adverse events were reported in 
57.3% of patients treated with PAS-LAR and in 21.7% of patients treated with oc-
treotide LAR in the C2305 study (188). In the PAOLA study, hyperglycaemia-related 
adverse events occurred in 65% of patients treated with pasireotide LAR and 30% of 
patients in the active control group (189). Hyperglycaemia occurred early after drug 
initiation, with fasting plasma glucose (FPG) and glycosylated haemoglobin (HbA1c) 
levels increasing in the first 3 months, and plateauing thereafter with additional 
antidiabetic medication (192). In the ACCESS study, designed to assess the safety 
of PAS-LAR treatment in patients with acromegaly, hyperglycaemia-related adverse 
events were reported in 46% of patients and about 9% discontinued PAS-LAR because 
of hyperglycaemia (202). Predictors for pasireotide-induced hyperglycaemia were 
higher baseline glucose levels (FPG >5.55 mmol/l) and patients receiving antidia-
betic medication (203). Mechanistic studies in healthy volunteers have revealed that 
pasireotide inhibits secretion of insulin, glucagon-like peptide I (GLP-I) and gastric 
inhibitory polypeptide (GIP), and modestly suppresses glucagon secretion. However, 
pasireotide did not affect hepatic or peripheral insulin sensitivity as evaluated with 
the hyperinsulinaemic-euglycaemic clamp test and OGTT (204, 205). The effects of 
pasireotide on insulin, glucagon and incretin secretion can be explained from its SSTR 
binding profile. SST5 is known to be expressed on pancreatic β-cells which mediate 
insulin secretion, but also on enteroendocrine L-cells which produce GLP-I (132-134). 
In contrast SST2 is mainly expressed on pancreatic α-cells which mediate glucagon 
secretion (206, 207), which may explain the modest effect of pasireotide on glucagon 
secretion.
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Scope and Aims of the Thesis
Over the last decade SRL and PEGV combination treatment has been established as 
an effective and safe second line treatment modality for acromegaly patients with 
inoperable pituitary adenomas and who are refractory to medical treatment. In the 
Rotterdam cohort over 90% of patients achieved IGF-I normalization with combination 
treatment. Despite this high efficacy, PEGV poses an economic burden due to its high 
treatment costs. Furthermore, 4 weekly SRL injections and daily to weekly PEGV 
injections may negatively impact long-term adherence and quality of life of patients. 
With the goal to improve patient adherence we hypothesized that it is possible to 
temporarily withdraw SRL treatment in patients using combination treatment. There-
fore, in chapter 2 we aimed to determine the efficacy of temporary withdrawal of 
SRL treatment and switch to (twice) weekly PEGV monotherapy in patients controlled 
with combination treatment. For how long can biochemical control be maintained 
without a need to increase the PEGV dose?
As PAS-LAR has demonstrated superior efficacy over first-generation SRL and is ap-
proved a second line medical treatment for acromegaly, the question arises what 
the position is of PAS-LAR in relation to PEGV in the modern medical management of 
acromegaly. Switching from SRL and PEGV combination treatment to PAS-LAR could 
lead to a reduction in the PEGV dose required to control disease activity. A lower 
PEGV dose and/or less PEGV injections (i.e. PEGV sparing effect) could contribute to 
an improvement in quality of life and patient convenience. What is the safety of PEGV 
and PAS-LAR combination treatment? Especially with respect on glucose metabolism? 
What are predictors for pasireotide-induced hyperglycaemia? To address these ques-
tions we conducted the Pasireotide LAR and PEgvisomant (PAPE) study, a prospective 
single-centre open-label trial to study the efficacy and safety of switching to PAS-LAR 
alone or in combination with PEGV in patient who were well-controlled with SRL and 
PEGV combination treatment. In chapter 3 the 24-weeks efficacy and safety results 
(PAPE core study) are presented.
chapter 4 focuses on the results of the extension phase until 48-weeks results. The 
main goal of the extension phase was to find the optimal PAS-LAR and PEGV dose to 
achieve IGF-I normalization. In addition, we aimed to investigate whether baseline 
insulin secretion as measured with the OGTT correlates with hyperglycaemia after 
PAS-LAR treatment during the study.
Based on the results of PAPE study we aimed to investigate in active acromegaly, 
whether the responsiveness to PAS-LAR treatment during the PAPE study correlated 
with the previous responsiveness to SRL monotherapy in the same patients. Secondly, 
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we assessed to what extent SST2 and SST5 protein expression on somatotroph adenoma 
were correlated to responsiveness to PAS-LAR treatment. It has previously been sug-
gested that SST5, and not SST2, protein expression of the somatotroph adenomas pre-
dicted responsiveness to PAS-LAR treatment (208, 209). In chapter 5 aimed to confirm 
whether this is indeed the case in our cohort of patients included in the PAPE study.
Ghrelin is an important peptide hormone regulated by the GH-axis and is modulated by 
medical treatment. In acromegaly SRL treatment reduces ghrelin levels, while PEGV 
treatment increased ghrelin levels. It is however unknown what the net effect of SRL 
and PEGV combination treatment is on ghrelin levels in acromegaly patients. Previous 
studies have only measured total ghrelin using unspecific radioimmunossay methods 
and have not distinguished between AG and UAG levels. Therefore, in chapter 6 
we aimed to assess plasma AG and UAG levels, and the AG/UAG ratio in acromegaly 
patients on SRLs and PEGV combination treatment, compared with the control groups 
using PEGV monotherapy and medically naïve patients.
PEGV is approved for the medical treatment of acromegaly since 2003. Patients are 
long-term exposed to high doses of PEG compared with other PEGylated biological 
drugs. Little is known about how PEGV is cleared from the body and which type of 
cells are involved. We postulated that PEGV is cleared by the mononuclear phagocyte 
system (MPS) because PEG is considered to be a non-biodegradable molecule. Kupffer 
cells are the most important macrophages of the MPS and have been reported to clear 
PEGylated nanomaterials in a previous study. In chapter 7 we presented the finding 
of a pilot study in which we assessed in two acromegaly patients whether PEGV is 
expressed in the liver, and if so whether Kupffer cells are involved in the clearance of 
PEGV using immunofluorescence studies.
chapter 8 provides a summary of the generated data, critically reviews the strengths 
and limitations of the aforementioned studies and brings forward future perspectives 
of outstanding questions. The discussion section is ended by presenting our clinical 
recommendations on the position of PAS-LAR in the modern medical management of 
acromegaly.
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Chapter 2
AbstrAct
context: While combination therapy of acromegaly with long-acting somatostatin 
analogues (LA-SSAs) and pegvisomant (PEGV) normalizes insulin-like growth factor-I 
(IGF1) levels in the majority of patients, it requires long-term adherence. Switching 
from combination therapy to monotherapy with weekly PEGV could improve patient 
comfort, but the efficacy is unknown.
objective: to assess the efficacy of switching to PEGV monotherapy in patients well 
controlled on combination therapy of LA-SSAs and PEGV.
design: Single center, open-label observational pilot study. LA-SSA therapy was dis-
continued at baseline and all patients were switched to PEGV monotherapy for 12 
months. If IGF1 levels exceeded 1.0 times upper limit of normal (ULN), PEGV dose was 
increased by 20 mg weekly.
subjects and methods: 15 subjects (8 males) were enrolled, with a median age of 58 
years (range 35-80) on combination therapy of high-dose LA-SSAs and weekly PEGV for 
>6 months, and IGF1 levels within the normal range. Treatment efficacy was assessed 
by measuring serum IGF1.
results: After 12 months of weekly PEGV monotherapy, 73% of the subjects’ IGF1 
levels remained controlled. In one patient LA-SSA had to be restarted, due to recur-
rence of headache. IGF1 levels increased from a baseline level of 0.62 x ULN (range 
0.30-0.84) to 0.83 x ULN (0.30-1.75) after 12 months, while the median weekly PEGV 
dose increased from 60 (30-80) mg to 80 (50-120) mg.
conclusion: Our results suggest that switching from combination therapy of LA-SSAs 
and PEGV to PEGV monotherapy can be a viable treatment option for acromegaly 
patients without compromising efficacy.
What is the efficacy of switching to weekly pegvisomant in acromegaly patients?
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Introduction
Acromegaly is a rare disease characterized by somatic overgrowth and endocrine 
dysfunction due to excessive secretion of growth hormone (GH) and subsequent 
elevation of insulin like growth factor-I (IGF1) levels. In more than 90% of patients 
it is caused by a benign growth hormone-secreting pituitary adenoma (1). The main 
causes of death in acromegaly patients are cardiovascular and respiratory diseases (2, 
3). Normalization of GH and IGF1 levels will result in normal mortality rates, reduced 
morbidity and a reduction in symptoms (3).
The growth hormone receptor antagonist pegvisomant (PEGV) is the medical treat-
ment that has the highest reported efficacy (4). PEGV can be administered with or 
without long-acting somatostatin analogues (LA-SSAs) (5, 6). Administration of PEGV 
alone at a mean weekly dose of 130 mg can normalize IGF1 levels in over 90% of 
patients (7). If LA-SSAs and PEGV are used together, a similar efficacy of over 90% 
is achieved. However, a considerably lower mean weekly dose of 77-80 mg PEGV is 
required, this may result in a more cost-effective treatment.
Both LA-SSAs and PEGV are administered, respectively as intramuscular and subcuta-
neous injections. LA-SSAs are injected every four weeks, while PEGV can be injected 
either as a daily or as a weekly injection. While most studies on efficacy have been 
based on clinical trials that evaluated the daily injection (7, 8), only one study has 
assessed the weekly injection. Higham et al reported a normalization of IGF1 in 71% 
of acromegaly patients (n = 7) treated with weekly PEGV monotherapy (9).
Switching patients from combined therapy of LA-SSAs and PEGV to monotherapy 
with PEGV can reduce the total number of injections, and therefore improve patient 
adherence. In addition, PEGV monotherapy allows for easier dose adaptation.
In this pilot study, we assessed the effect of switching from combination therapy to 
weekly PEGV monotherapy. The main outcome parameters were the proportion of 
patients with normalized IGF1 levels after 12 months follow-up with weekly PEGV 
monotherapy.
subJects ANd MetHods
Patients
In 2009, a prospective observational study enrolled 15 subjects (8 males) with 
acromegaly from a single centre, who were treated with a combination of LA-SSAs 
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(13 Lanreotide Autogel, 2 octreotide LAR) and PEGV (table 1). These patients received 
combination therapy because their serum IGF1 levels exceeded the normal range or 
because their acromegaly symptoms persisted during high dose of LA-SSA monotherapy 
(5). Inclusion criteria for the present study were a stable LA-SSA dose, the use of PEGV 
as a weekly injection and biochemical remission for over 6 months before enrolment, 
defined by an IGF1 within the normal range for sex and age of < 1.0 ULN (8). The cause 
of acromegaly needed to be a GH secreting pituitary adenoma and the allowed dose of 
weekly PEGV was ≤ 80 mg. The median age of the study group was 58 (range 35 – 80) 
years. Three patients had received surgery of the pituitary adenoma in the past, while 
6 patients had been treated with both surgery and radiotherapy. Radiotherapy was 
administered at least 5 years before study entry. Six patients had only received medi-
cal treatment. Three patients had diabetes and were using oral medication, while one 
diabetes patient also used insulin. All patients gave their written informed consent, 
and the study was approved by our local IRB.
One patient had to be restarted with LA-SSAs during the study period due to a recur-
rence of symptoms and therefore did not want to continue with the PEGV alone. 
This patient was reported as uncontrolled and was censored from the results after 
withdrawal, but was counted as treatment failure.
table 1: Baseline characteristics of all subjects (n = 15)
N (%)
Demographics
 Sex, female 8 (53.3)
 Age, median (range) 58 (35 – 80)
Diabetes mellitus type 2 3 (20)
Previous treatments
 Transsphenoidal surgery 3 (20)
 Transsphenoidal surgery and radiotherapy 6 (40)
 Primary medical therapy 6 (40)
Weekly PEGV dose (mg) – median (range) 60 (9.3 – 33.4)
Serum assessments median (range)
 IGF1 (nmol/L) 15.7 (9.3 – 33.4)
 IGF1 x ULN 0.62 of ULN (0.30 – 0.84)
 GH (μg/L) 3.03 (0.19 – 15.95)
 Glucose (mmol/L) 5.4 (3.4 – 20)
 HbA1c (mmol/L) 6.1 (5.1 – 9.2)
Long-acting somatostatin analogues
 Lanreotide Autogel 13 (87)
 Octreotide LAR 2 (13)
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Study
At the start of the study LA-SSAs were discontinued for 12 months and only PEGV 
was continued. Every 6 weeks patients visited our outpatient clinic for measure-
ments of IGF1 levels, HbA1c, glucose, insulin, cholesterol, free fatty acids (FFA), 
and triglycerides. During the visits, data on symptoms and safety assessments were 
collected and the dose of PEGV was adjusted if necessary. IGF1 levels were measured 
by immunometric assays (Diagnostic Products Corp., Los Angeles, CA) and were in-
terpreted according to the sex and age dependent ranges (10). GH and serum PEGV 
levels were measured at the start of the trial, after 6 months and after 12 months. 
Since endogenous GH was in the presence of PEGV, GH levels were measured using a 
specific assay free of interference of the drug (11). When IGF1 levels exceeded the 
normal range, the PEGV dose was further increased by 20 milligrams per week. This 
was continued until the IGF1 levels were within the normal range for sex and age and 
PEGV dose was not changed. Doses were divided into two equal portions per week 
when PEGV exceeded 80 mg. Efficacy of PEGV monotherapy was assessed 12 months 
after discontinuation of the combination therapy. Safety assessment included mea-
surement of serum alkaline phosphatase, γ-glutamyl transpeptidase (γ-GT), alanine 
aminotransferase (ALT), aspartate aminotransaminase (AST), lactate dehydrogenase 
and total bilirubin. A pituitary MRI was performed before study entry and after the 
study.
Statistics
Prism version 5.00 for windows (Graphpad Software, San Diego CA) was used for 
the statistical analyses of the data. Although the nature of the study was mainly 
descriptive, pertinent data were analysed by Wilcoxon’s signed-rank test. Statistical 
significance was defined by P <0.05 (two-tailed). Data are expressed as median ± 
(range), unless specified otherwise.
results
Efficacy
Fifteen patients were enrolled in this study. At baseline the IGF1 levels of all patients 
were controlled with a median IGF1 level of 62% of the upper limit of normal (ULN) 
(range 30 % to 84 %), (figure 1).
At 6 months, IGF1 levels started to increase to 100% of the ULN (range 43–220%). The 
slow increase of IGF1 started 12 weeks after cessation of the LA-SSA. At baseline, 
patients were using PEGV at a median dose of 60 mg (range 30–80 mg).
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After 12 months, median IGF1 levels increased to 83% (30–175%) of the ULN (P < 0.05) 
(figure 1). The median PEGV dose had been increased to 80 mg (50 – 120 mg) (P < 
0.05). IGF1 remained controlled in 11 of 15 subjects (73 %) after 12 months of weekly 
PEGV monotherapy.
At the start of the study median serum PEGV levels were 3.00 mg/L (0.25 – 19.44). 
After an initial decrease in serum PEGV levels 2.23 (0.44 – 12.10) at 6 months, PEGV 
levels increased to 4.36 mg/L (range 1.12 – 21.28) at 12 months. Between 6 and 12 
months the serum PEGV levels were significantly higher (p = 0.01), but no difference 
was found between baseline and 6 or 12 months.
We compared PEGV levels between the subjects in whom IGF1 levels were elevated 
and those who had levels that remained within the normal range after 12 months. We 
observed that after 12 months, acromegaly patients with an elevated IGF1 tended to 
have lower PEGV levels, this was 3.85 mg/L (1.30 – 4.39 mg/L) in non-controlled pa-
tients compared with 5.54 mg/L (1.12 – 21.28 mg/L) in controlled patients (p = 0.25). 
Weekly PEGV doses and increases in doses were not different between controlled and 
non-controlled patients: the baseline median PEGV dose was respectively 60 (30 – 80 
mg) in controlled versus 60 (40 – 80 mg) in non-controlled patients. After 12 months 
the respective median PEGV dose increased to 80 (50 – 120 mg) in controlled versus 
100 (80 – 120 mg) in non-controlled patients. The median increase in PEGV dose was 
+10 (0 – 60 mg) in those who were controlled after 12 months, while this was +40 
(20 – 40 mg) for those who were non-controlled.
figure 1. IGF1 levels at baseline and after 12 months of pegvisomant therapy. IGF1 levels ex-
pressed as times upper limit of normal, at baseline (n = 15) and after 12 months (n = 14). One 
patient restarted somatostatin analogues due to recurrence of symptoms.
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Five subjects did not require changes in PEGV dosing, since their IGF1 level remained 
within the age adjusted normal limits. All 5 had received combination therapy longer 
(5.88 (2.26 – 6.01) years) than the other 10 subjects (2.52 (1.48 – 6.39) years).
Over time the GH levels tended to increase during PEGV monotherapy. At baseline we 
measured 2.99 μg/L (range 0.19 – 15.95 μg/L) compared with 3.22 μg/L (0.12 – 79.14) 
at 6 months, and 6.36 μg/L (range 0.180 – 31.45 μg/L) at 12 months. The GH levels 
at baseline, 6 months and 12 months were significantly different (p<0.05), except for 
baseline vs. 12 months (p = 0.055).
Safety
No significant safety issues were observed during PEGV monotherapy. After 12 months 
glycosylated haemoglobin (HbA1c) decreased significantly from 6.0 % (5.1 – 9.2 %) to 
5.9 % (5.0 – 9.1 %) (p = 0.02). The patients with diabetes had no alterations to their 
anti-diabetic medication during the study. No significant elevation of liver enzymes 
was observed and the pituitary MR did not show any change in tumour-size. The 
one patient who withdrew from the study had severe headaches that resolved after 
reinitiating LA-SSAs.
dIscussIoN
In this study we followed 15 acromegaly patients who previously were biochemically 
controlled with LA-SSAs and weekly PEGV. These patients had been switched to combi-
nation therapy since their IGF1 levels could not be controlled by LA-SSA monotherapy. 
In this study, we discontinued LA-SSAs and continued with weekly PEGV monotherapy. 
At baseline, 100% of the subjects had IGF1 levels within the normal limits during 
combination therapy. After 12 months follow-up 73% remained controlled.
The efficacy of 73% is in the same range as the efficacy of 68% reported by the AC-
ROSTUDY group. However, we achieved this proportion of IGF1 normalization at a 
median PEGV dose of 80 mg/week after 12 months, whereas the ACROSTUDY group 
reported this at a median PEGV dose of 17.2 mg/day after 5 years, which corresponds 
to approximately 120 mg/week(12). The subjects enrolled in our study used relatively 
low doses of PEGV and had used the combination with LA-SSAs for at least 1.5 years. 
Since this may have had an impact on our results, these results cannot be extrapolated 
to all patients using combination therapy.
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The slow and gradual increase in serum IGF1 levels that we observed sixteen weeks 
after discontinuation of LA-SSAs is in line with the expected wash-out time of the LA-
SSAs and the carry-over effect of the LA-SSAs of about 15-20 weeks(5, 13, 14). During 
12 months of follow-up five of 15 patients did not need any dose adaptation. Although 
IGF1 levels also increased in these patients, they remained within the age-adjusted 
normal range. Combination therapy in these 5 patients lasted for longer, than for the 
other patients in the study. A longer period of treatment with LA-SSA might result in 
prolonged “suppression” of GH, which may improve the efficacy of PEGV, a competi-
tive inhibitor of the GH receptor(4). In the total population, single measurements of 
GH tended to increase at 6 and 12 months during the study. However, subjects in 
whom IGF1 remained within the normal range tended to have lower GH levels than 
those with elevated IGF1 levels.
Subjects in whom IGF1 levels increased after the discontinuation of the LA-SSAs 
tended to have lower PEGV serum levels, despite treatment with similar doses of 
PEGV. One would expect that PEGV levels would decrease after discontinuation of LA-
SSAs, since LA-SSAs increase the PEGV serum levels by approximately 20% compared 
with an identical dose of PEGV alone(6, 11). This observation explains the difference 
in PEGV levels between controlled and uncontrolled patients at 6 months, but not the 
difference in PEGV levels at 12 months. A potential explanation is that uncontrolled 
patients do not increase in PEGV serum levels as much as controlled patients when the 
weekly dose of PEV is increased. The large difference in serum PEGV levels between 
subjects has been reported before(15).
Possibly due to the small sample size of our study however, we found no association 
between PEGV dose and previously reported characteristics such as adiposity and 
body weight.
The one patient who was discussed in the safety analysis was withdrawn from the 
study because she suffered from severe headaches, even though IGF1 was controlled 
(98% of ULN). After recommencing LA-SSA co-treatment the headache disappeared. 
The pituitary MRI scan showed no explanation for the headache. In this specific case, 
we suspect that there was a causal relationship between discontinuation of LA-SSA 
and the headache. As expected, HbA1c levels decreased significantly in these patients 
in our study. However, the change was very small, and therefore of dubious clinical 
relevance.
This was a pilot study on monotherapy with weekly PEGV to assess whether ceasing 
LA-SSAs is a viable option in a selection of our patients on combination therapy. 
What is the efficacy of switching to weekly pegvisomant in acromegaly patients?
51
2
A drawback of this pilot is the small sample size. Nevertheless, our results suggest 
that a significant number of acromegaly patients on low-dose PEGV in combination 
with LA-SSAs can temporarily stop their LA-SSA treatment for at least a year. These 
treatment interruptions may improve patient adherence to the medication and reduce 
the economic burden of long-term use of expensive medications.
We conclude that discontinuing LA-SSAs and continuing with PEGV may be an inter-
esting alternative for a selected group of patients that are well-controlled with a 
combination of LA-SSAs and relatively low-doses of PEGV. It is possible to maintain 
biochemical control up to 12 months in a substantial number of patients without rais-
ing the dose of PEGV. In patients who have previously been treated for an extended 
time with LA-SSAs, there is no need to adjust therapy even after 12 months. It seems 
sensible to determine the usability of structured interruptions in medical therapy in 
patients with acromegaly in a larger study.
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AbstrAct
Aim: To assess the efficacy and safety of pasireotide long-acting release (PAS-LAR) 
alone or in combination with pegvisomant by switching acromegaly patients who were 
well-controlled with somatostatin analogues (LA-SSAs) and pegvisomant to PAS-LAR 
with or without pegvisomant.
Methods: 61 acromegaly patients were enrolled in a prospective open-label study. We 
included patients with an IGF-I ≤1.2 x Upper Limit of Normal (ULN) during treatment 
with LA-SSAs and pegvisomant. At baseline, the pegvisomant dose was reduced by 
50% up to 12 weeks. When IGF-I remained ≤1.2 x ULN after 12 weeks, patients were 
switched to PAS-LAR 60 mg monotherapy. When IGF-I was >1.2 x ULN, patients were 
switched to PAS-LAR 60 mg and they continued with the 50% reduced pegvisomant 
dose.
results: At baseline, mean IGF-I was 0.97 x ULN, while median pegvisomant dose was 
80 mg/week. At 12 weeks, mean IGF-I increased to 1.59 x ULN, while IGF-I levels ≤1.2 
ULN were observed in 24.6% of participants. At 24 weeks, IGF-I levels were reduced 
into the reference range in 73.8% of patients. Between baseline and 24 weeks the 
pegvisomant dose was reduced by 66.1%. PAS-LAR was well tolerated, while hyper-
glycemia was the most frequent adverse event. The frequency of diabetes increased 
from 32.8% at baseline to 68.9% at 24 weeks.
conclusions: Switching to PAS-LAR, either as monotherapy, or combination with pegvi-
somant, can control IGF-I levels in the majority of patients. PAS-LAR demonstrated 
a pegvisomant sparing effect of 66% compared to the combination with LA-SSAs. 
Hyperglycemia was the most important safety issue.
Efficacy and safety of switching to pasireotide in acromegaly patients (core study)
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INtroductIoN
Acromegaly is an endocrine disorder predominantly caused by a pituitary adenoma 
characterized by excess growth hormone (GH) and insulin-like growth factor I (IGF-I) 
secretion. Persistently elevated GH and IGF-I levels result in reduced life-expectancy, 
reduced quality of life and multisystem comorbidities (1). Normalization of IGF-I and 
GH normalizes life-expectancy and improves quality of life and comorbidities (2). 
Current medical treatment regimens focus on inhibiting pituitary GH hypersecretion 
and blocking peripheral GH actions.
First-generation long-acting somatostatin analogues (LA-SSAs) such as octreotide 
long-acting repeatable (LAR) and lanreotide Autogel (ATG) are the cornerstones of 
pharmacological treatment of acromegaly. They inhibit pituitary GH secretion by 
preferential binding to somatostatin receptor subtypes 2 and 5 (SST2, SST5). In clini-
cal practice only about 40% of patients treated with monotherapy LA-SSAs achieve 
biochemical normalization of GH and IGF-I. Therefore, most patients treated with 
LA-SSAs need additional therapies (3-5).
The GH receptor antagonist pegvisomant (PEGV) is a competitive GH receptor blocker, 
and the most effective drug to normalize IGF-I levels in acromegaly. IGF-I normaliza-
tion can be achieved in 60 to over 90% of patients, provided that the dose is sufficiently 
increased (6-11). Importantly, PEGV improves glucose homeostasis by increasing he-
patic and peripheral insulin sensitivity, even after normalization of GH and IGF-I levels 
(12-15). Combination treatment of LA-SSA and PEGV shows similar high efficacy of over 
90%, with the added benefit of lowering the required PEGV dose (16, 17).
Pasireotide LAR (PAS-LAR) is a second-generation LA-SSA which targets multiple soma-
tostatin receptors, with the highest affinity for SST5, followed by SST2, SST2 and SST1. 
Compared with octreotide and lanreotide, pasireotide has a higher affinity for SST5 
and lower affinity for SST2 (18). PAS-LAR has been shown to provide superior clinical 
efficacy over octreotide LAR. This has been shown in two clinical trials, in treatment-
naïve acromegaly patients and in patients inadequately controlled with LA-SSAs (19, 
20). Although the effect of PAS-LAR and octreotide LAR on the reduction of GH levels 
is superimposable, PAS-LAR appears to be more effective in lowering IGF-I levels (19).
PAS-LAR has a similar safety profile to the LA-SSAs, with the exception of a higher 
frequency and degree of hyperglycemia-related adverse events, which have been 
reported in about 60% of patients (19). These are presumably caused by a suppression 
of insulin secretion and a reduced incretin response (21-23).
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The combination treatment of PEGV with PAS-LAR has not been extensively studied 
yet. A potential advantage of this combination may be a reduction in the PEGV dose 
to control acromegaly activity. This PEGV sparing effect of PAS-LAR could lead to a 
reduction in the number of patients that need PEGV co-treatment, or a reduction in 
the number of injections of PEGV and, thereby, a reduction of costs of this treatment.
The effects of combination treatment of PEGV and PAS-LAR on glucose homeostasis 
are unknown. We hypothesized that the improvement of glucose homeostasis with 
PEGV may offset pasireotide LAR-induced hyperglycemia.
The aim of the present study was to assess the efficacy and safety of PAS-LAR alone, or 
in combination with PEGV by switching acromegaly patients who were well-controlled 
with LA-SSAs and PEGV to PAS-LAR with or without PEGV in a prospective open-label 
trial.
MetHods
study design
The PAPE study is a 24 weeks, prospective, single-center, open-label, investigator-
initiated conversion study. We recruited patients from the Erasmus University Medical 
Center outpatient clinic. After enrolment, LA-SSA treatment was continued, and the 
PEGV dose was reduced by 50% in the first 12 weeks (run-in phase, figure 1).
When IGF-I levels remained within the reference range (IGF-I ≤1.2 x ULN) after 12 
weeks, patients were switched to PAS-LAR 60 mg monotherapy every 4 weeks. When 
IGF-I levels exceeded 1.2 x ULN after 12 weeks, patients were switched to PAS-LAR 
60 mg, while the 50% reduced PEGV dose was continued. Between 12 and 24 weeks 
dose adaptations of PEGV were not permitted unless IGF-I decreased below the age 
adjusted normal limits. In that case, the dose of PEGV was decreased by 20 mg weekly, 
until IGF-I increased to age-specific reference ranges. PAS-LAR injections were ad-
ministered at home by endocrine nurses, and PEGV injections were administered by 
patients themselves.
The study was conducted in accordance with the ethical principles of the Declaration 
of Helsinki and reported in accordance with the International Conference on Harmoni-
sation Harmonised Tripartite Guideline for Good Clinical Practice. The study protocol 
was approved by the medical ethics committee of the Erasmus University Medical 
Centre. An independent Data Safety Monitoring Board (DSMB) was established for the 
Efficacy and safety of switching to pasireotide in acromegaly patients (core study)
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purpose of safety surveillance, to perform interim analyses on the safety and efficacy 
data, and to evaluate patient safety and scientific integrity. The DSMB consisted of a 
clinical expert in endocrinology and a clinical epidemiologist. All patients provided 
written informed consent to participate in the PAPE study. This study was registered 
with ClinicalTrials.gov, number NCT02668172, the Dutch Trial Register and the WHO 
International Clinical Trials Registry Platform, number NTR5282.
Patients
We enrolled 61 (32 male) patients, aged 18 years or older, with well controlled ac-
romegaly (defined as IGF-I concentration ≤1.2 times the age and sex-adjusted Upper 
Limit of Normal [ULN]). Eligible patients had received entry combination treatment 
with weekly PEGV and monthly injections of either 30 mg octreotide LAR or 120 mg 
lanreotide ATG for at least 6 months prior to study. Eight patients received LA-SSAs 
every three weeks. Two patients who also used the dopamine-receptor agonist caber-
goline were also included, but their dose of cabergoline was not changed during the 
study period. Key exclusion criteria included; diabetic patients with poor glycemic 
control, defined as HbA1c levels ≥9.0%; pituitary surgery or radiotherapy within the 
previous 6 months; patients with compression of the optic chiasm causing any visual 
field defect that required acute surgical intervention; patients with risk factors for 
figure 1. PAPE study design.
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torsades de pointes, i.e. patients with a baseline QTcF >450 ms in males and >460 
ms in females; patients who had congestive heart failure (NYHA Class III or IV), un-
stable angina, sustained ventricular tachycardia, clinically significant bradycardia, 
advanced heart block, history of acute MI less than one year prior to study entry or 
clinically significant impairment in cardiovascular function; patients diagnosed with 
liver disease such as cirrhosis or chronic active hepatitis; patients with an abnormal 
hepatic function, defined as alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), gamma-glutamyltransferase, alkaline phosphatase, or total bilirubin 
> 3 times the upper normal limit; patients with symptomatic cholelithiasis and or 
chronic pancreatitis; patients with renal insufficiency defined as clearance < 50 ml/
min; patients with hypothyroidism or adrenal insufficiency who are not on adequate 
replacement therapy.
Procedures
Blood measurements
Total IGF-I, IGFBP3, GH concentrations were measured with the commercially avail-
able immunometric assay (IDS-iSYS; Immunodiagnostic Systems Limited; Boldon, 
United Kingdom). IGF-I intra-assay and inter-assay coefficients of variation (CVs) 
were respectively 5.7-8.1% and 1.5-2.1%, and IGF-I was interpreted according to the 
sex and age-dependent ranges by Bidlingmaier et al (24). PEGV does not interfere 
with the GH immunoassay that was used (25). Serum cortisol was measured using 
chemiluminescence immunoassay (Immulite 2000 XPi, Siemens AG). Testosterone was 
measured using the LC-MS/MS method (Thermo Fisher Scientific BV). TSH and FT4 
levels were determined using chemiluminescence immunoassays (Vitros ECI, Ortho 
Clinical Diagnostics, Rochester, NY). Fasting plasma glucose, insulin, HbA1c levels, 
serum concentrations of (ALT), aspartate aminotransferase (AST), alkaline phospha-
tase, glutamyl transpeptidase, total bilirubin, coagulation and kidney function were 
determined with standard laboratory methods.
Study assessments
Safety assessments included: electrocardiogram at baseline, and 24 weeks. The sever-
ity of adverse events was evaluated at every study visit as mild (grade 1), moderate 
(grade 2), severe (grade 3), or life-threatening (grade 4) according to the Common 
Terminology Criteria for Adverse Events (CTCAE) (26). With respect to hyperglycemia-
related adverse events, grade 1 was defined as a fasting glucose value of >6.1–8.9 
mmol/l, grade 2 >8.9 – 13.9 mmol/l, grade 3 >13.9–27.8 mmol/l or requiring hospital-
ization, grade 4 >7.8 mmol/l.
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Outcomes
The primary efficacy endpoint was descriptive in nature and was defined as the 
percentage of responders at 24 weeks in the intention-to-treat population in each 
treatment arm (PAS-LAR monotherapy, LA-SSA/PEGV combination treatment), with 
an exact 95% confidence interval (CI). Response was defined, similar to the inclusion 
criteria, as IGF-I ≤1.2 x ULN. For missing data imputation based on last observa-
tion carried forward (LOCF) was used. Secondary descriptive endpoints for efficacy 
included the cumulative PEGV dose reduction at 24 weeks compared with baseline. 
Secondary endpoints for safety included the incidence of adverse events, incidence 
of hyperglycemia and diabetes, vital signs, clinical examination, electrocardiogram, 
standard hematology, kidney function, endocrine function tests, serum concentra-
tions of (ALT), aspartate aminotransferase (AST), alkaline phosphatase, glutamyl 
transpeptidase, and total bilirubin.
Changes in diabetic category during the study were determined using the following 
American Diabetes Association (ADA) criteria (27):
• Normal glucose tolerance: fasting plasma glucose < 5.7 mmol/l and/or HbA1c < 
5.7%.
• Prediabetes: fasting plasma glucose ≥ 5.7 < 7 mmol/l and/or HbA1c ≥ 5.7 < 6.5%.
• Diabetes: patients taking antidiabetic medication, or having fasting plasma glucose 
≥ 7.0 mmol/l, or HbA1c ≥ 6.5%.
Statistics
The power calculation for the primary endpoint was based on a prospective ran-
domized double blind phase III study of Colao et al (19). In this study, medically 
naïve or post-surgery patients with acromegaly were randomized to PAS-LAR 40 mg 
or octreotide LAR 20 mg every 28 days. The results revealed that after one year 
38.8% of patients on PAS-LAR achieved normal IGF-I levels compared to 23.6% on 
octreotide LAR. In this head-to-head superiority study, PAS-LAR showed an overall 
response rate of about 60% more in the pasireotide group (19). Therefore, we esti-
mated that PAS-LAR had 40% higher efficacy than first-generation LA-SSAs. The 95% CI 
was calculated using a percentage ranging from 25% to 40%. Statistical analyses were 
performed using SPSS software (version 24 for Windows; SPSS Inc., Chicago, Illinois) 
and GraphPad Prism® Version 6.04 (GraphPad Software, San Diego, USA). Categorical 
data were represented as observed frequencies and percentages. Continuous data 
were represented as mean and 95% confidence interval (CI) or median and range. 
The Kolmogorov-Smirnov and the Shapiro-Wilk test were used to test normality of 
variables. If assumption of normality was met, the paired t-test was used. For non-
normally distributed variables the Wilcoxon signed-rank test was used. We considered 
P-values of <0.05 to be statistically significant.
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results
Between August 24, 2015 and July 26, 2016, 100 acromegaly patients were screened 
and 61 patients were enrolled in the PAPE study (figure 1 appendix page 74). These pa-
tients comprised the intention-to-treat (ITT) set. Table 1 shows the patients’ baseline 
clinical and biochemical characteristics. The mean age was 53 years, the median time 
since diagnosis was 8.9 years, and the median time since start of combination treat-
ment was 6.1 years. 44.2% of patients had previously received surgery and 6 patients 
(9.8%) had previously received radiotherapy after surgery. The prevalence of diabetes 
was 32.8% at baseline and 20% of these patients were managed with oral antidiabetic 
therapy, while 3 patients were on insulin therapy.
table 1. Baseline patient characteristics
characteristics Patients (n = 61)
Age (median, range) 53 (26 – 80)
Female patients 29 (47.5%)
Time since diagnosis (mean, 95% CI) 9.7 (8.0 – 11.4)
Time since LA-SSA/PEGV treatment (mean, 95% CI) 6.2 (5.3– 7.1)
Previous surgery (%) 27 (44.2%)
Time since surgery (mean, 95% CI) 12.0 (9.0 – 15.1)
Previous surgery and radiotherapy (%) 6 (9.8%)
Time since radiotherapy (mean, 95% CI) 20.3 (10.5 – 30.1)
Prior acromegaly medication
 Lanreotide Autogel 35 (57.4%)
 Octreotide LAR 26 (42.6%)
 Cabergoline 2 (3.3%)
Pegvisomant dose (mg/week, mean, 95% CI) 134 (103–166)
IGF-I (x ULN, mean, 95% CI) 0.97 (0.91 – 1.02)
Presence of diabetes 20 (32.8%)
Oral antidiabetic therapy 12 (19.7%)
Insulin therapy 3 (4.9%)
Efficacy
In figure 2A IGF-I levels and the PEGV doses are shown. At baseline, the mean IGF-I 
was 0.97 x ULN (CI; 0.91 – 1.02) with a mean PEGV dose of 134 mg/week (CI; 103 – 
166). At 12 weeks, as by protocol, the mean PEGV dose was decreased to 61 mg/week 
(CI; 44 – 78), and IGF-I levels increased to 1.59 x ULN (CI; 1.45 – 1.73). In 15 (24.6%) 
patients IGF-I levels remained within the reference range, so they were switched to 
PAS-LAR 60 mg monthly as monotherapy, while the remaining 46 (75.4%) of patients 
with elevated IGF-I levels continued with their reduced dose of PEGV treatment but 
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now in combination with PAS-LAR 60 mg monthly. After 24 weeks from baseline, IGF-I 
levels dropped back to within the normal range in 45 (73.8%) patients, (mean IGF-I of 
1.04 x ULN (CI; 0.91 – 1.17)). Stratified by treatment, IGF-I levels within the reference 
range could be induced in 14/15 (93.3%) patients in the PAS-LAR monotherapy group, 
and in 31/46 (67.4%) of patients in the PAS-LAR /PEGV combination group. After 24 
weeks from baseline, the mean PEGV dose could be further decreased to 48 mg/week 
(CI; 21–74), while PEGV could be discontinued in 67.8% of patients. The cumulative 
reduction in PEGV dose was 66.1% in all patients at 24 weeks compared to baseline.
figure 2A. IGF-I serum levels and the weekly pegvisomant (PEGV) dose are expressed as mean (95% 
CI). Dotted straight black line reflects the 1.2 x ULN cut-off. The first 12 weeks patients continued 
with first generation LA-SSAs treatment, and the PEGV dose was reduced by 50%. From week 12 
until week 24 patients received in total 3 injections of pasireotide LAR 60 mg in combination with 
or without PEGV.
GH levels decreased significantly during the study (figure 2B). At baseline, the 
mean GH level was 9.3 µg/l (CI; 4.3 – 13.9), and significantly decreased to 7.4 µg/l 
figure 2b. Growth hormone (GH) levels are expressed as mean (95% CI), and are stratified to 
patients using pasireotide LAR monotherapy (grey line) and patients using pasireotide LAR and 
pegvisomant combination treatment (black line).
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(CI; 3.1 – 11.7; P < 0.0001) after 12 weeks, whereas IGF-I levels increased significantly 
in the same time period. After 24 weeks, after subsequent treatment with PAS-LAR, 
mean GH levels further decreased significantly to 5.5 µg/l (CI; 1.3 – 9.6; P < 0.0001). 
Stratified to treatment group; in the PAS-LAR monotherapy group mean GH levels 
decreased from 2.5 µg/l (baseline) (CI; 0.9 – 4.2) to 0.6 µg/l (24 weeks) (CI; 0.3 – 0.8). 
In the PAS-LAR/PEGV combination group, mean GH levels decreased from 11.5 µg/l 
(baseline) (CI; 5.6 – 17.5) to 7.3 µg/l (24 weeks) (CI; 1.7 – 3.0).
In table 1 of supplementary data the differences are shown between patients who 
did achieve and who did not achieve IGF-I normalization at 24 weeks. Patients who 
were biochemically controlled at 24 weeks were using a significantly lower baseline 
PEGV dose, and had a lower baseline bodyweight. Between biochemically controlled 
and non-controlled patients, we found no difference in age, sex, BMI, HbA1c, and 
presence of diabetes. After correction for age and baseline bodyweight, the baseline 
PEGV dose was the most important predictor for IGF-I levels at 24 weeks with an Odds 
Ratio of 0.986 (CI; 0.976 – 0.996) (table 2 supplementary data). In clinical terms, a 
lower weekly PEGV dose at baseline increased the chance of reaching normal IGF-I 
levels within the reference range after 24 weeks (for each 10 mg PEGV reduction, the 
increase of IGF-I levels within the reference range was 14.0%).
Hyperglycemia and diabetes
The most common recorded adverse event (AE) during the study was hyperglycemia 
(table 2). We noted a total of 54 (88.5%) AEs were hyperglycemia-related, of which 40 
(65.6%) were grade 1 and 2. Grade 3 and 4 hyperglycemias were reported in 14 (23.0%) 
patients, and were all related to PAS-LAR treatment.
table 2. Adverse events regardless of study-drug relationship (> 5%) first 24 weeks
Adverse events All grades grades 3/4
Hyperglycemia 54 (88.5%) 14 (23.0%)
New-onset diabetes 22 (36.1%) 0
Diarrhoea 18 (29.5%) 0
Myalgia 16 (26.2%) 0
Fatigue 13 (21.3%) 0
Headache 10 (16.4%) 0
Arthralgia 10 (16.4%) 0
Dizziness 10 (16.4%) 0
Nausea 6 (9.8%) 0
Data are expressed as mean (95% confidence interval), median (interquartile range), or n (%).
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Mean fasting plasma glucose and HbA1c concentrations rose slightly between baseline 
and 12 weeks, but increased significantly after start of PAS-LAR treatment (figure 3).
figure 3. A. HbA1c concentrations are expressed as mean (95% CI). b. Fasting plasma glucose 
levels are expressed as mean (95% CI). c. Incidence normal glucose tolerance, prediabetes and 
diabetes over time according to the American Diabetes Association (ADA) criteria.
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Between 12 and 24 weeks, mean fasting plasma glucose rose from 6.1 mmol/l (95% CI 
5.9 – 6.3) to 9.1 mmol/l (95% CI 8.1 – 10.1) (P < 0.0001), and HbA1c from 6.1% (95% 
CI 5.9 – 6.3) to 7.3% (95% CI 6.9 – 7.7) (P < 0.0001). While 20 (32.8%) patients had 
diabetes at baseline, this number doubled to 42 (68.9%) patients at 24 weeks.
At 24 weeks, diabetic patients had a significantly higher baseline HbA1c compared 
to non-diabetic patients (table 3 supplementary data). Diabetic patients were insig-
nificantly slightly older. Between diabetic and non-diabetic patients, we found no 
differences in sex, PEGV dose at baseline, IGF-I at 12 weeks, weight, or BMI. After 
correction for fasting plasma glucose levels and age, baseline HbA1c was the most 
important predictor for development of diabetes at 24 weeks. Logistic regression 
analysis of HbA1c tertiles revealed that patients in the second and third tertiles had 
increased odds (OR 5.5 and OR 55.0, respectively) of development of diabetes at 24 
weeks compared with patients in the lowest HbA1c tertile (table 4 and 5 supplemen-
tary data).
After 24 weeks, nearly a third (32.9%) of patients required no change or initiation 
of antidiabetic medication, while the majority of patients required a combination 
of metformin and a DPP4 inhibitor. Seven patients required at least one antidiabetic 
drug. Three patients had to start insulin treatment, of whom two patients developed 
serious AEs involving severe hyperglycemia after the first PAS-LAR injection. These 
patients had pre-existing diabetes which was managed with either maximum oral 
antidiabetic drugs, a GLP-I analogue, or insulin treatment. After initiation of insulin 
treatment, PAS-LAR treatment was discontinued and they were all switched back 
to their previous LA-SSA and PEGV treatment, after which their diabetes recovered 
completely (supplementary data).
table 3. Antidiabetic medications initiated after pasireotide LAR initiation.
Antidiabetic medication baseline 24 weeks
None 46 (75.4%) 19 (31.1%)
Metformin 15 (24.6%) 19 (31.1%)
DPP4 inhibitors 0 14 (23.0%)
Sulfonylureas 3 (4.9%) 12 (19.7%)
Insulin 3 (4.9%) 6 (9.8%)
GLP-I analogues 2 (3.3%) 3 (4.9%)
Thiazolidinediones 1 (1.6%) 1 (1.6%)
Patients may have taken more than one antidiabetic medication.
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Non-diabetes related adverse events
In the run-in phase during reduction of the PEGV dose, (28 of 61) 46% of patients 
developed symptoms of active acromegaly such as fatigue, increased sweating, 
arthralgia, and headache. We observed no transient elevated transaminases during 
the study. Two thirds (12 of 18) of patients with diarrhea experienced symptoms 
of steatorrhoea. These symptoms were generally mild and transient. Although no 
diagnostic evaluation was performed to confirm exocrine pancreatic insufficiency, 
patients generally experienced symptomatic improvement with temporary pancreatic 
enzyme supplementation.
dIscussIoN
The PAPE study is the first study to assess the efficacy and safety of PAS-LAR in acro-
megaly patients previously using combination treatment of first generation LA-SSAs 
and PEGV. Our results show that 12 weeks of PAS-LAR treatment results in a 66.1% 
reduction in PEGV dose, while 73.8% of the patients attain IGF-I within the reference 
range (≤1.2 ULN). Moreover, 67.8% of patients could discontinue PEGV at 24 weeks. 
These findings indicate that PAS-LAR has an important PEGV sparing effect. However, 
this came at the expense of a higher frequency of diabetes which doubled from 32.8% 
at baseline to 68.9% after 24 weeks treatment.
The patients who had normal IGF-I levels at 12 weeks (PAS-LAR monotherapy group) 
had a significantly lower baseline PEGV dose than those with elevated IGF-I levels 
at 12 weeks (combination treatment group) 64 mg/week (CI; 50–78) versus 157 mg/
week (CI; 118–197) (P = 0.008). Furthermore, patients in the PAS-LAR group also had 
significantly lower baseline IGF-I levels than those in the combination treatment 
group; 0.83 x ULN (CI; 0.71 – 0.95) versus 1.01 x ULN (CI; 0.96 – 1.07) (P = 0.002). The 
observed trend of a higher frequency of patients after radiotherapy in the PAS-LAR 
monotherapy group (20.0%) compared to the combination treatment group (6.5%) was 
not statistically significant (P = 0.15). We found no differences in the frequency of 
previous surgery between both groups. Apparently, patients in the PAS-LAR group have 
a lower disease activity at baseline, which is reflected by their lower baseline PEGV 
dose, IGF-I level, and GH level, or that they are more sensitive to LA-SSA, possibly due 
to a higher SST2 expression.
An additional interesting observation is the rapid decrease in IGF-I levels after the 
first injection of PAS-LAR. This observation could be related to a decrease in insulin 
secretion, which reduces IGF-I production (28). After two PAS-LAR 60 mg injections, 
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mean IGF-I levels decreased from 1.44 x ULN (CI; 1.44 – 1.73) to 1.08 x ULN (CI; 0.95 
– 1.22). We cannot rule out a carry-over effect of LA-SSAs, but these rapid reductions 
are usually not observed during treatment with first generation LA-SSA.
After the reduction in the PEGV dose during the first 12 weeks, mean GH levels 
decreased, while IGF-I levels increased. This finding is compatible with reports of 
increased GH levels during PEGV treatment (6). At 24 weeks, GH levels were further 
significantly decreased in all subjects, both in the PAS-LAR monotherapy as in the 
PAS-LAR and PEGV group. Probably, the lower GH levels can be explained by the 
discontinuation of, or further dose reduction in PEGV, plus the additional suppressive 
effect of PAS-LAR on GH secretion.
In our study the frequency of hyperglycemia-related adverse events was higher 
(88.5%) than in previous studies (19, 20, 29-31), but the increase in frequency of 
diabetes (32.9% at baseline to 68.9% at 24 weeks) is in line with the PAOLA study (22% 
to 70%) (20). The higher frequency of hyperglycemia related adverse events could be 
explained by the inclusion of older subjects while we included more patients with 
pre-existing diabetes at baseline compared to previous studies. We used an HbA1c 
cut-off of <9.0% as an inclusion criterion, whereas previous studies used a cut-off of 
<8.0%. The reduction of the PEGV dose during the first 12 weeks worsened glucose 
metabolism, due to an increase in GH actions.
The degree of hyperglycemia after PAS-LAR treatment is dependent on the degree 
of glycemic control at baseline. The patients who required insulin treatment are 
the patients that developed rapid hyperglycemia after the first injection of PAS-LAR. 
The non-insulin group had a slower onset of hyperglycemia and the diabetes they 
developed was less severe. In general, their diabetes could be managed after the 
third injection with oral medication.
We observed an increased frequency of steatorrhoea after initiating PAS-LAR treat-
ment which we ascribed to exocrine pancreatic insufficiency. This is a rare AE during 
treatment with LA-SSA (32). Because patients in our study had already been exposed 
for more than 6 months to LA-SSAs, we did not expect an increase in the incidence 
of steatorrhea. Although we did not formally assess exocrine insufficiency, the exog-
enous addition of exocrine pancreatic enzymes improved the symptoms and after a 
few months most patients could stop this replacement therapy.
Several limitations of our study warrant consideration. Firstly, the efficacy of PAS-
LAR we observed at 24 weeks (ie. after 12-weeks of PAS-LAR treatment) could be 
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influenced by a carry-over effect of octreotide LAR or lanreotide ATG following their 
discontinuation at 12 weeks. After withdrawal of LA-SSA, patients may remain in 
biochemical remission for up to four months, and this appeared to be dependent on 
the IGF-I level at time of discontinuation (27, 33). The efficacy of 73% in our study 
is higher than reported previously (19, 20). This may be explained by the carry-over 
effect of first-generation LA-SSAs in our study, and the fact that patients in our study 
were controlled before study entry. Secondly, the diagnosis of diabetes mellitus was 
based on the ADA criteria (27). Although healthy volunteer data have recommended 
incretin-based therapies for management of PAS-LAR-induced hyperglycemia, in the 
Netherlands these drugs are only reimbursed if patients fail on maximum doses of 
metformin, sulfonylureas, and a BMI of ≥ 35 kg/m² (23). The patients who developed 
severe hyperglycemia after the first injection had pre-existing diabetes and they 
all required swift interventions with insulin treatment. Therefore, intensive blood 
glucose monitoring is required after the start of treatment and antidiabetic treat-
ment should be promptly initiated, preferably DPP4 inhibitors and GLP-I analogues, 
because treatment with metformin and sulfonylureas appears to be not very effec-
tive. Baseline HbA1c levels are the most important predictors for development of 
diabetes during the study. GH levels significantly decreased during the study. This is 
partly caused by the discontinuation and reduction in dose of PEGV, but mainly by 
treatment with PAS-LAR.
Our data indicate that PEGV treatment can neither compensate nor offset PAS-LAR-
induced hyperglycemia. Probably, because PEGV improves insulin sensitivity and the 
hyperglycemic effect of PAS-LAR is independent of insulin sensitivity and is considered 
to be more an insulin and incretin suppressive effect (12-15, 23). Additionally, reduc-
ing the PEGV dose that causes active acromegaly may lead to more insulin resistance, 
while treatment with PAS-LAR leads to a further deterioration of glycemic control, 
especially in patients with (pre)diabetes.
Although the efficacy of pasireotide LAR, with or without PEGV, is high, caution should 
be paid to the long-term sequelae of the pasireotide-induced diabetes. The PEGV 
sparing effect of PAS-LAR and thereby proposed cost reductions will very likely be con-
sumed by the diabetes mellitus related medication and healthcare costs. It is unknown 
whether patients that initially do not develop pasireotide-induced hyperglycemia, 
have a higher lifetime risk of developing diabetes and could create additional costs. 
Therefore, more long-term follow-up studies are needed.
In conclusion, pasireotide LAR is a viable treatment option in patients previously 
controlled with combination treatment of first-generation LA-SSA and PEGV.
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Switching to pasireotide LAR enables a reduction in the necessary PEGV dose and/or 
in a lower number of injections. However, switching to PAS-LAR coincides with a 
higher frequency of diabetes.
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Appendix
100 patients assessed for eligibility
39 ineligible:
30 not interested
7 did not meet diagnostic criteria
1 had unacceptable laboratory test results
1 withdrew consent
1 withdrew consent due to hyperglycemia related AE
1 withdrawn due to hyperglycemia related SAE
59 patients completed treatment at 24 weeks
61 patients in the intention-to-treat (ITT) set
figure 1. Trial profile.
AE = Adverse Event, SAE = Serious Adverse Events
Serious adverse events
The first patient was a 68-years old male diagnosed with acromegaly in 1995, for 
which has underwent transnasal adenectomy. His acromegaly was controlled with 
octreotide LAR 30 mg and PEGV 80 mg/week, and his diabetes was controlled with 
maximum doses of metformin and gliclazide. After the first injection he developed 
severe hyperglycemia with glucose levels of 33 mmol/l and his HbA1c rose from 6.0 
to 9.8%. He was admitted for treatment with long-acting insulin. After the second pa-
sireotide LAR injection he was switched back to his previous combination treatment, 
and his diabetes recovered completely within two months. The second patient was a 
65-years old male diagnosed with acromegaly in 2005. His acromegaly was controlled 
with lanreotide 120 mg and PEGV 120 mg/week, and he his diabetes was managed 
with twice daily insulin treatment. After reduction of the PEGV dose his glycemic 
control worsened (HbA1c increased from 6.7 to 9.4%), and after the first injection he 
also developed severe hyperglycemia with glucose levels of 31 mmol/l and his HbA1c 
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increased further to 12.6%. He was admitted and he was switched to once daily long-
acting and three times daily short-acting insulin treatment. After the fourth injection 
of pasireotide LAR he was switched back to his previous combination treatment, 
and his glycemic control improved. The third patient was a 54-years old male with 
acromegaly well controlled with lanreotide ATG and PEGV 100 mg/week. Although 
his diabetes was well controlled with metformin and weekly exenatide treatment. 
After the first injection he developed hyperglycemia (glucose increased from 6.9 to 
23 mmol/l, and HbA1c from 6.3 to 10.6%), requiring insulin treatment. Although his 
IGF-I normalized from 2.19 x ULN at week 12 weeks to 0.84 x ULN at 20 weeks, and 
he could discontinue PEGV, he decided to withdraw from the study because he was 
declined to use daily insulin injections.
Binomial regression statistics
Binomial logistic regression analysis was carried out to identify independent predictors 
for normalization of IGF-I at 24 weeks, and the development of diabetes at 24 weeks. 
First, we assessed linearity of the continuous variables with respect to the logit of 
the dependent variable via the Box-Tidwell procedure. Secondly, we analysed the 
presence of multicollinearity using the Variance Inflation Factor (VIF) and tolerance 
values. If the assumption of linearity of the logit was met, and no significant multi-
collinearity (VIF <5 and tolerance >0.2) was present, we assessed the independent 
variables using univariate logistic regression analysis. Each independent variable was 
also analysed for interaction, and if the interaction term was significant (P <0.05), it 
was included in the final model. Only independent variables with P-values <0.20 were 
included in the final multivariate logistic regression model.
We first assessed the influence of age, sex, BMI, baseline PEGV dose, IGF-I, GH, previ-
ous surgery, radiotherapy and diabetes on the likelihood that participants normalised 
their IGF-I levels to within the reference range at 24 weeks. Univariate regression 
analysis revealed that of the nine included variables only baseline PEGV dose, body-
weight and age had a P-value < 0.20, and these three variables were included in the 
final multivariate logistic regression analysis (table 1 supplementary data). The model 
explained 38.5% (Nagelkerke R²) of the variance in IGF-I levels.
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table 1. Differences between controlled and non-controlled patients at 24 weeks
Igf-I normal
at 24 weeks
Igf-I elevated
at 24 weeks
P-values
N 45 16
Age (years, mean 95% CI) 55.0 (11.8) 49.3 (11.2) 0.10
Females (n, %) 23 (51%) 6 (37.5%) 0.35
PEGV dose baseline (mg/week, mean 95% CI) 98 (80 – 116) 236 (137 – 335) < 0.0005
Weight baseline (kg, mean 95% CI) 90.6 (85.6 – 95.7) 101.9 (92.4 – 111.4) 0.022
BMI baseline (kg/m², mean 95% CI) 28.7 (27.5 – 29.9) 31.1 (28.2 – 34.0) 0.27
Presence of diabetes at 24 weeks (n, %) 27 (62.8%) 8 (50.0%) 0.37
HbA1c baseline (%, mean 95% CI) 6.0 (5.6 – 6.4) 6.0 (5.8 – 6.1) 0.96
IGF-I normal defined as IGF-I ≤ 1.2 x ULN. IGF-I elevated defined as IGF-I > 1.2 x ULN. Data are 
expressed as mean (95% confidence interval), median (interquartile range), or n (%).
We analyzed the impact of baseline HbA1c, fasting plasma glucose levels, age, sex, 
BMI, baseline PEGV dose, IGF-I, GH, previous surgery, and radiotherapy on the likeli-
hood that participants develop diabetes after 24 weeks. Univariate regression analysis 
revealed that of the 10 variables only baseline HbA1c, fasting plasma glucose and 
age had a P-value <0.20, and these variables were included in the final multivariate 
logistic regression model (table 2 supplementary data). This model explained 58.4% 
(Nagelkerke R²) of the variance in diabetes at 24 weeks.
table 2. Multivariate regression analysis of predictors associated with IGF1 normalization at 24 
weeks (n = 61
Predictor B se Wald df P or 95% cI for or
lower upper
Baseline PEGV dose −0.014 0.005 7.495 1 0.006 0.986 0.976 0.996
Baseline bodyweight −0.026 0.20 1.587 1 0.208 0.975 0.937 1.014
Age 0.013 0.031 0.165 1 0.685 1.013 0.953 1.076
Constant 4.796 2.822 2.889 1 0.089 121.033
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table 3. Differences between diabetic and non-diabetic patients at 24 weeks
diabetic patients 
at 24 weeks
Non-diabetic
at 24 weeks
P-values
N 41 20
Age (years, mean 95% CI) 55.5 (52.2 – 58.8) 49.3 (43.0 – 55.6) 0.053
Females (n, %) 17 (41.5%) 12 (60.0%) 0.17
HbA1c baseline (%, mean 95% CI) 6.2 (6.0 – 6.4) 5.6 (5.5 – 5.7) < 0.0001
PEGV dose baseline (mg/week, mean 95% 
CI)
137 (90–176) 133 (94–179) 0.45
Weight baseline (kg, mean 95% CI) 94.0 (88.2 – 99.8) 92.5 (85.8 – 99.3) 0.76
BMI baseline (kg/m², mean 95% CI) 29.4 (28.0 – 30.8) 29.3 (27.3 – 31.3) 0.92
Data are expressed as mean (95% confidence interval), median (interquartile range), or n (%).
table 4. Multivariate regression analysis of predictors associated with development of diabetes at 
24 weeks (n = 61).
Predictor B se Wald df P or 95% cI for or
lower upper
Baseline HbA1c 6.125 1.731 12.528 1 0.001 457.60 13.374 15657.722
Baseline glucose 1.254 0.779 2.589 1 0.108 3.504 0.761 16.136
Age −0.11 0.036 0.091 1 0.763 0.989 0.922 1.061
Constant −41.480 11.985 11.979 1 0.001 0.000
table 5. Logistic regression analysis of HbA1c tertiles associated with development of diabetes at 
24 weeks (n = 61). Tertile 1 = HbA1c lowest to 5.7% Tertile 2 = HbA1c 5.7% – 5.9% Tertile 3 = HbA1c 
5.9% and higher.
Predictor B se Wald df P or 95% cI for or
lower upper
Tertile 1 (reference) 16.780 2 < 0.0005
Tertile 2 1,705 0.838 4.140 1 0.042 5.5 1.065 28.416
Tertile 3 4.007 0.979 16.770 1 <0.00005 55.0 8.080 374.380
Constant −1.299 0.651 3.979 1 0.046 0.273
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AbstrAct
objective: to assess the efficacy and safety after 48 weeks of treatment with pa-
sireotide long-acting-release (PAS-LAR) alone or in combination with pegvisomant 
in patients with acromegaly. In addition, we assessed the relation between insulin 
secretion and pasireotide-induced hyperglycemia.
design: The PAPE extension study is a prospective follow-up study until 48 weeks after 
the core study of 24 weeks.
Methods: 59 out of 61 patients entered the extension study. Efficacy was defined as 
the percentage of patients achieving IGF-I normalization (≤ 1.2 x the Upper Limit of 
Normal (ULN)) at 48-weeks through protocol-based adjustment of pegvisomant and 
PAS-LAR doses. At baseline, insulin secretion was assessed by an oral glucose toler-
ance test (OGTT).
results: At the end of the study median IGF-I was 0.98 x ULN, and 77% of patients 
achieved normal IGF-I levels with a mean pegvisomant dose of 64 mg/week, and an 
overall cumulative pegvisomant dose reduction of 52%. Frequency of diabetes mellitus 
increased from 68% at 24 weeks to 77% at 48 weeks, and 9 patients discontinued 
PAS-LAR treatment, mainly because of severe hyperglycemia. Pasireotide-induced 
hyperglycemia was inversely correlated with baseline insulin secretion (r = −0.37, P 
< 0.005).
conclusions: PAS-LAR normalizes IGF-I levels in most acromegaly patients, with a fifty 
percent pegvisomant-sparing effect. However, PAS-LAR treatment coincided with a 
high incidence of diabetes mellitus. The risk for developing diabetes during PAS-LAR 
treatment seems inversely related to insulin secretion at baseline.
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INtroductIoN
Acromegaly is a systemic condition most commonly caused by pituitary adenomas 
secreting excess growth hormone (GH) and insulin-like growth factor I (IGF-I) levels, 
leading to increased mortality and morbidity (1). The main goals of the present treat-
ment for acromegaly are to normalize GH and IGF-I levels, reduce or control tumor 
size, and to improve quality of life (QoL) and multisystem comorbidities (2, 3).
First-generation long-acting somatostatin analogues (LA-SSAs) are considered the 
mainstay medical treatment of acromegaly. LA-SSAs suppress GH secretion by pref-
erential binding to somatostatin receptor subtype 2a (SST2a). LA-SSAs have favorable 
safety profiles and a clinically neutral impact on glucose homeostasis (4, 5).
In clinical practice only about 40% of patients treated with monotherapy LA-SSAs 
achieve biochemical normalization of GH and IGF-I. Therefore, most patients are 
refractory to treatment with LA-SSAs, and require additional therapies (6-8).
The competitive GH receptor antagonist pegvisomant (PEGV) is currently the most ef-
fective treatment to normalize circulating IGF-I levels in acromegaly, as monotherapy 
or in combination with LA-SSA (9-14). PEGV has as advantage that it improves insulin 
sensitivity (15-18). In combination with LA-SSA a lower necessary PEGV dose is re-
quired to normalize IGF-I levels in acromegaly than compared with PEGV monotherapy 
(19, 20).
Pasireotide long-acting release (PAS-LAR) is a second-generation multi-receptor 
somatostatin analogue designed with a broader binding somatostatin receptor pro-
file than first-generation LA-SSAs (21). PAS-LAR has been shown to provide superior 
clinical efficacy over LA-SSA in treatment-naïve acromegaly patients and in patients 
inadequately controlled with LA-SSAs (22, 23). PAS-LAR has a similar safety profile to 
LA-SSAs, with the exception of a higher incidence of hyperglycemia, and this inci-
dence has been reported to occur in about 60-88% of patients during treatment with 
PAS-LAR (22-24). Recently, we have reported the efficacy and safety of PAS-LAR alone 
or in combination with PEGV in acromegaly patients up to 24 weeks treatment (PAPE 
core study) (24). Switching to PAS-LAR treatment resulted in a 66% reduction in PEGV 
dose, but was simultaneously associated with a higher incidence of diabetes mellitus. 
Here, we present the long-term 48 weeks results of the efficacy and safety of PAS-LAR 
alone or in combination with PEGV treatment in acromegaly.
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subJects ANd MetHods
study design
The PAPE study is a prospective, open-label, single-centre study in acromegaly pa-
tients, designed to assess the efficacy and safety of PAS-LAR alone, or in combination 
with PEGV (24) (ClinicalTrials.gov, number NCT02668172). The primary endpoint was 
to assess efficacy at 24 weeks. Here, we report the secondary endpoints: efficacy and 
safety from 24 up to 48 weeks. During this follow-up, the goal was to achieve IGF-I 
normalization (IGF-I ≤ 1.2 x ULN) through protocol-based dose titration of PEGV and 
PAS-LAR (Figure 1). In the core study two groups of patients continued in the extension 
phase: the PAS-LAR 60 mg monotherapy group and the PAS-LAR/PEGV combination 
group (24).
Patients in the PAS-LAR 60 mg monotherapy group continued with the 60 mg dose 
until 48 weeks, unless their IGF-I levels decreased below the median sex- and age 
adjusted IGF-I normal limits. In that case, the PAS-LAR dose was decreased to 40 mg 
every 4 weeks. Subsequently, if after at least two PAS-LAR 40 mg injections, IGF-I 
levels remained suppressed (below the median IGF-I), the PAS-LAR dose was further 
figure 1. PAPE study design. The number of participants in each study arm were based on the 
intention-to-treat population (n = 61).
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decreased to 20 mg (ARM A). However, if IGF-I became elevated (≥ 1.2 x ULN) during 
PAS-LAR monotherapy, PEGV treatment was restarted in the same dose of the run-in 
phase (ARM B).
Patients in the PAS-LAR/PEGV combination group who achieved IGF-I normalization 
at 24 weeks using PEGV doses ≤ 80 mg/week, were after 24 weeks instructed to 
discontinue PEGV treatment and to continue with PAS-LAR 60 mg monotherapy during 
follow-up (ARM C) (Figure 1). In patients using PEGV doses higher than 80 mg/week, 
the dose was reduced by 50% every 4 weeks until their IGF-I was normalized (≤ 1.2 x 
ULN). If IGF-I levels became elevated above 1.2 x ULN during combination treatment, 
the PEGV dose was further increased every 4 weeks depending on the measured IGF-I 
levels after adjusting treatment (ARM D):
• IGF-I between 1.2–1.5× ULN, the PEGV dose was increased by 20%.
• IGF-I between 1.5–1.7× ULN, the PEGV dose was increased by 30%.
• IGF-I between 1.7–2.0× ULN, the PEGV dose was increased by 40%.
• IGF-I ≥ 2.0 x ULN, the PEGV dose was increased by 50%.
If monitoring revealed glucose levels in the diabetic range according to the American 
Diabetes Association (ADA) criteria (25), metformin was initiated as first-line treat-
ment option. If glycemic control was not achieved after metformin treatment, a 
DPP-4 inhibitor was added as second choice. When patients still did not achieve nor-
moglycemia they were switched to a treatment with sulfonylureas or GLP-1 receptor 
analogues. Finally, insulin was started in patients intolerant to GLP-I analogues or 
when glycemic control was not achievable with GLP-1 analogues. All patients received 
intensive blood glucose monitoring after start of treatment. Patients who developed 
rapid hyperglycemia received insulin treatment. The PAPE study was approved by the 
medical ethics committee of the Erasmus University Medical Centre, and all patients 
provided written informed consent.
Patients
After 24 weeks, 59 out of 61 patients entered the extension phase (supplemental fig-
ure 1). The in- and exclusion criteria have been reported previously (24). Briefly, key 
inclusion criteria were patients with good metabolic control of acromegaly (IGF-I ≤ 
1.2 x ULN) for at least 6 months combination treatment of weekly PEGV and maximum 
doses of first-generation LA-SSAs. Key exclusion criteria were pituitary surgery or 
radiotherapy within the 6 months prior to study entry and poorly controlled diabetes 
mellitus, defined as HbA1c ≥ 9.0%.
84
Chapter 4
study assessments
Laboratory measurements were described previously in the core study (24). Safety 
assessments included: assessment of heart function by electrocardiogram at baseline, 
24 weeks, and 48 weeks. The severity of adverse events (AEs) was evaluated according 
to the Common Terminology Criteria for Adverse Events (CTCAE) (26). At baseline after 
an overnight fast, a standardized oral glucose tolerance test (OGTT) was performed 
with 1.75 g glucose per kg body weight (maximum 75 g while simultaneously glucose 
and insulin levels were measured at t = −15 minutes, t = 0 min., t = 30 min., t = 60 
min., t = 90 min., and t = 120 min. (27). We used published indexes of β-cell function 
to estimate the first phase and second phase insulin secretion during the OGTT (28).
outcomes
The secondary efficacy endpoints were descriptive in nature and were based on the 
intention-to-treat population. For patients who discontinued the study before 48 
weeks imputation based on the principle of last observation carried forward (LOCF) 
was used. Main efficacy endpoint was defined as the percentage of responders at 
48 weeks in the intention-to-treat population, and in each treatment arm (PAS-LAR 
monotherapy and PAS-LAR/PEGV combination treatment), with an exact 95% confi-
dence interval (95% CI). Response was defined as IGF-I ≤ 1.2 x ULN. Other descriptive 
endpoints for efficacy included the percentage of patients who could stop PEGV 
treatment after 48 weeks, and the percentage cumulative PEGV dose reduction, 
which was calculated as the sum of all administered PEGV doses of all patients at 48 
weeks compared with baseline. As reported previously (24), secondary endpoints for 
safety included the incidence of hyperglycemia and diabetes mellitus, vital signs, and 
electrocardiogram.
Statistical analyses were performed using SPSS software (version 24 for Windows; 
SPSS Inc., Chicago, Illinois) and GraphPad Prism® Version 6.04 (GraphPad Software, 
San Diego, USA). Categorical data were represented as observed frequencies and 
percentages. Continuous data were represented as mean and 95% CI or median and 
range. The Kolmogorov-Smirnov and the Shapiro-Wilk test were used to test normality 
of variables. If assumption of normality was met, the paired t-test was used. For 
non-normally distributed variables the Wilcoxon signed-rank test was used. For data 
that did not meet the criteria for normality, logarithmic transformation was applied. 
Correlation analyses were performed using the Pearson correlation test. P-values of < 
0.05 were considered statistically significant.
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results
Efficacy
The baseline characteristics of the study population have been published before in 
the core study (24). The percentage of patients achieving IGF-I and GH normalization 
are shown in table 1.
table 1. Percentage of patients achieving normal IGF-I and GH levels during the study
baseline 12 weeks 24 weeks 48 weeks
IGF-I ≤ 1.2 x ULN
Overall 53/61 (86.9%) 15/61 (24.6%) 45/61 (73.8%)* 47/61 (77.0%)*
PAS-LAR monotherapy 14/15 (93.3%) 15/15 (100%) 14/15 (93.3%) 14/15 (93.3%)*
PAS-LAR/PEGV combination 39/46 (84.8%) 0/46 (0%) 31/46 (67.4%) 33/46 (71.7%)*
GH ≤ 2.5 µg/l
Overall 23/61 (37.7%) 29/61 (47.5%) 41/61 (67.2%)* 41/61 (67.2%)*
PAS-LAR monotherapy 10/15 (66.7%) 11/15 (73.3%) 15/15 (100%)* 14/15 (93.3%)*
*Data based on last observation carried forward (LOCF).
At 48 weeks, 77.0% of patients had IGF-I levels within the reference range with a mean 
IGF-I of 0.98 x ULN (95% CI 0.90 – 1.06) (table 1 and figure 2A). Stratified by treatment 
group; 93.3% of patients using PAS-LAR monotherapy achieved IGF-I normalization at 
24 weeks, which was sustained at 48 weeks. While 67.4% of patients using PAS-LAR and 
PEGV combination therapy achieved IGF-I normalization at 24 weeks, which increased 
to 71.7% at 48 weeks. Overall after 48 weeks, 12 of the 14 non-controlled patients had 
IGF-I levels between 1.2–1.4× ULN. During the extension phase the mean PEGV dose 
had to be increased from 47 mg/week (95% CI 21–73) to 64 mg/week (95% CI 33–95). 
At 48 weeks the cumulative reduction in PEGV dose decreased to 52.0% after 48 weeks 
compared with baseline, and 50.8% (31/61) of patients were off PEGV treatment at 
the end of study.
In figure 2B GH serum levels are shown stratified by treatment group. Patients in the 
PAS-LAR monotherapy group had significantly lower baseline GH levels (GH 2.5 µg/l 
(95% CI 0.8 – 4.2)) than patients in the PAS-LAR/PEGV combination group (GH 11.5 
µg/l (95% CI 5.5 – 17.4)). Both groups showed a significant decrease in GH serum levels 
after initiation of PAS-LAR treatment, with subsequently stable suppressed GH levels 
in the PAS-LAR monotherapy group until 48 weeks.
The 15 patients in the PAS-LAR monotherapy group remained controlled throughout 
the study (Figure 1). In fact, in 10 patients (66.7%) a dose reduction was possible 
to PAS-LAR 40 mg and 20 mg (ARM A). No patients had to restart PEGV treatment 
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in this group (ARM B). In patients using PAS-LAR and PEGV combination therapy, 16 
(34.8%) patients switched to PAS-LAR monotherapy during the extension phase, and 
in one patient a further dose reduction was possible to PAS-LAR 40 mg (ARM C). The 
remaining 30 patients required PAS-LAR and PEGV combination treatment, of which 13 
patients (21.3%) achieved less than 25% PEGV dose reduction (ARM D). In 12 patients 
(19.7%) between 25 to 50% PEGV dose reduction was achieved, and in 5 patients 
(8.2%) a reduction of more than 50% could be attained.
Pasireotide LAR monotherapy
Among the 15 patients that were switched to PAS-LAR 60 mg monotherapy at 12 
weeks, 10 patients had a progressive decline in IGF-I during follow-up, with levels 
dropping below the median IGF-I reference range. In these patients, the PAS-LAR dose 
figure 2. IGF-I serum levels and the weekly PEGV dose (2A). Dotted straight black line reflects the 
IGF-I 1.2 x ULN cut-off. GH serum levels (2B) are depicted in the PAS-LAR monotherapy group in 
grey and in the combination PAS-LAR/PEGV group in black. Data are expressed as mean (95% CI).
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was therefore reduced to 40 mg every 4 weeks. Subsequently, in five of those patients 
the dose was further decreased to 20 mg. At baseline, these patients used a relatively 
low median PEGV dose of 60 mg/week. In one additional patient who could stop PEGV 
after 24 weeks, the PAS-LAR could be further reduced to 40 mg during the follow-up.
Partial and non-responders
We observed that 10 patients on combination treatment who achieved IGF-I normal-
ization after 24 weeks and therefore could stop PEGV, had to restart PEGV treatment 
during follow-up because their IGF-I levels again increased above 1.2 x ULN (arm D). 
One patient required a higher dose of PEGV after 48 weeks (100 mg/week) than at 
baseline (80 mg/week). In three patients using very high doses of PEGV (at baseline 
(mean baseline PEGV dose 580 mg/week), we could not attain a significant PEGV dose 
reduction (mean PEGV dose was remained 560 mg/week after 48 weeks).
safety
Hyperglycemia and diabetes mellitus
The most common AE related to PAS-LAR treatment was hyperglycemia, and mainly 
recorded during the core study (24). In total 60 out of 61 patients had a hyperglycemia-
related AE, of which 47 (77.0%) were grade 1 and 2 (table 2). During the extension 
study grade 3 hyperglycemia was recorded in two patients, while no patients had a 
grade 4 hyperglycemia-related AE.
table 2. Adverse events regardless of study-drug relationship (>5%) until 48 weeks
Adverse events grade 1/2 grades 3/4
Hyperglycemia 48 (78.7%) 14 (23.0%)
Diarrhoea 21 (34.4%) 0
Fatigue 19 (31.1%) 0
Arthralgia 16 (26.2%) 0
Myalgia 16 (26.2%) 0
Headache 13 (21.3%) 0
Pain injection site 12 (19.7%) 0
Dizziness 11 (18.0%) 0
Hypoglycemia 9 (14.8%) 0
Arthralgia 16 (26.2%) 0
Nausea 7 (11.5%) 0
Alopecia 5 (8.2%) 0
Abdominal pain 4 (6.6%) 0
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At 48 weeks, diabetes of most patients was managed with a combination of metformin 
and a DPP-4 inhibitor. 73.8% patients required at least one antidiabetic medication. 
Between 24 and 48 weeks, five patients developed mild diabetes which required ad-
ditional treatment with metformin alone or combined with a DPP-4 inhibitor. Due 
to hypoglycemic symptoms related to sulfonylurea treatment, four patients were 
switched to a GLP-I analogue (supplementary table 1).
figure 3. HbA1c (3A), fasting plasma glucose (3B), fasting plasma insulin (3C) concentrations are 
expressed as mean (95% CI).
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During the extension phase the incidence of diabetes mellitus increased slightly from 
68.9% to 77.0%. Mean HbA1c and fasting plasma glucose levels increased significantly 
after PAS-LAR treatment, but decreased slightly after initiation of antidiabetic treat-
ment during follow-up (Figure 3A and 3B).
Mean HbA1c concentrations increased from 6.0% (5.8 – 6.1) at baseline to 7.3% (6.9 
– 7.7) after 24 weeks, but decreased slightly to 7.0% (6.6 – 7.4) after 48 weeks. Strati-
fied by treatment group; in the PAS-LAR monotherapy group, mean HbA1c increased 
from 6.0% (95% CI 5.5– 6.5%) at baseline to 7.1% (95% CI 6.3 – 7.9%) at 24 weeks, and 
decreased to 6.8% (95% CI 6.0 – 7.7%) at 48 weeks. In the combination treatment 
group, HbA1c levels showed a similar pattern, increasing from 6.0% (95% CI 5.9 – 6.1%) 
at baseline to 7.4% (95% CI 6.9 – 7.9%) at 24 weeks, and decreasing to 7.1% (95% CI 
6.6 – 7.5%) after 48 weeks. No significant difference was observed in HbA1c levels 
between patients using PAS-LAR monotherapy and combination treatment at baseline 
(P = 0.36), 24 weeks (P = 0.72), and after 48 weeks (P = 0.26).
Fasting plasma glucose levels followed a similar profile with 6.2 mmol/l (5.8 – 6.5) 
at baseline to 9.2 mmol/l (8.1 – 10.3) at 24 weeks, and 8.7 mmol/l (95% CI 7.7 – 9.6) 
after 48 weeks.
Excluding patients that were receiving insulin therapy at baseline (n = 3), fasting insu-
lin levels rose from 67.5 mmol/l (95% CI 48.8 – 86.2) at baseline to 161.4 mmol/l (95% 
CI 113.5 – 209.3) after 12 weeks. Insulin levels dropped significantly after initiation 
of PAS-LAR treatment. After 24 weeks, fasting insulin levels decreased significantly 
to 89.0 mmol/l (95% CI 54.9 – 123.1). We observed a significant inverse relation-
ship between the insulin area under the curve (AUC) during OGTT at baseline and 
the increase in HbA1c levels between baseline and 24 weeks (r = −0.30, P = 0.03). 
The estimates for β-cell function showed a stronger correlation with the increase in 
HbA1c; first phase insulin secretion (Stumvoll index, r = −0.37, P = 0.005) and second 
phase insulin secretion (r = −0.38, P = 0.004).
Non-hyperglycemia related adverse events
After hyperglycemia, diarrhea (34.4%), and fatigue (31.1%) were the most common 
AEs (table 2). Headache was reported by 13 (21.3%) patients and most frequently 
experienced in the first week after initiation of PAS-LAR treatment, but resolved later 
after consecutive injections. One patient was diagnosed with sick sinus syndrome dur-
ing PAS-LAR treatment. After discontinuation of PAS-LAR this AE resolved and she was 
successfully switched to PEGV monotherapy. Slightly more patients developed diar-
rhea during the extension phase (n = 21) compared to core phase of the study (n = 18).
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dIscussIoN
The results of this clinical study suggest that the efficacy of PAS-LAR was long-term 
sustained, as after 48 weeks, 77% of patients achieved IGF-I normalization while a 
cumulative PEGV dose reduction of 54.2% could be achieved, reconfirming the PEGV 
sparing effect of PAS-LAR. Hyperglycemia was the most important and most common 
adverse event during the follow-up until 48 weeks. The incidence of diabetes mellitus 
increased from 68.9% at 24 weeks to 77% at 48 weeks.
It is important to note that the extension phase of our study was not designed to 
detect a statistically significant difference between the treatment groups after 48 
weeks, but it was undertaken to optimally titrate the PEGV and PAS-LAR dose to 
achieve control of IGF-I within the reference ranges. To achieve IGF-I normalization, 
we used a systematic PEGV and PAS-LAR dose titration protocol.
We observed that PAS-LAR elicited a wide range of clinical response in this study, 
ranging from patients that were very sensitive to very resistant. On one hand of 
the spectrum, patients could stop PEGV treatment and switch to a lower PAS-LAR 
dose of 40 mg and even 20 mg/month. This IGF-I over-suppression to below median 
range during PAS-LAR treatment has also recently been described in two patients with 
acromegaly that were uncontrolled with octreotide LAR 20-30 mg/month and, after 
crossover to PAS-LAR 40 mg/month, achieved suppressed IGF-I levels below the nor-
mal range (29). Conversely, on the other end of the spectrum, a number of patients 
achieved less than 25% PEGV dose reduction. This heterogeneous clinical response to 
PAS-LAR may be explained by the inclusion of a heterogeneous acromegaly population 
with a large variation in baseline PEGV dose.
It is unlikely that a carry-over effect of first-generation LA-SSAs had a large impact in 
our study on the ultimately achieved PEGV dose reduction after 48 weeks. Neverthe-
less, it is possible that the initial response in IGF-I normalization of the 10 patients 
who had to restart PEGV treatment during the extension phase was related to a disap-
pearing carry-over effect of the first-generation LA-SSAs.
It is not clear why the three patients using the highest doses of PEGV could not reduce 
their PEGV dose after switching to PAS-LAR. Theoretically, one could hypothesize that 
patients using combination treatment of LA-SSA and high doses PEGV have relatively 
low SST2 and high SST5 expression compared to patients using LA-SSA monotherapy, 
and that therefore these patients would be good responders to PAS-LAR treatment. 
It remains to be determined whether SST2 or SST5 protein expression is responsible 
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for driving the response to PAS-LAR treatment in our study. Furthermore, it is still 
unknown how PEGV is metabolized in humans, and a wide inter-individual variation in 
PEGV serum levels have been observed when the same doses were administered (17, 
30-32). PEGV serum levels are increased during combination treatment of LA-SSA and 
PEGV, but it is unknown whether this also occurs during combination treatment with 
PAS-LAR. Therefore, theoretically patients using high doses of PEGV may benefit less 
from switching to PAS-LAR.
The insulin-suppressive effect of PAS-LAR may be related to the degree of pasireotide-
induced hyperglycemia, as insulin AUC and (more pronounced) baseline β-cell function 
were inversely correlated with the observed increase in HbA1c between baseline and 
24 weeks. These findings indicate that the lower the insulin secretion is at baseline, 
the greater will be the risk of pasireotide-induced hyperglycemia during follow-up, 
even in patients with well-controlled diabetes at baseline. Therefore, besides pre-
treatment baseline glucose and HbA1c levels (33), pancreatic β-cell function is prob-
ably an additional and independent risk factor of pasireotide-induced hyperglycemia. 
Patients using PAS-LAR and PEGV combination treatment did not have a lower HBA1c 
level than patients using PAS-LAR monotherapy. This observation suggests that the 
PEGV insulin sensitizing effect does not work in pasireotide-induced hyperglycemia 
(33).
Our results show that PAS-LAR treatment reduces IGF-I and GH levels after two in-
jections which parallels the reduction in insulin levels which also occurs after two 
injections, suggesting that the early onset effect of PAS-LAR on IGF-I reduction may 
be (partly) mediated by suppressing insulin secretion. This is further supported by the 
observation that although the effects of PAS-LAR on GH suppression were superimpos-
able compared with octreotide LAR, PAS-LAR treatment induced a greater suppression 
of IGF-I (22).
coNclusIoNs
PAS-LAR monotherapy or in combination with PEGV normalizes IGF-I levels in most 
acromegaly patients despite an about fifty percent reduction in cumulative PEGV 
doses. However PAS-LAR therapy coincides with a high incidence of diabetes mellitus, 
and the risk for developing diabetes during PAS-LAR therapy seems inversely related 
to insulin secretion at baseline.
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APPeNdIX
Supplemental figure 1. Trial profile. AE = Adverse Event, SAE = Serious Adverse Events
supplemental table 1. Antidiabetic medications initiated after pasireotide LAR initiation.
Antidiabetic medication baseline 24 weeks 48 weeks
None 46 (75.4%) 19 (31.1%) 16 (26.3%)
Metformin 15 (24.6%) 19 (31.1%) 25 (41.0%)
DPP4 inhibitors 0 14 (23.0%) 17 (27.9%)
Sulfonylureas 3 (4.9%) 12 (19.7%) 8 (13.1%)
Insulin 3 (4.9%) 6 (9.8%) 6 (9.8%)
GLP-I analogues 2 (3.3%) 3 (4.9%) 7 (11.5%)
Thiazolidinediones 1 (1.6%) 1 (1.6%) 1 (1.6%)
Patients may have taken more than one antidiabetic medication. Data based on last observation 
carried forward (LOCF).
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AbstrAct
background: The response to first-generation somatostatin receptor ligands (SRLs) 
treatment in acromegaly correlates with expression of somatostatin receptor subtype 
2 (SST2). However, pasireotide shows the highest binding affinity for SST5. It has been 
suggested that in acromegaly SST5 expression is better at predicting the response to 
pasireotide LAR (PAS-LAR) treatment than SST2 expression.
Aim: To investigate in active acromegaly patients whether response to SRL treatment 
correlates to PAS-LAR treatment, and to what extent SST2 and SST5 expression are 
correlated to response to PAS-LAR treatment.
Methods: We included 52 patients from a cohort that initially received SRL treatment, 
followed by SRL and pegvisomant combination treatment, and finally PAS-LAR treat-
ment. The long-term response to PAS-LAR was evaluated using a PAS-LAR score. In 14 
out of 52 patients, somatotroph adenoma tissue samples were available to evaluate 
SST2 and SST5 expression using a previously validated immunoreactivity score (IRS).
results: The percentage IGF-I (x ULN) reduction which was observed after SRL treat-
ment correlated with PAS-LAR response score during follow-up (r = 0.40, P = 0.003, n 
= 52). After exclusion of SRL pretreated patients, SST2 IRS was positively correlated 
to PAS-LAR score (r = 0.58, P = 0.039, n = 9), while SST5 IRS showed no relation (r = 
0.35, P = 0.36, n = 9).
conclusions: In a cohort of patients partially responsive to SRLs, the IGF-I lowering 
effects of PAS-LAR treatment correlated with the effect of SRLs treatment and seemed 
to be mainly driven by SST2 expression instead of SST5.
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INtroductIoN
Acromegaly is a severe systemic condition most commonly caused by a somatotroph 
adenoma that secretes excessive levels of growth hormone (GH) and insulin-like 
growth factor I (IGF-I), leading to increased mortality and morbidity (1). Treatment 
modalities that normalize GH and IGF-I levels restore normal life expectancy (2). This 
goal can be achieved pharmacologically, both by inhibiting pituitary GH secretion and 
blocking peripheral GH action.
First-generation long-acting somatostatin receptor ligands (SRLs, octreotide and 
lanreotide) represent the cornerstone for medical treatment of acromegaly. The bio-
chemical response to SRL treatment has been consistently shown to be positively cor-
related to somatostatin receptor subtype 2 (SST2) protein expression on the adenoma 
(3-7).These compounds inhibit pituitary GH secretion by preferential binding with 
high affinity to SST2. However, biochemical normalization of GH and IGF-I can only be 
achieved in about 40% of patients. Therefore, the majority of patients are partially or 
even completely resistant to SRLs. An effective treatment option to normalize IGF-I 
levels in partially resistant patients is the addition of the GH receptor antagonist 
PEGV to SRLs. A recent study from our group showed that patients using SRLs and 
PEGV combination treatment had a lower SST2 expression at time of surgery compared 
with medically naïve patients (8). The required PEGV dose to achieve IGF-I normaliza-
tion was inversely correlated to SST2 expression, but not to SST5 expression (8).
Pasireotide long-acting release (PAS-LAR) is a novel multireceptor somatostatin 
analogue, which binds with high affinity to all SSTR subtypes but SST4. In contrast to 
octreotide, pasireotide shows high subnanomolar affinity to SST5 (9). In vitro studies 
have shown that pasireotide modulates somatostatin receptor trafficking and phos-
phorylation in a distinct manner from octreotide (10, 11), inducing less SST2 inter-
nalization, phosphorylation and β-arrestin recruitment than octreotide. In medically 
naïve acromegaly patients PAS-LAR has demonstrated superior efficacy in reducing 
IGF-I levels over octreotide LAR, while the effect on GH reduction was superimposable 
(12). This latter observation was also recently confirmed in vitro (13). We recently 
reported the 24-weeks results of the Pasireotide LAR and Pegvisomant (PAPE) study 
(14). This prospective open-label conversion study assessed the efficacy and safety 
of PAS-LAR alone or in combination with PEGV in acromegaly patients controlled 
with SRLs and PEGV combination treatment (14). Switching to PAS-LAR resulted in a 
significant PEGV dose reduction, but also a higher incidence of diabetes mellitus (14).
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It is assumed that the efficacy of a given somatostatin receptor ligand is directly 
correlated to the SSTR subtype binding profile and the pattern of SSTR expression in 
the somatotroph adenoma (5, 6). However, although guidelines do not report specific 
recommendations so far, it is generally assumed that octreotide and lanreotide are 
more effective when SST2 is highly and predominantly expressed, while pasireotide is 
more effective when SST5 is the predominant subtype and SST2 is absent or poorly ex-
pressed (15). The aims of the present study were therefore: 1) to investigate whether 
the IGF-I response after SRL treatment correlates to the IGF-I response after PAS-LAR 
treatment; 2) to investigate to what extent SST2 and SST5 immunoreactivity are cor-
related to responsiveness to PAS-LAR treatment in somatotroph adenomas.
MAterIAls ANd MetHods
Patients and somatotroph adenoma tissue selection
Data collection of acromegaly patients was performed at the Erasmus MC Pituitary 
Center in Rotterdam. We initially started with a cohort of 61 acromegaly patients 
who received PAS-LAR treatment during their participation in the PAPE study (Figure 
1) (14).
All these patients have previously been treated with SRLs, followed by SRL and PEGV 
combination therapy. Cabergoline was used in 7 patients in combination with SRLs, 
and in two patients during the PAPE study (14). After exclusion of patients that re-
ceived postoperative radiotherapy (n = 7), and patients that received SRL treatment 
less than 4 months (n = 2), 52 patients remained and were finally included in the 
study cohort. In total 19 out of these 52 patients previously underwent neurosurgery. 
Reasons for surgery included adenomas with reasonable chance for cure such as (in-
trasellar) microadenomas, or macroadenomas with risk of visual impairment.
We selected only those patients with sufficient adenoma tissue available to perform 
immunohistochemistry (IHC). One patient underwent a second surgery during follow-
up. For clarity, in this latter case we analyzed only the tissue sample of the first 
surgery. From the 14 remaining somatotroph adenoma tissue samples included for 
IHC analysis (SSTR subcohort), 10 tissue samples have been stained previously (8), 
while 4 cases were newly stained (figure 1). We retrospectively collected data on 
medical history and clinical response to first-generation SRLs. Prospective data on the 
PEGV dose and IGF-I levels were used from the PAPE study (14). The PAPE study was 
registered with ClinicalTrials.gov, number NCT02668172. All patients were included 
after written informed consent.
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outcomes
Response to SRL treatment was defined as IGF-I x age-adjusted upper limit of normal 
(IGF-I x ULN), and as percentage of IGF-I suppression after at least 4 months SRL 
treatment. In patients that underwent surgery, post-operative IGF-I levels after at 
least 3 months were considered. Response to PAS-LAR during the PAPE study was 
divided into short-term and long-term response. Short-term treatment response was 
defined as IGF-I levels (x ULN) at 24 weeks (i.e. after 3 injections of PAS-LAR 60 mg). 
During the extension phase from 24 until 48 weeks, both the PAS-LAR dose and PEGV 
dose were titrated according to a protocol to achieve IGF-I levels within the normal 
range. Therefore, the long-term response to PAS-LAR was based on a composite “PAS-
LAR treatment response score” (PAS-LAR score) in order to fully capture the effect 
of PAS-LAR taking into account PEGV dose reduction, discontinuation and eventually 
PAS-LAR dose reduction. The PAS-LAR score comprised five categories representing the 
difference in PEGV dose and PAS-LAR dose at week 48 versus baseline (week number 
0): 0 = PEGV dose reduction 0-33% (in combination with PAS-LAR 60 mg), 1 = PEGV dose 
figure 1. Flowchart of the selection procedure for the study cohort and the somatotroph adenoma 
tissue samples included in the SSTR subcohort.
All patients eventually received SRL and PEGV combination treatment, and were switched to pa-
sireotide LAR treatment during the PAPE study (14). SRL = first-generation long-acting somatostatin 
receptor ligands; PEGV = pegvisomant; PAPE = pasireotide LAR and pegvisomant study; SSTR = 
somatostatin receptor subtype; IHC = immunohistochemistry.
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reduction 33-66% (+ PAS-LAR 60 mg), 2 = PEGV dose reduction 66-100% (+ PAS-LAR 60 
mg), 3 = PEGV treatment discontinued and PAS-LAR dose reduced to 40 mg, 4 = PEGV 
treatment discontinued and PAS-LAR dose reduced to 20 mg every 4 weeks. 100% PEGV 
dose reduction corresponds to PAS-LAR 60 mg monotherapy. Higher PAS-LAR score 
corresponds to a better response to PAS-LAR treatment.
Igf-I assays
Total IGF-I serum concentrations during the PAPE study were measured by the immu-
nometric IDS-iSYS assay (Immunodiagnostic Systems Limited; Boldon, United Kingdom; 
intraassay coefficient of variation (CV) 8.1%, interassay CV 2.1%) (16). Total IGF-I serum 
concentrations before and after SRL treatment were measured using different assays: 
Immulite 2000 assay, a solid-phase, validated enzyme-labelled chemiluminescent 
immunometric assay (DPC Biermann GmbH/Siemens, Fernwald, Germany; intraassay 
variability of 2–5%, interassay variability of 3–7%), the immunometric IDS-iSYS assay 
(Immunodiagnostic Systems Limited; Boldon, United Kingdom; intraassay coefficient 
of variation (CV) 8.1%, interassay CV 2.1%), and two different radioimmunoassays 
(Diagnostic Systems Laboratories, Webster, Tex., USA, intraassay CV 3.9%, interassay 
CV 4.2%), and Medgenix Diagnostics, Fleurus, Belgium; intraassay coefficient of varia-
tion (CV) 6.1%, interassay CV 9.9%). Total IGF-I was interpreted according to the sex 
and age-dependent ranges used in accordance with previous reports (17, 18). Because 
different IGF-I assays were used over time, IGF-I levels were expressed as upper limits 
of normal (ULN), and not as the absolute values.
Immunohistochemistry
Somatotroph adenoma tissues were stained for hematoxylin and immunostained 
for SST2 and SST5. Formalin-fixed paraffin-embedded tumor samples were cut into 
sequential 4-μm-thick sections and deparaffinized and stained using a fully automated 
Ventana BenchMark ULTRA stainer (ref: 790-2208, Ventana, Tucson, Ariz., USA) ac-
cording to the manufacturers’ instructions at the Pathology Department. Binding 
of peroxidase-coupled antibodies was detected using 3,39-diaminobenzidine as a 
substrate, and the sections were counterstained with hematoxylin. The rabbit mono-
clonal anti-SSTR2 antibody clone UMB-1 (SS-8000, BioTrend, Köln, Germany) was used 
at a dilution of 1:50, and the rabbit monoclonal anti-SSTR5 antibody clone UMB-4 
at a dilution of 1:400 (ab109495, Abcam, Cambridge, UK). Normal pancreatic tissue 
served as a positive control for both SST2 and SST5 staining. For negative controls, 
the primary antibody was omitted. Immunostaining of the adenomas was scored 
semiquantitatively based on an immunoreactivity scoring system (IRS). The IRS is cal-
culated by the product of the percentage of positive stained cells (0: 0%; 1: <10%; 2: 
10–50%; 3: 51–80%; 4: 80%) and the staining intensity (0: no staining; 1: weak staining; 
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2: moderate staining; 3: strong staining) (19). The IRS ranges between 0 and 12. The 
newly stained somatotroph adenoma tissue samples were scored by two independent 
investigators (A.M. and E.C.) based on the histopathological description of the sample 
provided by the pathologist. Both investigators were blinded to each other’s findings 
and the patients’ characteristics. Figure 2 shows two representative cases.
statistical methods
Categorical data were represented as observed frequencies and percentages. Continu-
ous data were represented as mean and 95% confidence interval (CI) or median and 
range. The Kolmogorov-Smirnov and the Shapiro-Wilk test were used to test normality 
of variables. If assumption of normal data distribution was met, the paired t-test was 
used. For non-normally distributed variables the Wilcoxon signed-rank test was used. 
Results of correlation analyses were represented as Spearman’s Rank correlation 
figure 2. SST2 and SST5 protein expression of somatotroph adenomas scored by the immunoreac-
tivity score (IRS).
HE = Haematoxylin and eosin; SSTR2 = somatostatin receptor subtype 2; SSTR5 = somatostatin 
receptor subtype 5, IRS = immunoreactivity score.
104
Chapter 5
coefficients (r). We considered P-values < 0.05 (two-tailed) to be statistically signifi-
cant. Statistical analyses were performed with SPSS version 24 (IBM SPSS Statistics for 
Windows, Armonk, N.Y., USA) and graphs were drawn using GraphPad Prism version 6 
for Windows (GraphPad Software, San Diego, California, USA).
results
Patient characteristics and treatment modalities
Characteristics of the 52 patients included in the study cohort are presented in Table 
1. After initial treatment with SRLs, most patients (84.6%) had IGF-I levels above 1.2 x 
the ULN. All patients continued to receive SRL and PEGV combination treatment with 
a median PEGV dose of 100 mg/week (IQR 60–160).
table 1. Patient characteristics entire cohort
characteristics Patients (n = 52)
Age (median, range) 53.5 (26 – 80)
Female patients (n, %) 22 (42.3%)
Macroadenomas (n, %) 44 (84.6%)
Previous surgery (n, %) 19 (34.6%)
SRL treatment prior to surgery (n, %) 5 (9.6%)
SRL treatment duration (months, mean, 95% CI) 11.2 (8.2 – 14.2)
IGF-I before SRL therapy (x ULN, mean, 95% CI) 3.14 (2.80 – 3.49)
IGF-I after SRL therapy (x ULN, mean, 95% CI) 2.13 (1.82 – 2.45)
IGF-I ≤ 1.2 x ULN after SRL monotherapy (n, %) 13 (27.1%)
Weekly PEGV dose (mg, mean, 95% CI) 137 (101–172)
IGF-I levels are shown before initiation of SRL monotherapy and after ≥ 4 months SRL monotherapy. 
PEGV dose during SRL and PEGV combination therapy at baseline of PAPE study.
Table 2 reports the characteristics of patients that were included in the SSTR sub-
cohort (n = 14). All these patients harboured a macroadenoma. 5 out of 14 patients 
had received SRL treatment prior to surgery, [4 achieved initial IGF-I normalization (< 
1.2 x ULN)] and the remaining nine patients were drug-naïve before surgery. During 
follow-up, all 14 patients received SRL and PEGV combination therapy (median PEGV 
dose 100 mg/week (IQR 80–145)). After 24 weeks, the median PEGV dose was 45 mg/
week (IQR 23–75) and decreased to 0 mg/week (IQR 0–70) after 48 weeks. Three out 
of 14 (21.4%) patients were on PAS-LAR monotherapy after 24 weeks, increasing to 
8 patients (57.1%) after 48 weeks. More in detail, in two patients PAS-LAR dose was 
reduced to 40 mg and in two other patients to 20 mg monotherapy every 4 weeks.
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In the study cohort (n = 52), at 24 weeks, the median PEGV dose was 45 mg/week (IQR 
30–80) and 10 of 52 (19.2%) patients were on PAS-LAR monotherapy. At 48 weeks, the 
median PEGV dose decreased to 40 mg/week (IQR 0 – 90) and 25 of 52 (48.1%) patients 
were on PAS-LAR monotherapy.
Protein expression of sst2 and sst5
The median SST2 IRS was 9 (IQR 5–12), the median SST5 IRS was 12 (IQR 5.5–12), and 
the median SST2/SST5 ratio was 1.0 (IQR 0.6 – 1.8). We did not find a statistically 
significant difference in SST2 and SST5 expression between medically naïve (n = 9) and 
SRL pre-treated (n = 5) patients (P = 0.31 and P = 0.25, respectively). More in detail, 
median SST2 IRS was 12 (IQR 5 – 12) in pre-treated patients and 8 (4 – 10.5) in the 
naïve ones, while median SST5 IRS was respectively 6 (2– 12) and 12 (8.5 – 12) in SRL 
pre-treated and naïve patients.
The relation between SSTR immunoreactivity and response to SRL treatment is shown 
in the supplemental data (page 118) (20). In line with previous findings, the percentage 
IGF-I reduction after SRL treatment was positively correlated to SST2 IRS, while an 
inverse trend was observed between SST2 IRS and IGF-I (x ULN) levels after SRL treat-
ment. The PEGV dose at baseline during the PAPE study was inversely correlated to 
the SST2 IRS.
relationship between response to srl treatment and PAs-lAr 
treatment in study cohort
We observed a significant positive correlation between IGF-I (x ULN) levels after SRL 
treatment and IGF-I levels after 24 weeks PAS-LAR treatment (r = 0.50, P = 0.0002, n 
= 52, 3A). However, no relation was observed between the percentage IGF-I reduction 
after SRL treatment and after 24 weeks PAS-LAR treatment (r = 0.026 P = 0.85, n = 52) 
(Supplemental Figure 1A) (20). With respect to response to PAS-LAR after 48 weeks, 
IGF-I (x ULN) levels after SRL treatment showed a strong inverse correlation with the 
PAS-LAR score (r = −0.53, P = 0.0006, n = 52, Figure 3B). Moreover, the percentage 
IGF-I (x ULN) reduction after SRL treatment was positively correlated to the PAS-LAR 
score (r = 0.40, P = 0.003, n = 52, Figure 3C) as well. We also observed a significant 
relationship between IGF-I (x ULN) levels after SRL treatment and after 48 weeks 
PAS-LAR treatment (r = 0.30, P = 0.028, n = 52) (Supplemental Figure 1B) (20).
relationship between response to srl treatment and PAs-lAr 
treatment in sstr subcohort
In the SSTR subcohort, we observed a positive correlation between IGF-I (x ULN) 
levels after SRL treatment and after 24 weeks PAS-LAR treatment (r = 0.58, P = 0.029, 
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n = 14, Figure 4A), while no corelation was observed with percentage IGF-I reduction 
(Supplemental Figure 1C) (20). Higher SST2 IRS was correlated with lower IGF-I levels 
(x ULN) after 24 weeks PAS-LAR treatment (r = −0.61, P = 0.020, n = 14, Figure 4B), 
while SST5 IRS did not show any relation to IGF-I levels (r = 0.16, P = 0.58, n = 14, 
Figure 4C).
figure 3. Relation between response to SRL treatment and response to PAS-LAR treatment in the 
study cohort. IGF-I (x ULN) levels after SRL treatment were correlated to IGF-I (x ULN) levels after 
PAS-LAR treatment at 24 weeks (3A), and inversely correlated to the PAS-LAR score at 48 weeks 
(3B). The percentage IGF-I (x ULN) reduction after SRL treatment was positively correlated to the 
PAS-LAR score at 48 weeks (3C).
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With respect to the 48 weeks PAS-LAR response, the PAS-LAR score at 48 weeks was 
inversely correlated to IGF-I (x ULN) levels after SRL treatment (r = −0.71, P = 0.005, n 
= 14, Figure 5A), and positively correlated to the percentage IGF-I reduction after SRL 
treatment (r = 0.80, P = 0.001, n = 14, Figure 5B). Furthermore, IGF-I (x ULN) levels 
figure 4. Relation between response to SRL treatment and the response to PAS-LAR treatment at 
24 weeks in the SSTR subcohort. IGF-I (x ULN) levels after PAS-LAR treatment at 24 weeks were 
correlated to IGF-I levels after SRL treatment (4A), and inversely correlated to SST2 expression 
(4B), but not to SST5 expression (4C).
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after SRL treatment were correlated to IGF-I (x ULN) levels after PAS-LAR treatment 
at 48 weeks (r = 0.58, P = 0.031, n = 14, Supplemental Figure 1D) (20).
We observed a trend, although not statistically relevant, for a direct correlation 
between SST2 IRS and the PAS-LAR score (r = 0.41, P = 0.14, n = 14, Figure 5C), and 
no relation was found between SST5 IRS and PAS-LAR score (r = −0.073, P = 0.80, n = 
14, Figure 5D). Interestingly, considering only those patients naïve to SRL treatment 
before surgery (n = 9), the correlation between SST2 IRS and the PAS-LAR score (r = 
0.69, P = 0.039, n = 9) was statistically significant, while this was not the case for 
SST5 IRS.
figure 5. Relation between response to SRL treatment and the response to PAS-LAR treatment at 
48 weeks in the SSTR subcohort. The PAS-LAR score at 48 weeks was inversely correlated to IGF-I (x 
ULN) levels after SRL treatment (5A), and positively correlated to the percentage IGF-I reduction 
after SRL treatment (5B). The PAS-LAR score showed a trend for a relation with SST2 expression 
(5C), but SST5 expression did not show any relation (5D).
110
Chapter 5
dIscussIoN
Our results suggest that in acromegaly patients the responsiveness to PAS-LAR treat-
ment is mainly correlated to SST2 expression, and not to SST5. This observation is 
further supported by the finding that after 48 weeks treatment the percentage IGF-I 
reduction after SRL treatment was correlated to the PAS-LAR treatment response 
score. Our study provides the novel finding that the in vivo response to PAS-LAR is 
directly correlated to both the clinical response to first-generation SRL treatment and 
SST2 expression on adenoma tissue.
However, these results are not unexpected. Indeed, our data confirm previous in vitro 
studies, carried out in primary cultures of GH-secreting adenomas, showing that the 
efficacy of naïve somatostatin (SRIF-14), octreotide and pasireotide in the reduc-
tion of GH secretion was positively correlated with SST2 mRNA expression, but not 
with SST5 (13, 21, 22). According to these findings, our group and other authors have 
reported that the effect of octreotide and pasireotide on GH suppression is almost 
superimposable both in vitro and in vivo (12, 13, 23).
The observed positive relation between SST2 protein expression and the percentage 
IGF-I reduction after SRL treatment, is in line with previous studies (5, 6). Further-
more, an inverse relation between the PEGV dose and SST2 expression was recently 
reported, suggesting that the required PEGV dose to normalize IGF-I levels in patients 
with partial response to SRLs is a surrogate marker for the degree of SRL resistance 
(8). In our cohort, the SRL pretreated patients had a trend for a higher SST2 expression 
than medically naïve patients. This finding is in contrast to previous studies (5, 6), and 
it is probably correlated to a lack of statistical power in our study (5 vs 9 adenoma 
samples).
Our results show that IGF-I levels after PAS-LAR treatment were directly correlated 
to SST2 expression, and not to SST5 expression. After exclusion of SRL pretreated 
patients, SST2 IRS was also significantly correlated to the PAS-LAR score, a tool de-
signed to uncover the impact of switching to PAS-LAR treatment in patients using 
SRLs and PEGV combination treatment. While there is no evidence that SST5 expres-
sion is affected by SRL presurgical treatment, it has been widely demonstrated that 
patients receiving SRL treatment prior to neurosurgery show significantly lower SST2 
protein expression compared to medically naïve patients (4-6, 13). Although this is 
not evident in our cohort, a pooled analysis of SRL pretreated and medically naïve 
patients can introduce bias. Exclusion of the SRL pretreated patients from our analysis 
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(n = 5) resulted in a stronger relationship between SST2 IRS and the response to PAS-
LAR treatment.
A strength of our study lies in the relatively large number of patients in which the 
clinical efficacy of SRLs, SRL/PEGV combination treatment and PAS-LAR treatment 
were systematically investigated in combination with data on SSTR expression 
of somatotroph adenomas in a well characterized subgroup of patients. The main 
limitation of our study lies in the retrospective collection of data on IGF-I levels 
during SRL treatment and the use of different IGF-I assays during follow-up. The IGF-I 
levels measured after 24 weeks PAS-LAR treatment may be partly influenced by the 
carry-over effect of withdrawal of SRLs after 12 weeks. While the carry-over effect 
of SRLs may have influenced the short-term response to PAS-LAR after 24 weeks, the 
response to PAS-LAR treatment after 48 weeks is probably not affected. In our cohort, 
the PAS-LAR score at 48 weeks might therefore be the most informative marker for 
responsiveness to PAS-LAR treatment.
Two studies have previously investigated the relationship between the immunohis-
tochemical expression of SST2 and SST5 in somatotroph adenomas and the clinical 
response to first-generation SRL and PAS-LAR treatment in acromegaly (24). Iacovazzo 
et al suggested that SST5 expression drives the responsiveness to PAS-LAR treatment 
in patients resistant to first-generation SRLs. These authors investigated a cohort of 
39 acromegaly patients requiring post-operative SRL treatment, of which 11 patients 
were resistant to SRL and were switched to PAS-LAR treatment. They observed that 
none of the patients lacking SST5 expression was responsive to PAS-LAR, whereas 5 
out of 7 patients with membranous expression of SST5 were responsive to PAS-LAR. 
Furthermore, patients with a higher SST5 score had a greater reduction in IGF-I levels. 
However, they found no difference in SST2 expression between pasireotide responders 
and non-responders.
These results are in contrast with our findings, which suggest that SST2 expression, 
and not SST5 expression, is more important for the clinical response to PAS-LAR. The 
main difference between our study and the study from Iacovazzo et al. (24), is that 
we included mainly patients who were partially responsive to SRLs, while Iacovazzo 
et al included only SRL resistant patients. Secondly, the patients in our cohort all 
received pegvisomant treatment before switching to pasireotide LAR during the PAPE 
study, whereas the patients in the Iacovazzo study did not receive PEGV treatment, 
and were directly switched to pasireotide LAR (Table 2). In addition, these differ-
ences are unlikely to be explained by the use of a different SSTR expression scoring 
system. Although the other authors used a scoring method proposed by Volante et al 
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which takes into account both subcellular localization and extent of staining (25), the 
method we used from Remmele et al is a semiquantitative score which takes into ac-
count both intensity and percentage of positive cells (19). Interestingly, both scoring 
systems have been recently found to show high inter-laboratory and inter-observer 
agreement for SSTRs expression in neuroendocrine tumors (26).
Furthermore, in our cohort we cannot rule out a direct effect of PEGV treatment on 
SSTR expression (8). PEGV is known to increase serum GH levels (27), which could 
result in reduced hypothalamic GHRH secretion, which in turn may lead to a down-
regulation of SSTR expression. Although the impact of PEGV on SSTR expression is 
plausible (28), there is no evidence that PEGV treatment plays a major role in the 
modulation of SSTR expression via the activation of GH-IGF-I axis.
While our study suggests that pasireotide acts mainly via SST2 in somatotroph adeno-
mas, in corticotroph adenomas SST5 seems to be more important. Several in vitro 
studies have demonstrated that pasireotide is more effective than octreotide in 
reducing ACTH secretion and/or intracellular cAMP levels in AtT20 cells or cortico-
troph adenomas primary cultures (29-32). On the other hand, preclinical studies have 
indicated that pasireotide and octreotide are equally effective (in vitro) in lowering 
GH levels (21, 23, 33, 34). This suggests a predominant role of SST2 in mediating the 
inhibitory effect of pasireotide on GH secretion in somatotroph adenomas.
In conclusion, our results suggest that SST2 expression of somatotroph adenomas is 
more important than SST5 in driving the responsiveness to PAS-LAR treatment in a 
peculiar subset of acromegaly patients (e.g. partial responders). It is plausible that 
the enhanced efficacy of PAS-LAR compared to first-generation SRLs is mediated by 
its stronger inhibition of insulin secretion, rendering the liver less sensitive to GH 
action (35). The enhanced efficacy of PAS-LAR could also be the consequence of a 
differential activation of SST2 by the different compounds (e.g. reduced activation of 
SST2 internalization and faster recycling on the cell membrane) (36, 37), rather than 
by the higher binding affinity of PAS-LAR for SST5. Future studies should investigate 
whether this is indeed the case.
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suPPleMeNtAl dAtA
Relationship between SSTR immunoreactivity and response to SRL treatment
The percentage IGF-I reduction after SRL treatment was positively related to SST2 IRS 
(r = 0.54, P = 0.046, n = 14), but no correlation was found with SST5 IRS (r = 0.090, P 
= 0.76, n = 14).
IGF-I (x ULN) levels after SRL treatment showed an inverse trend with SST2 IRS (r = 
−0.31. P = 0.28, n = 14), while no correlation was observed with SST5 IRS (r = −0.12, P 
= 0.69, n = 14) (Figure 2A and 2B). Exclusion of SRL pretreated patients did not change 
the relation to SST2 (r = −0.34, P = 0.37, n = 9) and SST5 IRS (r = 0.10, P = 0.98, n = 9).
Relationship between baseline PEGV dose during combination treatment and 
SSTR immunoreactivity
We observed an inverse correlation between the PEGV dose at baseline and SST2 IRS 
(r = −0.61, P = 0.020, n = 14), but SST5 IRS was not correlated with the PEGV dose (r 
= 0.32, P = 0.27, n = 14).
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AbstrAct
background: Data on plasma acylated ghrelin (AG) and unacylated ghrelin (UAG) lev-
els in acromegaly are limited. High ratios of AG/UAG are linked with type 2 diabetes, 
obesity and hyperphagia (e.g. in Prader-Willi syndrome).
objective: To assess fasting plasma AG and UAG levels, and the AG/UAG ratio in 
acromegaly patients on combination treatment of long-acting somatostatin analogues 
and pegvisomant. As a control, we used patients controlled with pegvisomant mono-
therapy, and medically naïve patients with active acromegaly.
Methods: Fasting venous blood samples (combination therapy N = 60; monotherapy N 
= 4; naïve N = 5) were collected and directly stabilized with AEBSF to inhibit deacyla-
tion of AG. Plasma AG and UAG levels were determined by double-antibody sandwich 
EIA and the AG/UAG ratio was calculated.
results: Plasma AG and UAG levels were significantly lower in acromegaly patients 
on combination treatment (AG: 8.5 pg/ml, 2.9-21.1 (median, interquartile range)) 
(UAG: 26.9 pg/ml, 11.2-42.1) compared to patients using pegvisomant alone (AG: 60.5 
pg/ml, 58.8-77.4) (UAG: 153.7 pg/ml, 127.3-196.0) and medically naïve acromegaly 
patients (AG: 24.0 pg/ml, 12.6-49.7) (UAG: 56.3 pg/ml, 43.4-61.5). However, AG/UAG 
ratios were similar in all groups.
conclusions: Although plasma AG and UAG are suppressed during combination 
treatment of LA-SSA and PEGV, the AG/UAG ratio remained similar. This shows that 
somatostatin analogues decrease both AG and UAG, which suggest that they do not 
alter metabolism significantly in acromegaly patients.
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INtroductIoN
Ghrelin is a small peptide hormone secreted mainly by neuroendocrine X/A cells in 
the stomach (1, 2). In the circulation it consists of two isoforms: acylated ghrelin (AG) 
and unacylated ghrelin (UAG). Both isoforms are detectable in equal amounts in the 
circulation (3). AG differs from UAG in being acylated by attachment of a medium-
chain fatty acid at its serine-3 residue. AG is acylated by the intracellular enzyme 
ghrelin O-acyl transferase (GOAT) and is responsible for the distinct metabolic and 
non-metabolic effects of ghrelin in vivo (4-11). AG acts on the hypothalamus through 
the growth hormone secretagogue receptor (GHSR1a) and is known to be diabetogenic, 
orexigenic and obesogenic. UAG does not bind to the GHSR1a receptor at physiologi-
cal concentrations and, therefore, was considered to be inactive. However, recent 
studies have shown that UAG is able to counteract the metabolic effects of AG (9, 12).
Because AG and UAG have distinct biological effects and can affect each other, the 
AG/UAG ratio may be a more important parameter than individual levels of AG and 
UAG (13-19). For example, elevated AG/UAG ratios have been associated with diabe-
tes, obesity and hyperphagia (13, 20-25). Hyperphagia is a hallmark of Prader-Willi 
syndrome, a rare cause of genetic early onset obesity, which is characterized by 
elevated total ghrelin levels, but changing AG/UAG ratios throughout life (20, 22, 
26). Recently, in patients with Azlheimer’s disease it was shown that rivastigmine, 
an acetylcholinesterase and butyrylcholinesterase inhibitor, improved appetite by 
increasing the AG/UAG ratio (27)
Regarding the relation of ghrelin with growth hormone (GH), it is known that ghrelin 
stimulates GH secretion, while ghrelin itself is reduced after GH infusion. However, the ex-
act physiological role of ghrelin in the regulation of GH release is not entirely established.
In acromegaly, a prototype disease characterized by excessive GH levels, the emerg-
ing picture from previous studies is that in medically naïve patients during active 
disease total ghrelin levels are lowered compared with controls (28-30). Ghrelin 
levels are elevated after surgery, while they are reduced during treatment with long-
acting somatostatin analogues (LA-SSAs) (29-32). Acromegaly patients treated with 
the competitive GH receptor blocker pegvisomant (PEGV) have higher total ghrelin 
levels than patients with active disease (33).
However, to our knowledge, the effect of combination treatment with LA-SSAs and 
PEGV on plasma AG and UAG levels in acromegaly remains unknown. Similarly, AG and 
UAG levels have not been assessed together in patients with acromegaly.
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Therefore, the aim of this study was to assess fasting plasma AG and UAG levels 
and to determine the AG/UAG ratio between acromegaly patients under combination 
treatment with somatostatin analogs and pegvisomant (N = 60), and compare them to 
pegvisomant monotherapy (N = 4) and medically naïve acromegaly patients (N = 5).
PAtIeNts ANd MetHods
study design
We prospectively recruited 69 acromegaly patients at our outpatient clinic at Erasmus 
University MC, Rotterdam between August 2015 and June 2016. The majority these 
patients were long-term biochemically controlled with combination treatment of LA-
SSAs and PEGV (N = 60), 4 patients were on pegvisomant monotherapy and 5 patients 
were medically naïve with active acromegaly. We excluded patients with eating dis-
orders, active malignancies, active inflammatory or infectious diseases, epilepsy and 
psychiatric disorders. Acromegaly patients were considered diabetic either if they 
were taking antidiabetic medication, or had a prior history of diabetes mellitus, or 
had glycated hemoglobin levels ≥ 6.5%.
In addition to measurement of plasma AG and UAG we assessed in the fasting state: 
glucose, insulin, HbA1c, IGF1 and GH. Also body weight and height. Serum glucose, 
insulin and HbA1c were determined with standard laboratory methods. The updated 
homeostasis model assessment (HOMA-2) was used to assess insulin resistance (HOMA-
IR) and beta cell function (HOMA-IB) from pairs of fasting glucose and insulin levels.
All patients gave their written informed consent, and the study was approved by the 
Medical Ethics Committee of Erasmus MC, Rotterdam.
Materials
Vacutainers were obtained from Becton Dickinson (Breda, Netherlands; cat# 367899; 
6 ml K2 EDTA), 4-(2-Aminoethyl) benzenesulphonyl fluoride hydrochloride (Pefabloc, 
SC AEBSF) was purchased from Roche Applied Science (cat# 11429876001; Almere, 
Netherlands). Stock solutions of 200 mg/ml AEBSF were prepared in distilled water 
(34, 35).
Human AG and UAG were determined by a double-antibody sandwich enzyme im-
munoassay (EIA) kits obtained from Bertin Pharma (Montigny-le-Bretonneux, France; 
A05106 and A05119, respectively) (34).
AG/UAG ratio is similar in acromegaly patients during different treatment regimens
125
6
Total IGF1 concentrations were measured by chemiluminescent immunometric assay 
(IDS-iSYS; Immunodiagnostic Systems Limited; Boldon, United Kingdom), and were 
interpreted according to the sex-dependent and age-dependent ranges. GH levels 
were measured using the IDS-iSYS assay, this assay is free of interference from PEGV 
(36).
blood collection, Aebsf treatment and storage
Overnight fasting venous blood samples for the measurement of plasma AG and plasma 
UAG were withdrawn and collected in EDTA tubes. One 4 ml EDTA tube per patient was 
collected. AEBSF was immediately added to all blood samples (dilution 1:100; final 
2mg/ml) to prevent deacylation of AG to UAG (34, 37). Whole blood was mixed gently 
by inversion (3x) and stored on water ice (4°C) until centrifugation at 2500 g at 4°C 
for 5 minutes. Plasma of these venous blood samples was then rapidly aliquoted in 
four 1.5 ml Eppendorf tubes (300 μl each). All plasma samples were stored at –80°C 
until the assay was performed. AEBSF was stored for a maximum of one month after 
dilution.
Acylated and unacylated ghrelin elIsAs
After thawing on ice, plasma samples were centrifuged for 1 min at 1500 g 4°C, and 
kept on ice before transferring to the assay plates. All samples were measured in 
duplicate (50 µl/well) according to the manufacturer’s protocol (34).
A sigmoidal third order cubic polynomial fitting was used to determine concentrations 
from the calibration curves. This resulted in r² values >0.99 in the majority of the 
assays. For the Bertin Pharma EIAs, the average intra-assay percent coefficient of 
variation (%CVs) for AG was 2.1 and for UAG 4.6. The average inter-assay %CVs for AG 
was 9.5 and for UAG 12.8. Their %CVs were assessed over six assays. The lower limit 
of detection was 4 pg/ml.
statistical analysis
Analyses were performed using SPSS software (version 24 for Windows; SPSS Inc., 
Chicago, Illinois) and GraphPad Prism® Version 6.04 (GraphPad Software, San Diego, 
USA). The Kolmogorov-Smirnov test was used to test normality of variables (data 
were considered to be normally distributed when p > 0.05). Comparisons across all 
groups were analysed with Kruskall-Wallis test. Comparisons between patient groups 
were analysed by Wilcoxon signed-ranks tests and Mann-Whitney U tests. Correlation 
analyses were done using Spearman’s rank correlation test. Data were expressed as 
median [interquartile range (IQR)] as they were not normally distributed. P-values of 
< 0.05 were considered statistically significant.
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results
clinical characteristics
Table 1 shows the patients demographics, characteristics and disease history. Plasma 
AG and UAG were measured in a total of 69 acromegaly patients. One third of pa-
tients (20/60) on combination treatment had previously received surgery, while 7 of 
60 patients had received surgery and radiotherapy in the past. In patients on PEGV 
monotherapy 2 of 4 patients had received both surgery and radiotherapy. In medically 
naïve patients with active disease 2 of 5 patients had previously received surgery. 
Clinical characteristics were comparable among the groups with respect to age, sex, 
BMI and previous therapy. Patients on combination treatment with LA-SSAs and PEGV 
and patients on PEGV monotherapy had IGF1 levels within the age- and sex adjusted 
normal limits.
Figure 1 shows the median fasting levels of AG, UAG and the AG/UAG ratio. Levels of 
AG and UAG were significantly different between the different groups (AG P = 0.004 
and UAG P = 0.005 Kruskal-Wallis test).
table 1. Characteristics of all patients in the three study groups.
Parameters lA-ssA + PegV PegV Medically naïve 
acromegaly
No. of patients 60 4 5
Sex – male (%) 32 (53) 2 (50) 2 (40)
Age, years, mean (range) 54 (27 – 81) 62 (44 – 82) 44 (29 – 62)
BMI (kg/m²) 28.8 (26.0 – 31.7) 30.9 (24.1 – 34.9) 30.3 (26.1 – 35.4)
Previous therapy
Surgery (%) 20 (33) 0 2 (40)
Radiotherapy (%) 0 0 0
Surgery and radiotherapy (%) 7 (11.7) 2 (50) 0
IGF1 (nmol/l) 25.7 (22.2 – 32.3) 27.0 (22.4 – 36.0) 96.1 (64.0 – 166.0)
IGF1 x ULN 0.99 (0.85 – 1.12) 1.09 (0.90 – 1.28) 3.63 (2.20 – 4.50)
GH (μg/L) 4.6 (1.7 – 8.6) 3.1 (0.7 – 17.6) 15.4 (11.7 – 112.0)
Fasting glucose (mmol/l) 6.1 (5.6 – 6.8) 4.6 (4.3 – 4.9) 5.5 (5.1 – 6.2)
HbA1c (%) 5.9 (5.7 – 6.2) 5.6 (5.5 – 5.9) 5.6 (5.3 – 6.4)
Diabetes mellitus (%) 14 (23) 0 (0) 1 (20)
HOMA-IR score 1.1 (0.7 – 1.5) NA NA
HOMA-β score 67.2 (49.3 – 90.5) NA NA
PEGV dose (mg/week) 100 (60 – 160) 175 (95 – 289) -
Data are expressed as median and interquartile range (IQR), unless specified otherwise. NA = not 
available
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Median (IQR) AG levels were significantly lower in patients using combination treat-
ment compared with patients using PEGV monotherapy and with medically naïve 
patients, 8.5 (2.9 – 21.1) pg/ml versus 60.5 (58.8 – 77.4) pg/ml (P = 0.0002 Mann-
Whitney U test) versus 24.0 (12.6 – 49.7) pg/ml (P = 0.03 Mann-Whitney U test). 
figure 1. Plasma acylated ghrelin (AG), plasma unacylated ghrelin (UAG) and acylated ghrelin/un-
acylated ghrelin (AG/UAG) ratio in acromegaly patients on combination treatment of LA-SSAs and 
PEGV (N=60), acromegaly patients on PEGV monotherapy (N=5), and medically naïve acromegaly 
patients (N=4). Data are expressed as median ± interquartile range (IQR).
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There was no significant difference in AG between patients using PEGV and medically 
naïve patients (P = 0.25 Wilcoxon Signed Rank test).
Although UAG levels were higher than AG levels in all groups, they showed a similar 
pattern. Median (IQR) UAG levels were significantly lower during combination treat-
ment compared with the other groups, 26.9 (11.2 – 42.1) pg/ml versus 127.3 (153.7 
– 196.0) pg/ml (P = 0.0002 Mann-Whitney U test), versus 56.3 (43.3 – 61.5) pg/ml (P 
= 0.03 Mann-Whitney U test). Similar to AG, UAG levels were not different between 
patients using PEGV and medically naïve patients (P = 0.13 Wilcoxon Signed Rank 
test).
AG/UAG ratios were not significantly different between the groups (P = 0.65). Median 
(IQR) AG/UAG ratio was 0.38 (0.16 – 0.59) in the combination group versus 0.40 (0.31 
– 0.60) in the PEGV monotherapy group versus 0.53 (0.24 – 0.90) in medically naïve 
patients.
The highest AG level of 140.6 pg/ml was observed in a 55-year-old male patient with 
long-term controlled acromegaly with lanreotide Autogel 120 mg every 4 weeks and 
PEGV 100 mg per week. At the time of the blood withdrawal this patient had an IGF1 
level of 1.17 times the ULN. His type 2 diabetes (HbA1c 6.9%) was well regulated with 
metformin and he received testosterone replacement due to hypogonadism.
In another patient, we observed the second highest AG level of 117.1 pg/ml and the 
highest observed UAG level of 177.5 pg/ml. This was a 27-year-old acromegaly patient 
who received a transsphenoidal hypophysectomy twice in the past. At the time of the 
blood withdrawal she was controlled with octreotide LAR every 4 weeks and PEGV 80 
mg per week.
Concentrations of plasma AG (figure 1A) and UAG (figure 1B) were very low in the 
LA-SSA and PEGV combination treatment group. In 17 (28%) patients on combination 
treatment AG levels were undetectable, while in 4 (6.7%) patients UAG levels were 
undetectable.
We found no statistically significant relationship in acromegaly patients between 
plasma AG, UAG and AG/UAG ratios versus biochemical (GH, IGF1, HbA1c levels, 
HOMA-IR score, HOMA-B score and clinical parameters (age, sex, BMI, diabetes, 
previous surgery, previous radiotherapy, PEGV dose) among the groups. Although not 
significant, a negative correlation (r = −0.25, P = 0.06) was observed between previous 
surgery and UAG levels in patients on combination treatment.
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dIscussIoN
Our main finding was that the AG/UAG ratio was not altered in acromegaly patients 
during different treatment regimens. AG and UAG levels were suppressed during 
combination treatment with LA-SSAs and PEGV, compared with patients using PEGV 
alone and with medically naïve active acromegaly. This is in line with literature on 
total ghrelin levels, although they lack information on the ratios between AG/UAG. 
It is questionable whether higher single AG and UAG levels have a physiological role 
during PEGV treatment and active disease if the ratios remain the same. Therefore, 
assessment of total ghrelin assessment is probably not clinically useful.
The AG/UAG ratio is probably more clinically relevant than measurement of total 
ghrelin. The main problem with previous studies examining ghrelin levels in acromeg-
aly patients is the small number of samples assessed and the use of ghrelin assays that 
do not distinguish between acylated and unacylated ghrelin. Commercial radioim-
munoassays (RIA) and one-site competitive ELISAs measure total human serum ghrelin 
by using labelled unacylated ghrelin as a tracer and a polyclonal antibody against the 
C-terminal end of human ghrelin. These assays overestimate ghrelin levels because 
they measure peptide fragments as well as full-length peptide. These fragments exist 
naturally in the circulation and lack the N-terminal region, but can also be artificially 
produced during the assay procedure. Two-site ELISAs use antibodies directed against 
both ends of the peptide, and are therefore highly specific and will only measure 
unfragmented ghrelin. Using their two-site sandwich ELISA as a comparison, Akamizu 
et al have demonstrated that about 40-60% of the total ghrelin measured by RIA is 
likely fragmented (38). This was further confirmed by Prudom et al who showed that 
their two-site sandwich-ELISAs for AG and UAG provided greater specificity (39). They 
found that dynamic changes in acyl-ghrelin were dampened and less visible in the 
RIAs. AG has a short half-life and in circulation it is rapidly degraded into UAG. For 
this reason, blocking deacylation is crucial for reliable measurements of AG and UAG 
(34, 37).
The observation of low AG and UAG levels during combination treatment of LA-SSA 
and PEGV suggests that this effect is caused by the somatostatin analogues. This 
finding is in line with previous studies showing that LA-SSAs suppress ghrelin levels in 
acromegaly patients (29, 31). Freda et al evaluated fasting- and serum ghrelin levels 
after an oral glucose tolerance test in patients with active acromegaly at baseline 
and after either surgery or administration of LA-SSAs. They observed that fasting total 
ghrelin levels were higher in patients after surgery, but fell significantly after treat-
ment with LA-SSAs. They suggested that the postoperative lowering of insulin levels 
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and improved insulin sensitivity may have contributed to the postoperative rise of 
ghrelin levels (29). Another report has also suggested that acromegaly patients with 
greater insulin resistance have lower total ghrelin levels (28). Several studies have 
indicated that hyperinsulinemia inhibits AG and UAG secretion, conversely AG itself 
inhibits insulin secretion (14, 40-42). However, we could only assess insulin levels in 
the combination group and, therefore, cannot draw any conclusions on the difference 
in insulin sensitivity between the groups.
The observation of higher AG and UAG levels in patients using PEGV suggests that 
PEGV itself can stimulate AG and UAG. Roemmler et al showed that acromegaly 
patients using PEGV treatment had higher total ghrelin levels compared with healthy 
controls, patients with active acromegaly and inactive acromegaly (33). This finding 
suggests that treatment with PEGV might disrupt the feedback loop of ghrelin and 
GH, leading to elevated ghrelin levels. The ghrelin receptor (GHSR1a) is expressed 
in normal pituitary and somatotroph adenomas (43). GH administration has been 
shown to suppress total ghrelin levels in GH deficient patients (44). In rodents, GH 
administration in cultured stomach tissue reduced total ghrelin secretion, whereas 
hypophysectomy increased ghrelin levels (45-47). These results support the notion 
that GH exerts a negative feedback action on ghrelin secretion. Although there are 
no studies evaluating the direct effect of pegvisomant on ghrelin secretion, these 
data indirectly suggest that blockade of the GH receptor with pegvisomant leads to a 
positive feedback action on ghrelin secretion.
In patients using combination treatment median plasma AG levels were 8.5 pg/ml 
(range 0-140.6 pg/ml) and median UAG levels 26.9 pg/ml (0-177.5 pg/ml). This is 
considerably lower than levels that have been observed in healthy controls, measured 
using equivalent two-site sandwich assays and stabilized with AEBSF. Adrichem et 
al found median plasma AG levels of 57.2 pg/ml (range 10–273 pg/ml) and median 
plasma UAG levels of 64.9 pg/ml (range 8–331pg/ml) in 28 healthy controls, while Liu 
et al reported AG levels ranging from 43-366 pg/ml in four healthy volunteers (35, 48).
AG and UAG exert distinct effects on glucose homeostasis and insulin sensitivity. AG 
has diabetogenic actions, it induces insulin resistance and reduces insulin secretion. 
However, UAG displays antidiabetogenic actions (13-19). UAG alone or in combination 
with AG improves insulin sensitivity through the suppression of AG levels in obese 
subjects with type 2 diabetes (9). Studies have shown that insulin resistant obese 
subjects have an elevated AG/UAG ratio compared to insulin sensitive obese subjects 
(13, 24, 25), which can be explained by a relative UAG deficiency in obese subjects (23). 
Conversely, low AG/UAG ratios are associated with an improved metabolic state (21).
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Prader-Willi syndrome is characterized by distinct nutritional phenotypes, from 
anorexia in infancy to hyperphagia and obesity in childhood (26). Recently, it was 
revealed that although total hyperghrelinemia was observed at all ages throughout 
life in PWS, the AG/UAG ratio changed over time driving opposite phenotypes. While 
the AG/UAG ratio was low during infancy it switched to a high AG/UAG ratio at later 
life (20, 22).
These data illustrate that AG and UAG have opposing actions, and that the AG/UAG 
ratio yields more physiological importance than measurement of absolute levels of AG 
and UAG. Although our patients on combination therapy had lower AG and UAG levels, 
the AG/UAG ratio was similar between all groups, this suggests that treatment with 
LA-SSAs and PEGV does not alter the relation of AG with respect to UAG.
In summary, the plasma AG/UAG ratio is not altered in acromegaly patients during 
medical treatment. Absolute levels of individual assessments of AG and UAG, however, 
were lower than observed during the assessment of total ghrelin levels. Assessment of 
the AG/UAG ratio is more clinically relevant, because it is a better reflection of the 
physiological bioactive state of ghrelin than measurement of total ghrelin. Therefore, 
we recommend assessment of AG and UAG separately and calculation of the AG/UAG 
ratio.
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INtroductIoN
The main goal of this thesis was to study the position of pasireotide LAR in the medical 
management of acromegaly in relation to pegvisomant. To meet this goal we conducted 
the pasireotide LAR and pegvisomant (PAPE) study with the aim to assess the efficacy and 
safety of switching to pasireotide LAR with and without PEGV treatment in acromegaly 
patients controlled with SRL and PEGV combination treatment. The results of the PAPE 
study were discussed in Chapters 3 and 4. Based on the PAPE study we formulated our 
recommendations on the optimal position of pasireotide LAR in the medical treatment 
algorithm of acromegaly. In Chapter 5 we assessed whether the responsiveness to 
pasireotide LAR treatment was correlated with the responsiveness to first-generation 
SRL treatment and whether this also correlated with the somatostatin receptor subtype 
protein expression of the somatotroph adenoma. In Chapter 6 we investigated acylated 
and unacylated ghrelin levels in acromegaly patients during combination treatment. 
Finally, in Chapter 7 we undertook a pilot study to examine whether Kupffer cells are 
involved in the clearance of pegvisomant in vivo. This chapter will review the strengths 
and weakness of the studies presented in this thesis. The section ends with discussion 
on future developments and perspectives on new medical treatments of acromegaly.
Pegvisomant monotherapy
In chapter 2 we aimed to assess the efficacy and safety of withdrawing SRL treatment 
and switching to weekly PEGV monotherapy in 15 acromegaly patients controlled with 
combination treatment. We observed that switching to weekly PEGV monotherapy is 
a feasible treatment strategy without compromising biochemical control. After 12 
months of PEGV monotherapy 73% of patients had IGF-I levels within the normal range. 
The efficacy of switching to PEGV monotherapy depends on the PEGV dose at baseline 
and the duration of SRL treatment. In this study we deliberately included patients 
that used low doses of PEGV of ≤ 80 mg/week, as we expected that these patients 
could maintain control of disease activity in the short term after withdrawal SRL 
treatment. We observed that IGF-I levels started to increase 4 months after SRL treat-
ment discontinuation. This so-called carry-over effect of SRLs confirms observations 
in previous studies (1-3). We observed a large variation in PEGV serum levels between 
controlled and non-controlled subjects which was remains not well understood (4). 
The major drawback of this study is the small sample size.
Pasireotide and pegvisomant study
The aim of the PAPE study was to assess the real life efficacy and safety of switch-
ing to PAS-LAR in acromegaly patients biochemically controlled with SRL and PEGV 
combination treatment. The patients included in this study all received SRL and PEGV 
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combination treatment because they were partially to completely resistant to SRL 
monotherapy. To assess the efficacy of PAS-LAR on IGF-I normalization patients had 
to be ‘uncontrolled’ which was achieved by reduction of the PEGV dose by 50% for 3 
months. We found that PAS-LAR treatment normalized IGF-I levels in 77% of patients 
and the PEGV dose could be reduced by 50% at 48 weeks. While the efficacy of PAS-LAR 
at 24 weeks is partly influenced by the carry-over effect of first-generation SRLs which 
can take up to 4 months, at 48 weeks this was not the case. We observed a hetero-
geneous and wide range of clinical response to PAS-LAR treatment. This ranged from 
patients who were overresponsive to PAS-LAR and could reduce PAS-LAR to the lowest 
available dose of 20 mg, and patients who were completely unresponsive and could 
not reduce their high PEGV dose. This heterogeneity is illustrated by the observation 
that the patients in the PAS-LAR monotherapy group had a lower disease activity at 
baseline, with lower PEGV dose, IGF-I levels and GH levels compared with patient in 
the PAS-LAR and PEGV combination group.
An important observation in our study was the potent reduction of IGF-I after the 
first PAS-LAR injection. Although this early onset of effect of PAS-LAR is to some 
extent influenced by the carry-over effect of SRL treatment, this rapid reduction is 
probably caused by suppression of insulin secretion. The concomitant suppression of 
IGF-I secretion and insulin secretion after the first two PAS-LAR injections suggests 
that suppression of insulin is an important mechanism which explains the efficacy of 
PAS-LAR. Another explanation is that unlike octreotide, pasireotide induces less SST2 
internalization which could imply that there is a lower likelihood desensitization to 
pasireotide treatment.
safety
Hyperglycemia and diabetes mellitus
The most common and clinically relevant adverse event during the PAPE study was the 
development of hyperglycemia and diabetes mellitus. At baseline 32.8% of patients 
had diabetes in our cohort, which increased to 77% at the end of the study. The major-
ity of patients developed mild to moderate hyperglycemia which occurred mainly 
during the core study and was manageable with a combination of metformin and or 
vildagliptin. Several reasons account for the higher frequency of hyperglycemia in our 
study compared with previous clinical studies (5-8). First we included more patients 
with diabetes, as we used a more liberal HbA1c cut-off (<9%) as inclusion criterion. 
Secondly, we included older patients and more patients with pre-existent diabetes 
who were already on antidiabetic medication. Third, the reduction of the PEGV dose 
during the study progressively worsened glucose metabolism.
General discussion and future perspectives
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As expected, and in line with previous studies (7, 9), the development of severe 
hyperglycaemia after PAS-LAR treatment was correlated with baseline HbA1c and 
use of antidiabetic medication (Chapter 3). In order to find better predictors for 
pasireotide-induced hyperglycaemia we performed an oral glucose tolerance test 
(OGTT) at baseline. We estimated β-cell function as a measure for insulin secretion 
based on a model by Stumvoll et al (10, 11). An important caveat for the interpre-
tation of insulin secretion during the OGTT is the use of antidiabetic medication. 
While we excluded the use of insulin as an obvious confounder, the results should be 
interpreted with caution in patients using sulfonylureas and GLP-I analogues as both 
antidiabetic drugs increase insulin secretion (12, 13). It was not feasible to discon-
tinue all antidiabetic drugs before the OGTT. A novel finding is that we observed an 
inverse correlation between both the insulin area under the curve and the (residual) 
β-cell function at baseline with the increase in HbA1c between baseline and at 24 
weeks (Chapter 4). This entails that patients with attenuated (first-phase) insulin 
secretion had a greater risk of pasireotide-induced hyperglycaemia during the study. 
These data demonstrate that the baseline β-cell function is an important independent 
determinant for hyperglycaemia during PAS-LAR treatment and probably a better 
marker than single measurements of HbA1c or fasting plasma glucose level. We do not 
know to what extent GLP-I secretion accounts for the increase in HbA1c levels during 
the study, as we did not measure GLP-I levels. Of note, the involvement of incretin 
response was previously suggested by van der Hoek et al (14). They observed that a 
single injection of short acting pasireotide elicited an acute increase in glucose levels 
after pasireotide injection in acromegaly patients, which could not be exclusively 
explained by concomitant insulin suppression, suggesting the involvement of the 
incretin response (14).
The patients using PAS-LAR and PEGV combination treatment did not have a lower 
HbA1c level than patients using PAS-LAR monotherapy. This observation suggests that 
the insulin sensitizing effect of PEGV cannot compensate for the insulin and incretin 
suppressive effect of PAS-LAR.
Our study was not designed to evaluate which antidiabetic treatment was most ef-
fective for pasireotide-induced hyperglycaemia. Previous studies have recommended 
DPP-4 inhibitors and GLP-I analogues for treatment of pasireotide-induced hypergly-
cemia. Following the Dutch reimbursement regulations we could only start DPP-4 in-
hibitors and GLP-I analogues after failure to achieve glycaemic control with maximum 
doses of metformin and sulfonylurea. However, ideally initiation of incretin-based 
antidiabetic drugs is the first-line treatment of choice.
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Exocrine pancreatic insufficiency
We observed a higher frequency of steatorrhea during PAS-LAR treatment in acro-
megaly patients than reported previously in clinical trials (5, 6). This adverse event 
was in general transient and improved with pancreatic enzyme supplementation 
(Chapter 3). Inhibition of exocrine pancreatic function is a well-known (side) effect 
of SRLs (15). To our knowledge, there are no studies that directly compared the effect 
of octreotide versus pasireotide on exocrine pancreatic function. But, because of 
its broader SSTR binding profile, pasireotide has been suggested to be more effec-
tive than octreotide in suppressing exocrine pancreatic function (16). For example, 
pancreatic surgeons have used pasireotide to suppress leakage of exocrine secretions 
following pancreatectomy (17), with the aim to reduce the risk of pancreatic fistula 
formation, a major cause of mortality and morbidity for these patients (18).
Costs
We hypothesized that the PEGV sparing effect of PAS-LAR would result in a reduction 
in treatment costs. Although we have not performed a cost-effectiveness analysis, it 
is likely that switching to PAS-LAR will not lead to a long-term reduction of overall 
treatment costs. As mentioned in the discussion of chapter 3, the PEGV sparing effect 
of PAS-LAR would likely be offset by the diabetes mellitus related medication and 
healthcare costs.
current consensus guideline second line medical treatment
In 2018, the Acromegaly Consensus Group published updated consensus guidelines 
with recommendations on the medical management of acromegaly (19). The consen-
sus statement recommended medical treatment for patients with persistent disease 
activity despite surgical resection of the adenoma and patients in whom surgery is not 
advisable (19). In line with the previous consensus statement published in 2014 (20), 
first-generation SRLs remain the first-line treatment for patients with persistent dis-
ease activity after surgery. The new consensus guideline recommends either PAS-LAR 
or PEGV treatment based on the presence or absence of clinically relevant residual 
tumour and impaired glucose tolerance. PEGV was recommended for patients with 
impaired glucose metabolism and/or those who experience worsening hyperglycemia 
on SRL treatment. PAS-LAR was recommended for patients with a clinically relevant 
residual tumour unsuitable for resection and without impaired glucose tolerance. 
However, in patients with a clinically relevant residual tumour and impaired glucose 
tolerance SRL and PEGV was recommended (19). In the next paragraphs we will out-
line our expert-opinion based clinical recommendations for the medical management 
of acromegaly with a focus on the position of PAS-LAR and the differences with the 
current consensus guideline.
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recommendations for the medical management of acromegaly
In figure 1 we present our recommendations for the second line medical management 
of acromegaly based on our clinical experience with PEGV and PAS-LAR (Chapter 3 
and 4) and clinical evidence from previous studies. In accordance with the consensus 
guideline (19), first-generation SRLs such as lanreotide autogel (ATG) and octreotide 
LAR are considered the first-line medical treatment of acromegaly (figure 1).
Second-line and alternative treatments
In line with the consensus guideline (19), we recommend PEGV combined with or 
substituted for first-generation SRL treatment as the second-line treatment of choice 
in patients with <20% IGF-I reduction (no significant response) during first-generation 
SRL monotherapy (figure 1).
figure 1. Proposed algorithm for the medical management of acromegaly. Radiation therapy is not 
mentioned in this algorithm, but it should be considered in patients with biochemically persistent 
disease and/or tumour growth despite surgery or medical therapy. Abbreviations: ATG, Autogel; 
DA, dopamine agonist; IGF-I, insulin-like growth factor 1; LAR, long-acting release; SRL, soma-
tostatin receptor ligand; PEGV, pegvisomant; ULN, upper limit of normal.
158
Chapter 8
PEGV, alone or in combination with first-generation SRL, can normalize IGF-I levels 
in the majority of patients, provided that the PEGV dose is sufficiently increased. In 
combination treatment the recommended starting dose with either lanreotide ATG or 
octreotide LAR every 4 weeks is the highest approved dose of respectively 120 mg and 
30 mg. To determine the optimal PEGV starting dose to achieve IGF-I normalization, 
the prediction formulas of Franck et al can be used (21).
In contrast to the current consensus guideline (19), we recommend first-generation 
SRLs and PEGV combination treatment as the second-line treatment of choice in all 
non-responders (figure 1). Combination treatment has the advantage of a lower re-
quired PEGV dose to normalize IGF-I levels compared with PEGV monotherapy (23-25). 
Due to PEGV dose reduction it may reduce the injection frequency for patients. In a 
subset of patients, combination treatment might improve QoL compared to SRL mono-
therapy, including those who are biochemically controlled (26). PEGV monotherapy 
does not increase tumour size, and combined with SRLs it does control tumour size 
and may induce tumour shrinkage in a vast majority of patients (25). Another ad-
vantage of SRL and PEGV combination treatment is that SRLs are generally effective 
in resolving headaches through a proposed mechanism of inhibition of nociceptive 
peptides, which makes it the preferable treatment for patients with headache (27, 
28). In general, if patients report improvements in clinical symptoms during SRL 
monotherapy, we recommend imitating SRL/PEGV combination treatment, except in 
those patients with poorly controlled or brittle diabetes during SRL treatment. These 
patients are good candidates for PEGV monotherapy, because PEGV improves glucose 
metabolism by reducing insulin resistance (29-34). This is in accordance with the cur-
rent consensus guideline (19), which also recommends PEGV monotherapy in patients 
without biochemical response to first-generation SRL treatment, but with pre-existing 
impaired glucose metabolism.
In patients with partial response to first-generation SRLs, defined as a significant 
reduction in IGF-I levels without normalization, we recommend combination treat-
ment with cabergoline (if IGF-I ≤1.5 x ULN) (35) (figure 1). In contrast to the current 
consensus guideline, who propose considering co-treatment with cabergoline (if IGF-I 
<2.5 x ULN) in patients with inadequate control on first-generation SRL treatment, we 
recommend co-treatment with cabergoline if IGF-I levels remains modestly elevated 
(IGF-I ≤1.5 x ULN), since IGF-I normalization was observed only in those patients (35). 
Besides, cabergoline is recommended in patients with no access to PEGV. Although 
the use of PEGV, combined with or substituted for first-generation SRLs in partial 
responders, is not covered by the current guidelines (19), we recommend SRL and 
PEGV combination treatment as the second-line treatment of choice (Figure 1). 
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Moreover, due to the marginal additional efficacy of dose escalating and shortening 
of the dosing intervals of SRLs in partial SRL responders (2, 36, 37), we recommend 
switching these patients to SRL and PEGV combination treatment or to consider pa-
sireotide LAR monotherapy according to the proposed algorithm (figure 1).
Switching to pasireotide LAR monotherapy can be considered as an alternative to 
PEGV monotherapy or combination therapies in patients with the following baseline 
clinical characteristics (Figure 1):
• Macroadenomas in young patients (aged <40 years) that show tumour growth dur-
ing first-generation SRL monotherapy (i.e., clinically aggressive tumours) (38). 
Pasireotide LAR monotherapy should be considered early in the management of 
resistant tumours in young patients, and as a treatment step before starting radio-
therapy. This is in line with the current consensus guideline (19), which recommends 
switching from first-generation SRL treatment to pasireotide LAR monotherapy in 
patients with a clinically relevant residual tumour that is insuitable for resection.
• The same argument can be applied for patients previously not controlled by first-
generation SRLs with tumour growth during PEGV monotherapy. Tumour growth may 
reflect the presence of an aggressive tumour, for that reason pasireotide LAR mono-
therapy can be considered as a next treatment step before starting radiotherapy.
• Patients previously not controlled by first-generation SRLs who experience side-
effects or who are intolerant to PEGV monotherapy, may benefit from switching to 
pasireotide LAR monotherapy.
• Patients with headache not responsive to first-generation SRL treatment. These 
patients with severe incapacitating headache have high a likelihood to experience 
improvement in headache symptoms with pasireotide LAR treatment.
Instead of PEGV, either as monotherapy, or in combination with first-generation SRL, 
switching to pasireotide LAR therapy combined with PEGV can be considered as third-
line treatment option in patients with the following baseline clinical characteristics 
(Figure 1):
• Patients without diabetes that use low PEGV doses (≤80 mg/week) during combina-
tion therapy with first-generation SRL and PEGV. Due to the PEGV sparing effect of 
pasireotide LAR, the PEGV doses can be reduced or some cases even discontinued.
• Patients with tumour growth during first-generation SRL and PEGV combination 
therapy. We postulate that pasireotide LAR monotherapy may improve tumour size 
control or even tumour shrinkage. However, at present there are no data on tumour 
response to pasireotide LAR and PEGV combination therapy available.
• Patients biochemically controlled during first-generation SRL and PEGV combination 
therapy, who use first-generation SRL every 3 weeks or have symptoms of active 
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acromegaly in the fourth week after first-generation SRL administration, may ex-
perience symptomatic improvement after switching to pasireotide LAR and PEGV 
combination therapy.
The package insert recommends starting pasireotide LAR 40 mg every four weeks 
(39), but we recommend to start with either 40 or 60 mg pasireotide LAR every four 
weeks. We expect that patients with SRL partial responders will require lower doses 
of pasireotide LAR, and then we recommend starting with pasireotide LAR 40 mg. For 
combination treatment with PEGV we recommend initiation of pasireotide LAR at a 
dose of 60 mg every four weeks while at the same time tapering down the PEGV dose 
by 33%.
In our experience, IGF-I levels decrease more rapidly with pasireotide LAR than with 
octreotide LAR or lanreotide ATG after treatment initiation. While it can take up 
to 6 months for IGF-I levels to normalize with first-generation SRLs therapy, pasire-
otide LAR induces a significant reduction in IGF-I levels within 2 months (40), and the 
early response is associated with the more long-lasting response at 48 weeks (41). If 
biochemical control cannot be achieved by pasireotide LAR monotherapy, then either 
switching to PEGV monotherapy or combination treatment with first-generation SRLs 
should be considered (figure 1). The same applies for pasireotide LAR and PEGV com-
bination treatment, but in this case the patients are switched back to their previous 
PEGV dose, alone or combined with SRL treatment.
Management of pasireotide-induced hyperglycemia
Optimal management of hyperglycemia during pasireotide LAR therapy is essential 
because of several reasons. First, optimal management is required to initially control 
diabetes as a long-term risk factor for cardiovascular disease in acromegaly. Secondly, 
early onset proactive management of hyperglycemia after pasireotide LAR initiation is 
likely to improve patient long-term compliance with pasireotide LAR. A wider use of 
pasireotide LAR in the medical management of acromegaly depends on the physician’s 
willingness to try pasireotide LAR and to applicate it in the appropriate patients. The 
challenge for the endocrinologist is to evaluate in each individual patient whether ad-
vantages of pasireotide LAR such as higher likelihood of biochemical control, tumour 
size control and quality of life outweigh side effects of hyperglycemia and diabetes. 
We provide recommendations to achieve optimal management of pasireotide-induced 
hyperglycemia in figure 2. In contrast to previous published recommendations for 
management of pasireotide-induced hyperglycemia (42-45), we use a more liberal 
strategy in frequency of monitoring our patients.
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figure 2. Proposed algorithm for management of pasireotide-induced hyperglycemia. Abbrevia-
tions: DPP-4, dipeptidyl peptidase-4; FPG, fasting plasma glucose; GLP-1, glucagon-like peptide 1; 
HbA1c, glycated haemoglobin, LAR, long-acting release.
Baseline HbA1c is the most important predictor for development of diabetes after 
pasireotide LAR administration (7, 9, 40, 41). We recommend that baseline FPG and 
HbA1c levels should be assessed prior to initiating pasireotide LAR treatment. In case 
of impaired fasting glucose and/or diabetes at baseline, lifestyle management and/
or adequate antidiabetic treatment should be started or optimized before initiating 
pasireotide LAR. Clinical studies have consistently shown that after pasireotide LAR 
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initiation FPG and HbA1c levels rise the first 3 months, and remain stable without 
further antidiabetic therapy (7, 9, 39, 46, 47). Therefore, proactive blood glucose 
monitoring is important, especially in the first 3 months after initiation. After the first 
3 months of pasireotide LAR treatment, the intensity of blood glucose monitoring can 
be decreased. In contrast to Wildemberg (44) and Samson (43), who propose home 
blood glucose monitoring twice a week for 3 months for patients with normoglycemia, 
and we recommend monitoring at the outpatient clinic with monthly FPG and HbA1c 
the first 3 months. Because of the low likelihood of deterioration of glucose tolerance 
in young patients (aged <40 years) with normal glucose tolerance at baseline, this 
latter group can be monitored less intensively and with a lower frequency (figure 2). 
However, patients with pre-existing impaired glucose tolerance and diabetes, which 
make up the majority of acromegaly patients, require more extensive monitoring. 
These patients should receive home blood glucose monitoring the first 3 months by 
measurement of daily fasting and 2-hours postprandial glucose levels, and monthly 
HbA1c monitoring at the outpatient clinic. For diabetic patients using insulin, we 
advise continued home blood glucose monitoring with additional HbA1c monitoring 
especially at the start of pasireotide LAR treatment, and thereafter every 3 months 
in accordance with the current American Diabetes Association (ADA) guidelines (48).
If glucose monitoring reveals glucose in the diabetic range per ADA criteria, we 
recommend first-line treatment with a dipeptidyl peptidase-4 (DPP-4) inhibitor and 
to consider metformin in patients with mild diabetes or if DPP-4 inhibitors are not 
available (figure 2). If patients do not achieve their ADA criteria based FPG/HbA1c 
goal with these interventions, we recommend switching to a GLP-1 receptor analogue 
once daily. If a GLP-1 receptor agonist is not available, we recommend treatment 
with sulfonylureas. Treatment with insulin is required in patients intolerant to GLP-1 
analogues or if GLP-1 analogues fail to provide glycemic control. In case of severe 
hyperglycemia (i.e., FPG >10 mmol/l or postprandial glucose levels >15 mmol/l), 
which may occur even after the first injection, it is important to promptly initiate 
insulin treatment. In our experience, diabetic patients using insulin treatment or 
high doses of oral antidiabetic agents have a high risk of severe hyperglycemia after 
the first injection of pasireotide LAR. On the other hand, in nondiabetic patients the 
onset of hyperglycemia occurs later during treatment and is less severe. Therefore, it 
is paramount to be aware of early-onset severe hyperglycemia and promptly initiate 
antidiabetic therapy, but also to be vigilant about the development of late-onset 
hyperglycemia and diabetes.
Pasireotide-induced hyperglycemia is reversible after discontinuation of pasireotide 
LAR (44). Our data indicate that within 8 weeks after discontinuation of pasireotide 
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LAR and re-initiation of first-generation SRL or PEGV, FPG and HbA1c levels return to 
baseline (40). To prevent hypoglycemia in patients using insulin or sulfonylureas, it is 
recommended to gradually taper down these antidiabetic agents with more frequent 
blood glucose monitoring. Sulfonylureas should be rapidly tapered down within the 
first 2 weeks to avoid hypoglycemia, whereas GLP-I receptor analogues can be safely 
continued with a lower dose for a longer period.
Prediction of pasireotide LAR treatment response in acromegaly
We hypothesized that SST5 protein expression of the somatotroph adenoma was cor-
related with clinical responsiveness to PAS-LAR in acromegaly. However, in our cohort 
we observed a positive correlation between the efficacy of PAS-LAR and the efficacy 
of first-generation SRLs. This was confirmed by the observation that SST2 protein 
expression of the somatotroph adenoma, and not of SST5, correlated with clinical 
responsiveness to PAS-LAR. Moreover, in the same patients we found a strong correla-
tion between the percentage of IGF-I reduction after first-generation SRL treatment 
and response to PAS-LAR treatment during the PAPE study. This does not mean that 
pasireotide and octreotide/lanreotide are equally effective in reducing IGF-I levels. 
The effect of pasireotide and octreotide on GH suppression is superimposable both 
in vitro and in vivo, but pasireotide is more effective in reducing IGF-I levels in vivo 
(5, 49). In other words, overall, patients who responded to first-generation SRLs also 
seemed to respond to PAS-LAR treatment and vice-versa. The latter is illustrated by 
our observation that the three patients using the highest doses of PEGV could not 
reduce their PEGV dose after switching to PAS-LAR (Chapter 4). Our observation that 
SST2 is the main receptor driving the biochemical responsiveness to PAS-LAR treatment 
builds on previous preclinical studies in primary cultures of somatotroph adenomas 
that pasireotide exerts its anti-secretory effects mainly via activation of SST2 (49-
52). Besides its broader binding affinity for the different SST2 subtypes, pasireotide 
activates intracellular second messenger pathways and modulates SST internalization 
and trafficking in a manner different from SRIF and octreotide (53, 54). For example, 
compared with octreotide, pasireotide induces less SST2 internalization and quicker 
recycling of SST2, which counteracts SST2-desensitization. These findings indicate that 
the mere concept of binding affinity is too limited to explain the complex biological 
activity of pasireotide. It is important to clarify that our results contrasted findings of 
Iacovazzo et al who found that SST5 expression on somatotroph adenomas correlated 
with responsiveness to PAS-LAR (55). As discussed in Chapter 5, the opposing results 
between the Iacovazzo study and our study is related to a different selection of pa-
tients. In our study we included patients who were mainly partially responsive to SRLs 
who received PEGV treatment, while Iacovazzo et al used only SRL resistant patients.
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Our results suggest that SST2 is the main driver of GH suppression to pasireotide in 
somatotroph adenomas, but we cannot exclude the involvement of SST5 in GH suppres-
sion (49, 55). In general, in patients that are partial responders to SRLs, pasireotide 
acts mainly via SST2. In presence of low SST2 expression or in adenomas resistant to 
SST2 targeting, pasireotide may also act via SST5, while this is not the case for first-
generation SRLs. Therefore, we can understand that in completely resistant patients 
(55) we observe an effect mainly driven via SST5. As recently carefully reviewed by 
Gatto et al (56), using the classification of acromegaly proposed by Cuevas-Ramos et 
al, pasireotide mainly acts via SST2 in type 1 disease (good response to first-generation 
SRLs, high SST2 expression), while its effects could also be mediated via SST5 in type 
2 and type 3 acromegaly (unsatisfactory response to first-generation SRLs, low SST2 
expression).
ghrelin acromegaly
In chapter 6 we investigated levels of plasma acylated ghrelin (AG), unacylated ghrelin 
(UAG), and the AG/UAG ratio in three groups of patients with acromegaly; in patients 
using SRL and PEGV combination treatment, patients using PEGV monotherapy, and 
medically naïve patients. We observed that both AG and UAG were suppressed during 
PEGV and SRL combination treatment and in some patients even undetectable. The 
underlying mechanism is probably a direct inhibitory effect of somatostatin on ghrelin 
secretion (57). Interestingly, the positive feedback action of PEGV on ghrelin secretion 
as observed in our study and by Roemmler et al (58) cannot offset the ghrelin sup-
pressive effects of somatostatin. This observation mirrors our observation in the PAPE 
study that the insulin suppressive effect of pasireotide LAR cannot be compensated by 
the improvement in insulin sensitivity by treatment with pegvisomant.
We observed that the AG/UAG ratio was similar irrespective of medical treatment. 
Secondly is that the assessment of the AG/UAG ratio is clinically more relevant than 
measurement of total ghrelin, because the total ghrelin assay is unspecific as it 
measures a combination of inactive AG/UAG fragments and the full-length peptide. 
An advantage of the AG/UAG ratio is that it takes into account the different and 
sometimes opposing biological actions of AG and UAG. An important limitation of this 
study was the low number of patients included in the control groups. Also, in general 
there is a lack of the healthy volunteer data on AG and UAG levels measured with the 
two-site sandwich ELISA. Future studies should account for this.
Pegvisomant clearance
In the 1970s Davis et al described PEGylation as a means to decrease the immuno-
genicity of non-human proteins (59-61). Since then at least 15 registered PEGylated 
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drugs are in clinical use, and more are under clinical investigation (62). Although PEGV 
has been used in clinical practice for over a decade and is one of the most PEGylated 
drugs available, it is not well understood how PEGV is metabolized and cleared from 
the body. Understanding PEGV clearance could be important to understand the differ-
ences in PEGV serum levels between patients. It is known that the presence of several 
polyethylene glycol (PEG) molecules in the drug reduce the immunogenicity and 
improve the clearance of PEGV (63). Because PEG is a non-biodegradable molecule 
it is assumed that PEG molecules are cleared from the circulation by cells from the 
mononuclear phagocyte system, such as Kupffer cells (64, 65). Animal studies have 
shown that repeated administration of PEGV was associated with the presence of 
vacuolated macrophages (66). However, no studies have demonstrated this in patients 
with acromegaly treated with PEGV. As reported in Chapter 7 we undertook this study 
to examine whether PEGV is expressed in the liver, and if so, whether it co-localizes 
with Kupffer cells. Using hepatic tissue material obtained from two acromegaly pa-
tients that were treated with PEGV, we observed immunohistochemical expression 
of PEG in the sinusoids where Kupffer cells are located. Immunofluorescence studies 
confirmed that PEG co-localized with Kupffer cells, but not with hepatocytes. The 
observation that PEG was not observed in hepatocytes is supported by a fundamental 
study by Tsoi et al (67). They examined the blood clearance mechanism of PEGylated 
nanomaterials in relation to hepatic cells of rats. They observed that after injection of 
PEG-coated quantum dots (PQD), PQD were internalized by cell mononuclear phago-
cyte system (MPS). The highest uptake was observed in Kupffer cells, but no uptake in 
hepatocytes. However, these data should be interpreted with caution as quantum dots 
have a substantially smaller molecular size compared to large molecules like PEGV. 
Kupffer cell activation in both cases can also be caused by liver diseases, which can 
impact hepatic metabolism of PEGV. Despite the possible confounding effect of liver 
diseases which could activate Kupffer cells and change PEG metabolism, both patients 
showed internalization of PEG in Kupffer cells. This suggests that the uptake of PEGV 
by Kupffer cells is independent of the underlying liver disease. Unfortunately, it is 
very difficult to obtain additional liver tissue samples of acromegaly patients using 
PEGV that do not have liver disease. We could also not study the relation between hy-
pertransaminasemia and PEGV treatment (i.e. PEGV-induced hepatotoxicity), because 
both patients had normal transaminase levels during PEGV treatment. In this study we 
highlighted the possible role of Kupffer cells in the clearance of PEGV.
166
Chapter 8
geNerAl coNclusIoN of tHesIs
The findings presented in this thesis represent a step forward in our understand-
ing of the position of PAS-LAR in the modern medical treatment of acromegaly. The 
results of the PAPE study demonstrated that PAS-LAR has a high efficacy, illustrated 
by a 50% PEGV sparing effect, and substantial number of patients who could switch 
to PAS-LAR monotherapy. While PAS-LAR was in general well tolerated, the high ef-
ficacy came at the expense of a high frequency of hyperglycemia-related adverse 
events. With respect to the long-term treatment of acromegaly with PAS-LAR, the 
benefits of biochemical control and the improvement in quality of life should be 
weighed against the disadvantages of potential (short- and long-term) complications 
of diabetes. The main conclusion of our recommendations is that, in general, SRL 
and PEGV combination treatment remains the second line medical treatment option 
of choice, and PAS-LAR should be reserved as a third line medical treatment option. 
However, in specific subgroups of patients PAS-LAR is a viable and preferred treat-
ment option for patients with tumour growth during SRL and/or PEGV treatment, 
patients with specific symptoms not responsive to SRLs, and patients using low doses 
of PEGV without diabetes. Besides baseline glycemia and use of antidiabetic drugs, 
residual beta cell function, as measured with the OGTT, is an important predictor for 
pasireotide-induced hyperglycemia. In our cohort previous response to SRL treatment 
and SST2 protein expression of the somatotroph adenoma was strongly correlated with 
response to PAS-LAR treatment. In patients well-controlled on SRL and low-dose PEGV 
combination treatment switching to weekly PEGV monotherapy is a viable treatment 
strateqy without significant compromise of biochemical control.
future PersPectIVes
In this thesis the results of the PAPE study are presented until 48 weeks. In order 
to observe whether PAS-LAR provides long-term efficacy and safety longer follow-up 
studies are needed. The insulin and incretin suppressive effects of pasireotide suggest 
that it is plausible that pasireotide increases the life time risk of diabetes in patients 
who do not develop hyperglycemia initially after treatment initiation. Longer follow-
up studies are required to evaluate the occurrence of late-onset hyperglycemia and 
whether diabetes indeed occurs earlier in patients using PAS-LAR. The availability 
of PAS-LAR has expanded the therapeutic options for patients to achieve biochemi-
cal control. However, whether PAS-LAR is indeed more effective van first-generation 
SRLs in reducing tumour volume has not extensively been studied. It is interesting 
to analyze whether PAS-LAR induces clinically relevant tumour size reduction in our 
General discussion and future perspectives
167
8
cohort, and whether this correlates with PAS-LAR treatment response score and SSTR 
protein expression of the somatotroph adenoma. Besides biochemical control and 
tumour size control, quality of life is an important treatment goal. Many acromegaly 
patients have impaired quality of life despite (long-term) biochemical control. In 
the PAPE study we systematically assessed quality of life using validated acromegaly 
health-related quality of life questionnaires. In the future we aim to publish our 
findings with respect to quality of life, with ultimate goal to predict which subset of 
patients is likely to experience an improvement in quality of life. Previous studies 
have indicated that patients with headache not responsive to SRL treatment might 
benefit from pasireotide treatment (68, 69). There is also a pressing need for robust 
biomarkers that reliably predict the response to PAS-LAR treatment. Beside SST2 and 
SST5 protein expression, other markers are needed, such as AIP protein expression, 
β-arrestin expression, the granulation pattern viewed under an electron microscope, 
pituitary adenoma signal intensity with MRI. Preferably all these markers should be 
integrated and validated in multiple cohorts of centers of excellence that treat a high 
volume of patients with acromegaly. As increased PEGV serum levels are observed 
during SRL and PEGV combination treatment the question arises whether PAS-LAR 
elicits the same effect.
future deVeloPMeNts IN MedIcAl treAtMeNt
Many new drugs are currently under investigation for acromegaly. Given the lack of ef-
ficacy of conventional SRLs and the hyperglycemia-related adverse events of PAS-LAR, 
there is a need for new drugs which provide improved biochemical control with less 
side effects and less frequent injections. Because PEGV requires frequent high dose 
injections, efforts have been made to develop a long-acting gHr antagonist (GHRA). 
A novel concept to extend the half-life of a GHRA is by generating a chimeric fusion 
molecule comprised of a mutated GH linked to GHBP (70). The investigators have 
developed a technology to link a ligand to the extracellular domain of its receptor, 
effectively providing the ligand with its own native binding protein within a single 
molecular entity. This ligand-receptor fusion molecule exists in solution as both a 
monomer and dimer where the GH moiety of one molecule bound to the receptor por-
tion of another molecule in a head-to-tail reciprocal dimer (70). The pharmacokinetic 
characteristics suggested this fusion molecule could requires injection every 21–28 
days compared to daily GHRA administration. In a proof of concept study, three fusion 
GHRA molecules have demonstrated delayed clearance and biological activity in vivo 
(71). An advantage of this technology is that no PEGylation is required to gener-
ate the long-acting GHRA, but whether this drug is cheap enough to manufacture 
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remains to be determined. somatoprim (DG3173) is an investigational SRL with high 
affinity for SST2, SST4, and SST5 with a pharmacokinetic profile similar to octreotide 
(72, 73). Somatoprim showed selectivity for GH suppression with minimal inhibition 
of insulin secretion (72, 74). Recently, a phase II trial of somatoprim in treatment-
naïve acromegaly patients was completed (73). AP102 is a dual SST2/SST5-specific 
SRL that has been designed with the aim to reduce GH secretion without causing 
hyperglycemia. AP102 is a disulfide-bridged octapeptide SRL containing synthetic 
iodinated amino acids. Receptor binding studies have demonstrated that AP102 binds 
with similar subnanomolar affinity to SST2 and SST5 as to native somatostatin 14 (75). 
In contrast to pasireotide, AP102 does not bind to SST1 and SST3 (75, 76). In a recent 
study in rats, the effects of AP102 and pasireotide were investigated on hormonal 
secretion and glucose metabolism following acute (single dose) and chronic (28-day) 
administration (77). In contrast to pasireotide, acute and chronic administration of 
AP102 did not lead to significant hyperglycemia or impaired glucose tolerance. The 
authors suggested that the neutral effect of AP102 on glucose metabolism was caused 
by balanced inhibition of insulin and glucagon secretion, and uninhibited GLP-I secre-
tion (77). Despite that both compounds have high binding affinities to SST2 and SST5, 
they produced different effects on glucose metabolism. Several possible mechanisms 
could account for this discrepancy. In addition to SST2 and SST5, pasireotide also binds 
with high affinity to SST1 and SST3, whereas AP102 shows selective binding to only 
SST2 and SST5. The broader SSTR binding profile could therefore also contribute to 
pasireotide-induced hyperglycemia. Besides SST5, SST1 is also expressed on pancreatic 
β-cells (78). Recently, knocking down expression of SST3 through the use of selective 
SST3 antagonist mediated glucose stimulated insulin secretion by β-cells (79, 80). 
The effects of AP102 on SST2 and SST5 phosphorylation patterns has not been studied 
yet, but may also account for the differences in glucose metabolism compared with 
pasireotide.
To what extent these upcoming agents will actually benefit acromegaly patients in 
real life remains to be seen. It is likely that there is no single agent that can be 
considered the “perfect agent” for all patients.
Besides medical treatment, lifestyle interventions such as diet and exercise may also 
contribute to biochemical and symptomatic control of acromegaly. Hypothetically, 
a carbohydrate restricted or ketogenic diet could improve insulin resistance, and 
therefore reduce the required dose of PEGV in acromegaly.
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Acromegaly is a chronic systemic condition caused by excessive growth hormone (GH) 
secretion from a pituitary adenoma. Combination treatment with first-generation 
somatostatin receptor ligands (SRLs) and pegvisomant (PEGV) is an established ef-
fective and safe treatment to normalise IGF-I levels in acromegaly. However, this 
combination treatment requires chronic monthly SRL injections and daily to weekly 
PEGV injections which can be troublesome for patients and negatively impact patient 
adherence. We therefore hypothesized in chapter 2 that switching patients from SRL 
and PEGV combination treatment to PEGV monotherapy can reduce the total number 
of injections, and therefore improve patient adherence. After 12 months treatment 
with PEGV monotherapy 73% of patients achieved IGF-I normalization, while the 
median weekly PEGV dose only minimally increased. No significant adverse events 
occurred during the study. Therefore we concluded that temporary switching from 
combination treatment to PEGV monotherapy is an effective and feasible treatment 
strategy. In line with previous studies we confirmed the carry-over effect of SRLs on 
IGF-I levels of over 4 months. The conclusion of this pilot study is that temporary 
switching from combination treatment tot PEGV monotherapy is an effective, safe and 
feasible treatment strategy.
Pasireotide (long-acting release) LAR is a second somatostatin receptor ligand ap-
proved for the treatment of patients with acromegaly for whom surgery is not option 
or not curative. Pasireotide LAR has shown superior efficacy over first-generation so-
matostatin analogues with respect to IGF-I reduction, but is associated with a higher 
frequency of hyperglycemia and diabetes mellitus. However, it is unknown what the 
optimal position is of pasireotide LAR in the modern management of acromegaly in 
relation to PEGV. We hypothesized that switching from combination treatment to 
pasireotide LAR could lead to a significant reduction in the required PEGV dose and 
therefore to a lower number of injections, and possibly lower costs. chapters 3 and 
4 cover the results of the results of the PAsireotide LAR and PEgvisomant (PAPE) 
study. The PAPE study assessed the efficacy and safety of switching from combina-
tion treatment of first-generation somatostatin analogues and PEGV treatment to 
pasireotide LAR treatment. The main results show that pasireotide LAR is an effective 
treatment, as 77% of patients achieved normalisation of IGF-I levels after 48 weeks, 
and on average 50% of the PEGV dose could be reduced. An important observation is 
the heterogeneous response to pasireotide LAR in term of IGF-I normalization. This 
was related to several factors, including the large heterogeneity in the PEGV dose 
at baseline. An interesting finding was the potent reduction in IGF-I after the first 
pasireotide LAR injection. This early onset and strong suppression of IGF-I is probably 
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a direct effect of pasireotide on inhibition of insulin secretion. The concomitant sup-
pression of both IGF-I and insulin is an important mechanism which can explain the 
efficacy of pasireotide LAR.
safety
De most common and clinically relevant adverse event during the PAPE study was 
the occurrence of hyperglycemia and diabetes mellitus. The frequency of diabetes 
mellitus rose from 32.8% at baseline to 77% at 48 weeks. Most patients had a mild 
hyperglycemia occurring mainly after initiation of pasireotide LAR treatment and 
manageable with metformin and vildagliptin. The subgroup of patient with severe 
hyperglycemia had pre-existent diabetes which was well regulated with multiple an-
tidiabetic drugs such as sulfonylureas, GLP-I analogues and insulin. The development 
of pasireotide-induced hyperglycemia was correlated with baseline HbA1c and use of 
antidiabetic drugs. An important novel independent predictor for pasireotide-induced 
hyperglycemia was the baseline β-cell function as a measure for insulin secretion 
based on the oral glucose tolerance test. We observed an inverse correlation between 
baseline insulin secretion and the increase in HbA1c at 24 weeks.
Predictors of clinical response to pasireotide lAr
As pasireotide exhibits a higher binding affinity to somatostatin receptor subtype 5 
(SST5) compared with SST2 we assumed that the efficacy of pasireotide LAR would 
correlate with the SST5 protein expression of the pituitary adenoma (chapter 5). 
In our cohort we observed a positive correlation between the clinical response of 
pasireotide LAR on IGF-I reduction and the clinical response of first-generation so-
matostatin analogues on IGF-I reduction. These clinical results were supported by in 
vivo observations that SST2, and not SST5 protein expression of the pituitary adenoma 
correlated with clinical response to pasireotide LAR treatment during the PAPE study. 
Moreover, in the same patients we found a strong correlation between the percentage 
IGF-I reduction after treatment with pasireotide LAR and after previous treatment 
with first-generation somatostatin analogues. With other words, patients with good 
clinical response to first-generation somatostatin analogues also seem to respond well 
to pasireotide LAR, and vice-versa.
The main conclusion of this translational study is that in our cohort SST2 is the most 
important predictor for IGF-I normalisation after treatment with pasireotide LAR.
ghrelin in acromegaly
The metabolic hormone ghrelin exists in two different isoforms in the circulation, 
respectively Acylated Ghrelin (AG) and Unacylated Ghrelin (UAG). Both isoforms have 
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different and (sometimes) opposing biological effects. Earlier studies indicated that 
measurement of both these isoforms with a validated immunoassay provides more 
biological information than measurement of total ghrelin. Although ghrelin can stimu-
late growth hormone secretion, and ghrelin itself can be inhibited growth hormone, 
the exact physiological role of ghrelin on growth hormone regulation remains not fully 
elucidated. It is also not well understood what the influence is of different medical 
treatments on ghrelin levels in acromegaly. In chapter 6 we therefore measured both 
AG and UAG in three different acromegaly patient groups. In this study patients bio-
chemically controlled with combination treatment were compared with patients with 
medically naïve active acromegaly and patients using PEGV monotherapy. We found 
that both AG and UAG were suppressed during combination treatment compared with 
the other patient groups. This effect is likely caused by a direct inhibitory effect of 
somatostatin on ghrelin release. Novel however is the finding that the AG/UAG ratio 
between the different patient groups is not significantly different. This suggests that 
combination treatment of SRL and PEGV does not affect the relation between AG and 
UAG. Another message of this study is that adequate measurement of AG and UAG and 
calculation of the AG/UAG ratio can yield relevant information on the bioactive state 
of ghrelin.
clearance of pegvisomant
Although PEGV is available for the treatment of pegvisomant for over 15 years, it 
remains unknown how pegvisomant is metabolized and cleared from the circulation. 
PEGV is a mutated GH molecule attached to multiple polyethylene glycol (PEG) 
molecules. These PEG molecules extend the half-life of the drug and reduce immuno-
genicity. We postulated that because PEG molecules are not biodegradable they are 
cleared by immune cells, such as kupffer cells (liver macrophages) of the mononuclear 
phagocytic system. Therefore, in the final chapter of this thesis, we performed this 
proof of concept study to investigate whether PEGV is expressed in the liver, and if 
so, whether PEGV can be taken up by kupffer cells. We observed that PEG is internal-
ized by kupffer cells and not by hepatocytes using immunofluorescence techniques in 
hepatic tissue obtained from two patients with acromegaly that were treated with 
PEGV. This study suggests the involvement of the immune system in the clearance of 
pegvisomant.
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Acromegalie is een chronische systemische aandoening veroorzaakt door overmatige 
groeihormoonsecretie uit een hypofyseadenoom. Combinatiebehandeling met eerste 
generatie somatostatine analoga (SRL) en pegvisomant (PEGV) is een effectieve en 
veilige behandeling om IGF-I te normaliseren in acromegalie. Echter deze combi-
natiebehandeling vereist langdurige maandelijkse SRL injecties en dagelijks tot 
wekelijkse PEGV injecties, wat een negatief effect kan hebben op de therapietrouw. 
Onze hypothese in hoofdstuk 2 van dit proefschrift was dat tijdelijk switchen van SRL 
en PEGV combinatiebehandeling naar PEGV monotherapie kan leiden tot een reductie 
van de totale aantal injecties wat mogelijk kan leiden tot een verbetering van de 
therapietrouw. Na 12 maanden behandeling met PEGV monotherapie hadden 73% van 
de patiënten IGF-I waarden binnen de normaalwaarden terwijl hierbij de mediane 
wekelijks PEGV dosis slechts minimaal steeg. Tijdens de studies traden geen klinisch 
significante bijwerkingen op. In lijn met voorgaande studies hebben we aangetoond 
dat somatostatine analoga minstens 4 maanden een doorwerkingseffect hebben op 
IGF-I waarden. De conclusie van deze pilot studies is dat tijdelijk switchen van com-
binatiebehandeling naar PEGV monotherapie een effectieve, veilige en praktische 
haalbare behandelstrategie is.
Pasireotide (langwerkende afgifte) LAR is een tweede generatie somatostatine 
analoog en is geregistreerd voor acromegaliepatiënten waarbij een operatie niet 
mogelijk of niet curatief is. Pasireotide LAR is effectiever dan eerste generatie soma-
tostatine analoga op IGF-I reductie, maar is geassocieerd met een hogere frequentie 
van hyperglycemie en diabetes mellitus. Het is echter niet bekend wat de optimale 
positie is van pasireotide LAR in relatie tot pegvisomant in de hedendaagse behande-
ling van acromegalie. Wij postuleerden dat switchen van combinatiebehandeling naar 
pasireotide LAR kan leiden tot een significante reductie van de pegvisomant dosis 
en daarmee tot minder injecties en mogelijk minder kosten. Hoofdstukken 3 en 
4 gaan over de resultaten van de PAsireotide LAR and PEgvisomant (PAPE) studie. 
In de PAPE studie wordt de effectiviteit en veiligheid onderzocht van het switchen 
van SRL en PEGV combinatiebehandeling naar pasireotide LAR. Uit de resultaten van 
de PAPE studie blijkt dat pasireotide LAR een effectieve behandeling is, aangezien 
77% van de patiënten normalisatie van IGF-I konden bereiken na 48 weken met hier-
bij een gemiddeld PEGV sparend effect van 50%. Een belangrijke observatie is de 
grote heterogeniteit in klinische respons op pasireoide LAR. Dit was gerelateerd aan 
verschillende factoren, waaronder de grote heterogeniteit van de gebruikte PEGV 
dosis op baseline. Een interessante bevinding was de sterke reductie van IGF-I na de 
eerste pasireotide LAR injectie. Deze vroegtijdige en sterke reductie van IGF-I is een 
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waarschijnlijk een direct effect van pasireotide op remming van de insuline secretie. 
De gelijktijdige suppressie van zowel IGF-I als insuline is een belangrijk mechanisme 
wat de effectiviteit van pasireotide LAR kan verklaren.
Veiligheid
De meest voorkomende en klinisch relevante ongewenste voorval tijdens de PAPE 
studie was het optreden van hyperglycemie en diabetes mellitus. De frequentie van 
diabetes mellitus steeg 32.8% bij aanvang van de studie naar 77% aan het einde. De 
meeste patiënten hadden hierbij een milde hyperglycemie voornamelijk optredend 
na het starten van behandeling met pasireotide LAR. Deze milde hyperglycemie kon 
worden gereguleerd met een combinatie van metformine en vildagliptine. De sub-
groep van patiënten met ernstige hyperglycemie hadden reeds diabetes mellitus die 
goed gereguleerd was met meerdere antidiabetische medicatie zoals sulfonylureum-
derivaten, GLP-I analoga en insuline. Het optreden van pasireotide-geinduceerde 
hyperglycemie werd voorspeld door de HbA1c waarde bij baseline en het gebruik van 
antidiabetische medicatie. Een belangrijke nieuwe onafhankelijke voorspeller voor 
hyperglycemie was de baseline β-cel functie als een maat voor de insulinesecretie 
gebaseerd op de orale glucose tolerantie test. Wij vonden een omgekeerde correlatie 
tussen de baseline insulin secretie en de stijging van het HbA1c op 24 weken.
Voorspellers van klinische respons op pasireotide lAr
Aangezien pasireotide een verhoogde bindingsaffiniteit heeft voor somatostatine 
receptor subtype 5 (SST5) vergeleken met SST2 veronderstelden wij dat de effecti-
viteit van pasireotide LAR correleert met de mate van SST5 eiwitexpressie op het 
hypofyseadenoom (hoofdstuk 5). In onze cohort vonden wij echter een positieve 
correlatie tussen de klinische respons van pasireotide LAR op IGF-I reductie en de 
klinische response van eerste generatie somatostatine analoga op IGF-I reductie. Deze 
klinische resultaten werden ondersteund door in vivo observaties dat SST2 en niet SST5 
eiwitexpressie van de hypofyseadenoom correleerde met de klinische response op 
pasireotide LAR tijdens de PAPE studie. Bovendien vonden wij in dezelfde patiënten-
groep een sterke correlatie tussen de percentage IGF-I reductie na behandeling met 
pasireotide LAR en na (eerdere) behandeling met eerste generatie somatostatine ana-
loga. Met andere woorden, patiënten die eerder goed reageerden op eerste generatie 
somatostatine analoga leken ook goed te reageren op pasireotide LAR en vice-versa. 
De belangrijkste conclusie van deze translationele studie is dat in onze cohort SST2 
eiwitexpressie de belangrijkste voorspeller is voor IGF-I normalisatie na behandeling 
met pasireotide LAR.
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ghreline levels in acromegalie
Het stofwisselingshormoon ghreline bestaat uit twee verschillende verschijningsvor-
men in de circulatie, respectievelijk Geacyleerd Ghreline (AG) en Ongeacyleerde 
Ghreline (UAG). Beide verschijningsvormen hebben verschillende en (soms) tegenge-
stelde biologische effecten. Uit eerdere studies is gebleken dat het meten van deze 
verschijningsvormen van ghreline in een gevalideerde immunoassay meer biologische 
informatie verschaft dan het louter meten van totale ghreline. Hoewel ghreline 
groeihormoonsecretie kan stimuleren en ghrelinesecretie geremd kan worden door 
groeihormoon is de fysiologische rol van ghreline in de regulatie van groeihormoon 
nog niet opgehelderd. Het is ook nog niet goed bekend wat de invloed is van de 
verschillende therapieën voor acromegalie op ghreline waarden. In hoofdstuk 6 is 
daarom AG en UAG gemeten in drie verschillende acromegalie patiëntengroepen. In 
deze studie werd patiënten die biochemisch gecontroleerd waren met SRL en PEGV 
combinatiebehandeling vergeleken met patiënten met medisch naïeve acromegalie 
en patiënten met PEGV monotherapie. Uit deze studie blijkt dat zowel AG als UAG 
waarden onderdrukt werden tijdens combinatiebehandeling vergeleken met de an-
dere patiëntengroepen. Dit effect wordt waarschijnlijk veroorzaakt door een direct 
remmend effect van somatostatine op ghrelineafgifte. Nieuw is echter de bevinding 
dat de AG/UAG ratio tussen de patiëntengroepen niet significant verschillend is. Dit 
suggereert dat combinatiebehandeling van SRL en PEGV de relatie tussen AG en UAG 
niet verandert. Een andere belangrijke boodschap van deze studie is dat adequate 
meting van AG en UAG en het bepalen van de AG/UAG ratio belangrijke informatie kan 
verschaffen over de bioactieve status van ghreline.
Klaring van pegvisomant
Hoewel PEGV meer dan 15 jaar beschikbaar is als behandeling van acromegalie is tot 
op heden nog niet bekend hoe PEGV gemetaboliseerd wordt en geklaard wordt uit de 
circulatie. Het unieke aan het PEGV is dat het een gemuteerde groeihoormoneiwit is 
die verbonden is met meerdere polyethylene glycol (PEG) moleculen die ervoor zorgen 
dat PEGV een verlengde halfwaardetijd heeft en minder immunogeen is. Wij postu-
leerden dat PEG moleculen, doordat zij niet biologisch afbreekbaar zijn, geklaard 
worden door immuuncellen, zoals kupffer cellen (lever macrofagen) van het mononu-
cleair fagocytair systeem. Daarom is in dit laatste hoofdstuk van dit proefschrift een 
proof of concept studie uitgevoerd om te onderzoeken of PEGV tot expressie komt in 
de lever, en zo ja, of PEGV opgenomen kan worden door kupffer cellen. Door middel 
van immunofluoresecentietechnieken in leverweefsel van twee acromegaliepatiënten 
die behandeld werden met PEGV hebben wij geobserveerd dat kupffer cellen PEG mo-
leculen opnemen, terwijl hepatocyten dit niet deden. Deze studie suggereert daarom 
betrokkenheid van het immuunsysteem in de klaring van pegvisomant.
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lIst of AbbreVIAtIoNs
AcroQoL Acromegaly quality of life questionnaire
ACTH adrenocorticotrophin hormone
ADA American Diabetes Association
ADH Antidiuretic Hormone
AE Adverse event
AEBSF 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride
AG Acylated Ghrelin
AIP Aryl hydrocarbon receptor-interacting protein
ALS Acid labile unit
ALT Alanine aminotransferase
AP102 Dual SST2/SST5 specific somatostatin analogue
AST Aspartate aminotransferase
AUC Area under curve
BMD Bone mineral density
BMI Body mass index
C2305 Pasireotide versus octreotide in acromegaly: head-to-head superior-
ity study by Colao et al
CI Confidence interval
CRT Conventional radiotherapy
CTCAE Common terminology criteria for adverse events
CV Coefficient of variability
D2R Dopamine subtype 2 receptor
DA Dopamine agonist
DAPI 4’,6-diamidino-2-fenylindool, fluorescent stain that binds strongly 
to adenine–thymine rich regions in DNA
DM Diabetes mellitus type II
DPP4 Dipeptidyl peptidase 4
DSGA Densely granulated somatotroph adenomas
DSMB Data safety monitoring board
EDTA Ethylenediaminetetraacetic acid
EIA Enzyme immune assay
EKG Electrocardiogram
ELISA Enzyme-Linked Immuno Sorbent Assay
EMA European Medicines Agency
ERK Extracellular signal-regulated kinases
FDA Food and Drug Administration
FFA Free fatty acids
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FFPE Formalin-fixed, paraffin-embedded
FIPA Familial isolated pituitary adenoma
FPG fasting plasma glucose
GH Growth hormone
GHBP Growth hormone binding protein
GHR Growth hormone receptor
GHRA Growth hormone receptor antagonist
GHRH Growth hormone releasing hormone
GHSR1a Growth hormone secretagogue receptor 1 a
GIP gastric inhibitory polypeptide
GLP-I Glucagon-like peptide-I
GOAT Ghrelin O-acyl transferase
GPCR G protein-coupled receptor
GPOS German pegvisomant observational study
HbA1c Glycosylated hemoglobin, type A1C
HE Haematoxylin eosin
HOMA-2 Homeostatic model assessment
HOMA-B Homeostatic model assessment β-cell function
HOMA-IR Homeostatic model assessment insulin resistance
IGFBP1 Insulin-like growth factor-binding protein 1
IGFBP3 Insulin-like growth factor-binding protein 3
IGF-I Insulin-like growth factor I
IHC Immunohistochemistry
IQR Interquartile range
IRB Institutional review board
IRS Immunoreactivity score
ITT Intention-to-treat
JAK2 Janus kinase 2
kDa kilodalton
LA-SSA Long-acting somatostatin analogue
LC-MS/MS Liquid chromatography–mass spectrometry
LFT Liver function tests
LH Luteinizing Hormone
LOCF last observation carried forward
MAP Mitogen-activated protein
MPS Mononuclear phagocyte system
MRI Magnetic resonance imaging
NYHA New York Heart failure Association classification
OCT Octreotide
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OGTT Oral glucose tolerance test
PAOLA Pasireotide versus continued treatment with octreotide or lanreo-
tide in patients with inadequately controlled acromegaly study by 
Gadelha et al
PAPE PAsireotide LAR and PEgvisomant study
PAS Pasireotide
PAS-LAR score Pasireotide LAR treatment response score
PAS-LAR Pasireotide long acting release
PASQ 
PEG 
PEGV 
PI3K 
PQD 
PRL 
QoL 
QTcF 
RAI 
RIA 
RT 
SAE 
SGSA 
SRIF 
SRL 
SRS 
SSA 
SST 
SST1 
SST2 
SST5 
SSTR 
STAT5 
TET 
TG 
TRH 
TSH 
TSS 
UAG 
ULN 
WAT 
Patient-assessed acromegaly symptom questionnaire 
Polyethylene glycol
Pegvisomant
Phosphoinositide 3-kinase
PEG-coated quantum dots
Prolactin
Quality of life
QT interval corrected by the Fridericia correction formula 
Radioactive iodine
Radioimmunossay
Radiotherapy
Serious adverse event
Sparsely granulated somatotroph adenomas 
Somatotropin releasing-inhibiting factor
somatostatin receptor ligand
Stereotactic radiosurgery
Somatostatin analogue
Somatostatin
Somatostatin receptor subtype 1
Somatostatin receptor subtype 2
Somatostatin receptor subtype 5
Somatostatin receptor
Signal transducer and activator of transcription 5 
Transient elevated transaminases
Total ghrelin
Thyroid releasing hormone
Thyroid stimulating hormone
Transsphenoidal surgery
Unacylated ghrelin
Upper limit of normal
White adipose tissue
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WHO World health organization
X-LAG X-linked acrogigantism
γ-GT γ-glutamyl transpeptidase
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